t helper cell differentiation during blood-stage ...450950/s... · r, james kr, fernandez-ruiz d,...
TRANSCRIPT
Defining cellular and molecular determinants of CD4+ T helper cell
differentiation during blood-stage Plasmodium infection
Kylie Renee James
Bachelor of Science (Hons)
A thesis submitted for the degree of Doctor of Philosophy at
The University of Queensland in 2016
School of Medicine
i
Abstract
Malaria is a disease resulting from infection with protozoan parasites of the genus,
Plasmodium. Malaria remains a leading cause of global deaths, particularly of children living in
sub-Saharan Africa. Despite significant research efforts, an effective strategy for inducing robust
Plasmodium-specific immunity remains elusive. CD4+ T helper (Th) cells are critical components
of the adaptive immune response to blood-stage Plasmodium parasites. During experimental
malaria in mice two major Th cell types arise, T helper 1 (Th1) and T follicular helper (Tfh) cells,
both of which are associated with improved infection outcomes. Immune mechanisms controlling
the emergence of Th1 and Tfh cells during Plasmodium infection remain poorly characterised, due
in part to the absence of appropriate in vivo reagents.
To elucidate mechanisms involved in the emergence of parasite-specific Th cells, recently
developed Plasmodium-specific CD4+ T cell receptor (TCR) transgenic T cells (termed PbTII cells)
were assessed for their in vivo response in mouse models of malaria. Adoptively-transferred PbTII
cells proliferated during infection in a manner dependent on MHCII-expressing cells and
conventional dendritic cells. By the peak of infection, PbTII cells had differentiated into Th1 and
Tfh cells, mirroring the endogenous polyclonal CD4+ T cell response, and emphasising the utility
of this reagent for further studies of in vivo Th responses.
Next, a relatively new technology, single-cell RNA sequencing (scRNAseq), was applied to
PbTII cells to explore at a molecular level the process of Th differentiation in vivo. After initial
priming events, emerging Th cells entered a state of high cell cycling, in which they expressed
genes associated with both Th1 and Tfh subsets. This occurred prior to their commitment to a
differentiated, and possibly terminal, Th1 or Tfh effector state. In this pre-Th state, cells remained
'impressionable' to external signals. Using scRNAseq, inflammatory monocytes were identified as
likely providing one such signal. Furthermore, in vivo depletion of monocytes after a period of
initial priming resulted in a reduction in Th1 but not Tfh cell responses.
Although numerous innate immune sensors have been implicated in the detection of blood-
stage Plasmodium infection, whether such molecules influence Th responses remains unclear.
Therefore, PbTII cells were employed to determine T-cell extrinsic signals that might drive Th
responses, and modest roles for individual innate immune sensing molecules were observed.
However, interferon regulatory factor 3 (IRF3), which sits downstream of several innate sensors,
played a strong role in the clonal expansion of PbTII cells during infection. Importantly, using Irf3-/-
mice, IRF3 was shown to support T cell clonal expansion and promote Th1 differentiation. IRF3
was also required for inflammatory monocytes to express MHCII, suggesting a possible
ii
contributory mechanism. Interestingly, IRF3 exerted a suppressive effect on humoral responses, by
limiting Tfh cell and germinal centre (GC) B cell responses. Notably, IRF3-deficiency improved
GC B cell responses, promoted stronger and longer-lasting Plasmodium-specific serum antibody
levels, and accelerated the resolution of infection. Finally, in mixed bone marrow chimeric mice,
IRF3-deficent B cells responded more effectively than WT counterparts, suggesting a B-cell
intrinsic suppressive role for IRF3.
In summary, PbTII cells have been demonstrated to be an effective tool for studying
Th1/Tfh differentiation in vivo. During experimental blood-stage malaria PbTII cells do not commit
to an effector state until several days after initial priming. Prior to this point, pre-Th cells remain
receptive to external inputs, such as those supplied by myeloid cells including inflammatory
monocytes. Finally, an innate immune transcription factor, IRF3, exhibits roles in sustaining Th1
differentiation, and suppressing Tfh cell and B cell responses. Therefore, IRF3 represents a
potential target for improving immunological protection against blood-stage Plasmodium parasites.
iii
Declaration by author
This thesis is composed of my original work, and contains no material previously published
or written by another person except where due reference has been made in the text. I have clearly
stated the contribution by others to jointly-authored works that I have included in my thesis.
I have clearly stated the contribution of others to my thesis as a whole, including statistical
assistance, survey design, data analysis, significant technical procedures, professional editorial
advice, and any other original research work used or reported in my thesis. The content of my thesis
is the result of work I have carried out since the commencement of my research higher degree
candidature and does not include a substantial part of work that has been submitted to qualify for
the award of any other degree or diploma in any university or other tertiary institution. I have
clearly stated which parts of my thesis, if any, have been submitted to qualify for another award.
I acknowledge that an electronic copy of my thesis must be lodged with the University
Library and, subject to the policy and procedures of The University of Queensland, the thesis be
made available for research and study in accordance with the Copyright Act 1968 unless a period of
embargo has been approved by the Dean of the Graduate School.
I acknowledge that copyright of all material contained in my thesis resides with the
copyright holder(s) of that material. Where appropriate I have obtained copyright permission from
the copyright holder to reproduce material in this thesis.
iv
Publications during candidature
Peer-reviewed papers
Lonnberg T, Svensson V, James KR, Fernandez-Ruiz D, Sebina I, Montandon R, Soon
MSF, Fogg LG, Nair AS, Liligeto U, Stubbington MJT, Ly LH, Bagger O, Zwiesssele M,
Lawrence ND, Souza-Fonseca-Guimaraes F, Bunn PT, Engerwda CR, Heath WR, Billker O,
Stegle O, Haque A, Teichmann SA, Single-cell RNA-seq and computational analysis using
temporal mixture modelling resolves Th1/Tfh fate bifurcation in malaria.Sci Immunol,
(2017)
Sebina I, James KR, Soon SF, Fogg LG, Best SE, de Labastida Rivera F, Montes de Oca
M, Amante FH, Thomas BS, Beattie L, Souza-Fonseca-Guimaraes F, Smyth MJ, Hertzog
PJ, Hill GR, Hutloff A, Engwerda CR, Haque A, IFNAR1-signalling obstructs ICOS-
mediated humoral immunity during non-lethal blood-stage Plasmodium infection, PLoS
Pathog, (2016) 12 1
Proserpio V, Piccolo A, Haim-Vilmovsky L, Kar G, Lonnberg T, Svensson V, Pramanik J,
Natarajan KN, Zhai W, Zhang X, Donati G, Kayikci M, Kotar J, McKenzie AN, Montandon
R, James KR, Fernandez-Ruiz D, Heath WR, Haque A, Billker O, Woodhouse S, Cicuta P,
Nicodemi M, Teichmann SA, Single cell analysis of CD4+ T cell differentiation reveals
three major cell states and progressive acceleration of proliferation. Genome Biol, (2016)
17 1 133
Khoury D, Cromer D, Best S, James KR, Sebina I, Haque A, Davenport M, Reduced
erythrocyte susceptibility and increased host clearance of young parasites slows
Plasmodium growth in a murine model of severe malaria. Sci Rep (2015) 6 5 9412
Edwards C, Zhang V, Werder R, Best S, Sebina I, James KR, Faleiro R, de Labastida
Rivera F, Amante F, Engwerda C, Phipps S, Haque A, Coinfection with blood-stage
Plasmodium promotes systemic type I interferon production during pneumovirus infection
but impairs inflammation and viral control in the lung. Clin Vaccine Immunol (2015) 5 477-
83
Edwards C, Best S, Gun S, Claser C, James KR, de Oca M, Sebina I, de Labastida Rivera
F, Amante F, Hertzog P, Engwerda C, Renia L, Haque A, Spatiotemporal requirements of
v
IRF7 in mediating type I IFN-dependent susceptibility to blood-stage Plasmodium infection,
Eur J Immunol (2015) 45 1 130-41
Haque A, Best S, Montes de Oca, M, James KR, Ammerdorffer A, Edwards C, Rivera F,
Amante F, Bunn P, Sheel M, Sebina I, Koyama M, Varelias A, Hertzog P, Kalinke U, Gun
S, Rénia L, Ruedl C, MacDonald K, Hill G, Engwerda C. Type I IFN blockade in CD8- DC
enhances Th1-immunity to malaria. J Clin Invest(2014) 124 6 2483-96
Khoury D, Cromer D, Best S, James KR, Kim P, Engwerda C, Haque A, Davenport M.
Effect of mature blood-stage Plasmodium parasite sequestration on pathogen biomass in
mathematical and in vivo models of malaria. Infection and Immunity. (2014) 82 1 212-20
Bunn P, Stanley A, Rivera F, Mulherin A, Sheel M, Alexander C, Faleiro R, Amante F,
Montes De Oca M, Best S, James KR, Kaye P, Haque A, Engwerda C. Tissue requirements
for establishing long-term CD4+ T cell-mediated immunity following Leishmania donovani
infection. J Immunol. (2014) 192 8 3709-18
Conference abstracts
James KR, Soon SF, Sebina I, Fernandez-Ruiz D, Heath WR, Haque A, IRF3 priorities
cellular immunity over humoral responses during blood-stage malaria, 2015, Australasian
Society for Immunology Annual Meeting, Canberra, Australia (oral presentation).
James KR, Lonnberg T, Fernandez-Ruiz D, Heath WR, Billker O, Teichmann SA, Haque
A, Using single-cell RNAseq to investigate CD4+ T cell differentiation during Plasmodium
infection, 2015, Immunology@Brisbane Conference, Brisbane, Australia (oral presentation).
James KR, Lonnberg T, Fernandez-Ruiz D, Heath WR, Billker O, Teichmann SA, Haque
A, Using Single-cell RNAseq to visualise CD4+ helper cell differentiation in vivo, 2014,
Brisbane Immunology Group Annual Conference, Gold Coast, Australia (poster
presentation).
James KR, Fernandez-Ruiz D, Heath WR, Haque A, Fate “decisions” in antigen-specific
CD4+ T helper cells during experimental blood-stage malaria, 2014, Gordon Research
Conference: 'Immunochemistry and Immunobiology', Newry, Maine, USA (poster
vi
presentation).
James KJ, Best SE, Montes De Oca M, Engwerda CR, Heath WR, Haque A, Role of IRF3
in controlling CD4+ T cell activation and effector function during Plasmodium
infection,2013, Brisbane Immunology Group Annual Conference, Kingscliff, Australia
(poster presentation).
Publications included in this thesis
No publications included
vii
Contributions by others to the thesis
Dr Ashraful Haque: Conceived the concept of projects, provided input into the design of
experiments, assisted with interpreting the results and edited this thesis.
Dr Tapio Lonnberg; Conceived the concept of scRNAseq analysis of PbTII cells, contributed to
non-routine technical work; analysed scRNAseq of PbTII cells and assisted with interpretation.
Mr Valentine Svensson; Developed the mathematical algorithm for modelling PbTII differentiation
in Chapter 4, contributed to analysis of scRNAseq of PbTII cells and interpretation of the results.
Miss Megan SF Soon; Assisted with routine experiments included in Chapter 5, analysis of results
and generation of ideas.
Mr Ismail Sebina; Assisted with generating ideas and performing the immunofluorescent
microscopy mentioned in section 4.3.8.
Miss Susanna Ng; Created summary graphics included as Figure 4.7 and Figure 4.19
Statement of parts of the thesis submitted to qualify for the award of another
degree
None
viii
Acknowledgements
This thesis would not have been possible without the contributions and support of many
people. Firstly, I would like to express gratitude to my supervisor Dr Ashraful Haque. Thank you
for your patience in mentoring me throughout the years, and for genuinely caring about me, as you
do with all of your students. I would especially like to thank you for pushing me to work hard and
encouraging me to take every opportunity to travel and network, this has really opened my eyes to
the field of science and opened doors for my future career. I would also like to thank my co-
supervisor, Professor Christian Engwerda, for his kind advice and guidance.
To Ismail Sebina and Megan Soon, I could not have hoped to work with cooler people.
Experimental time points were even enjoyable when we were working side-by-side. You are both
incredibly talented and special people. I look forward to catching up with you both in Uganda. To
Arabella Young, Steve Blake, Therese Vu and Teija Frame, thank you for providing me with some
semblance of a social life at QIMRB. When I look back on my candidature in years to come, I will
remember more than just FACS plots and mice; I will remember laughter and shenanigans shared
with you guys. My thanks are also extended to all past and present members of the Malaria
Immunology and Immunology and Infection Laboratories for their support and assistance.
I would like to acknowledge the financial support I received from the Australian
Government in the form of my Australian Postgraduate Award, the Higher Degrees Committee of
QIMRB for my Top-Up Award, and OzEMalaR, Australasian Society for Immunology, QIMRB
and EMBL Australia for travel awards and grants. Thank you to the QIMRB Core Facilities, my
research would not have been possible without you.
On a particularly personal note, I would like to thank and acknowledge my family. Thanks
to my sisters, Megan and Leisa, and more recently my brothers James and Ian, for always having
my back and for providing sibling rivalry; it has been instrumental in motivating me to succeed.
Special thanks to Megan for the many hours of Skype conversation and letters of encouragement
under my car windscreen; I can't tell you what a difference this made during my candidature.
Finally, I would like to thank my parents, Leone and Darryl, for teaching me the value of hard work
and perserverance, for ensuring that I was watered and fed (particularly while writing this thesis),
and most especially for your unwavering love.
ix
Keywords
t helper cell, malaria, plasmodium, interferon regulatory factor 3, irf3, single-cell rna sequencing,
scrnaseq, germinal centre b cell, innate immunity, monocyte
Australian and New Zealand Standard Research Classifications (ANZSRC)
ANZSRC code: 110704 Cellular Immunology, 60%
ANZSRC code: 110803 Medical Parasitology, 20%
ANZSRC code: 060102, Bioinformatics, 20%
Fields of Research (FoR) Classification
FoR code: 1107, Immunology, 70%
FoR code: 0699, Other Biological Sciences, 30%
x
Table of contents
Chapter One:Literature review ........................................................................................................ 1
1.2 Malaria ...................................................................................................................................... 2
1.2.1 Progress towards a successful malaria vaccine ................................................................... 4
1.3 Immunity to malaria ................................................................................................................ 5
1.3.1 Experimental models of malaria ......................................................................................... 5
1.3.2 Requirement for antibody-mediated protection .................................................................. 6
1.3.3 Requirement for CD4+ T cell responses ............................................................................. 7
1.3.4 Mechanisms of immune evasion ......................................................................................... 8
1.4 T cell-mediated immunity ....................................................................................................... 9
1.4.1 Development of antigen-specific T cells within the thymus ............................................... 9
1.4.2 Studying antigen specific T cell responses ....................................................................... 10
1.4.3 Antigen presentation to CD4+ T cells during malaria ....................................................... 12
1.4.4 Differentiation of CD4+ T cells ......................................................................................... 13
1.4.5 T helper responses provide protection during Plasmodium infection ............................... 17
1.4.6 CD4+ T cell memory to Plasmodium infection ................................................................. 19
1.4.7 CD8+ T cell during Plasmodium infection ........................................................................ 20
1.5.1 Antibodies ......................................................................................................................... 21
1.5.2 Micro-architecture of the spleen ....................................................................................... 21
1.5.3 Germinal centre reactions ................................................................................................. 22
1.5.4 B cell memory ................................................................................................................... 24
1.6 Innate immunity ..................................................................................................................... 25
1.6.1 Innate immune detection of Plasmodium infection .......................................................... 25
1.6.2 Interferon regulatory factors ............................................................................................. 25
1.6.3 Interferon Regulatory Factor 3 .......................................................................................... 26
1.7 Thesis aims .............................................................................................................................. 28
1.7.1 Thesis outline .................................................................................................................... 28
Chapter Two:Materials and methods ............................................................................................ 30
2.1 Materials ................................................................................................................................. 30
2.1.1 Mice ...................................................................................................................................... 30
2.1.2 Parasites ............................................................................................................................... 33
2.1.3 Infections .............................................................................................................................. 33
2.1.4 Harvesting tissues ................................................................................................................ 34
2.1.5 Processing spleens ............................................................................................................... 34
xi
2.1.6 Cell transfer ......................................................................................................................... 35
2.1.7 In vivo cell depletions .......................................................................................................... 36
2.1.8 Flow cytometry reagents and materials ............................................................................ 36
2.1.9 Antibodies and dyes ............................................................................................................ 37
2.1.10 Plasmodium-specific ELISA ............................................................................................. 41
2.1.11 Single-cell RNA sequencing (scRNAseq) ........................................................................ 41
2.2 Methods ................................................................................................................................... 43
2.2.1 Mice and ethics .................................................................................................................... 43
2.2.2 Adoptive transfer of Plasmodium-specific CD4+ T (PbTII) cells .................................... 44
2.2.3 CellTrace violet labelling of cells ....................................................................................... 44
2.2.5 In vivo cell depletion ............................................................................................................ 45
2.2.5.1 CD4+ T cells ................................................................................................................... 45
2.2.5.2 CD11c+ dendritic cells ................................................................................................... 45
2.2.5.3 LysM+ monocytes/macrophages .................................................................................... 46
2.2.5.3 B cell depletion .............................................................................................................. 46
2.2.6 Euthanasia ........................................................................................................................... 46
2.2.7 Processing tissues ................................................................................................................ 46
2.2.7.1 Spleens ........................................................................................................................... 46
2.2.7.2 Blood .............................................................................................................................. 47
2.2.7.3 Liver ............................................................................................................................... 47
2.2.7.4 Bone marrow .................................................................................................................. 47
2.2.8 Bone marrow chimeric mice .............................................................................................. 48
2.2.9 Flow cytometry .................................................................................................................... 48
2.2.9.1 Live/Dead stain .............................................................................................................. 48
2.2.9.2 Surface stain ................................................................................................................... 48
2.2.9.3 Secondary antibody stain ............................................................................................... 48
2.2.9.4 Intracellular stain with eBioscience Foxp3 intracellular kit .......................................... 49
2.2.9.5 Detection of apoptosis .................................................................................................... 49
2.2.10 FACS acquisition............................................................................................................... 49
2.2.11 ELISA analysis of Plasmodium-specific immunoglobulins in serum ........................... 49
2.2.12 Single-cell mRNA sequencing .......................................................................................... 50
2.2.13 Processing scRNAseq data and quality control .............................................................. 51
2.2.14 Statistics ............................................................................................................................. 51
xii
Chapter Three:Assessing the utility of Plasmodium-specific TCR transgenic CD4+ T cells for
studying T helper responses during experimental blood-stage malaria ..................................... 52
3.1 Abstract ................................................................................................................................... 52
3.2 Introduction ............................................................................................................................ 53
3.3 Results ..................................................................................................................................... 55
3.3.1 Generation of Plasmodium-specific TCR transgenic CD4+ T (PbTII) cells ..................... 55
3.3.2 PbTII responses are specific for Plasmodium infection .................................................... 56
3.3.3 Th1 and Tfh are distinct effector subsets .......................................................................... 58
3.3.4 PbTII display the capacity to differentiate into T regulatory 1 cells ................................ 60
3.3.5 PbTII cells migrate to the liver and display a Th1 phenotype .......................................... 62
3.3.6 PbTII cells develop into memory cells after acute PcAS infection .................................. 63
3.3.7 PbTII cells show cross-species reactivity to Plasmodium infection ................................. 64
3.4 Discussion ................................................................................................................................ 66
Chapter Four:Single-cell RNA-sequencing resolves a CD4+ T helper cell fate bifurcation ..... 70
4.1 Abstract ................................................................................................................................... 70
4.2 Introduction ............................................................................................................................ 71
4.3 Results ..................................................................................................................................... 75
4.3.1 Unbiased separation of Th1 and Tfh effector cells ........................................................... 75
4.3.2 Deducing concurrent Th trajectories during a Mixture of Gaussian Processes model ..... 78
4.3.3 Mechanisms underlying the differentiation of Th1 and Tfh cells ..................................... 82
4.3.4 IFNγ and IL-10co-producing PbTII cells emerge from Th1 cells .................................... 84
4.3.5 PbTII cells are receptive to chemokine signals at bifurcation .......................................... 85
4.3.6 B cells support Tfh responses ........................................................................................... 88
4.3.7 ScRNAseq assessment of myeloid cells during PcAS infection ...................................... 89
4.3.8 Ly6Chi monocytes support Th1 fate, but not Tfh fate, commitment ................................. 99
Chapter Five:Interferon Regulatory Factor 3 balances Th1 and Tfh-dependent immunity
during blood-stage Plasmodium infection .................................................................................... 109
5.1 Abstract ................................................................................................................................. 109
5.2 Introduction .......................................................................................................................... 110
5.3 Results ................................................................................................................................... 112
5.3.1 Individual PRRs play only modest roles in controlling Plasmodium-specific CD4+ T cell
responses during blood-stage infection .................................................................................... 112
5.3.2 Haematopoietic cells employ IRF3 to drive Plasmodium-specific Th responses ........... 113
xiii
5.3.3 IRF3-mediated Th1 support correlates with MHCII-expression by inflammatory
monocytes ................................................................................................................................ 117
5.3.4 Conventional dendritic cell activation during Plasmodium infection is independent of
IRF3 expression ....................................................................................................................... 119
5.3.5 IRF3 drives MHCII signalling by inflammatory monocytes to support accumulation of
PbTII cells ................................................................................................................................ 121
5.3.6 IRF3 suppresses humoral immunity during blood-stage Plasmodium infection ............ 123
5.3.7 IRF3 expression by B cells impairs development of humoral immune responses ......... 126
5.3.8 IRF3 contributes to disease severity during lethal experimental malaria ....................... 130
5.4 Discussion .............................................................................................................................. 131
Chapter Six:Final discussion......................................................................................................... 135
6.1 PbTII cells represent an effective tool for studying in vivo CD4+ T cell responses ........ 135
6.2 Modelling of scRNAseq analysis of PbTII cells reveals the emergence of Th fates in vivo
...................................................................................................................................................... 136
6.3 IRF3 balances Th1 and Tfh-mediated immune responses ............................................... 139
6.4 Concluding remarks ............................................................................................................ 140
Chapter Seven: ............................................................................................................................... 141
References ....................................................................................................................................... 141
xiv
Table of figures
Figure 1.1 Life cycle of Plasmodium spp. ……………………………………………………….. 3
Figure 1.2 CD4+ T helper cell differentiation. ………………………………………………….... 16
Figure 1.3 Architecture of the spleen. ……………………………………………………………. 22
Figure 1.4 Germinal centre. ……………………………………………………………………… 23
Figure 1.5 Innate signalling pathways converging on Interferon regulatory factor 3 (IRF3). …… 27
Figure 3.1 Gating strategy for sorted Plasmodium-specific CD4+ TCR transgenic (PbTII) cells. . 55
Figure 3.2 PbTII cells proliferate in an MHCII-dependent manner during PcAS infection. …….. 57
Figure 3.3 Plasmodium-specific TCR transgenic CD4+ T (PbTII) cells bifurcate into Th1 and Tfh
cells during PcAS infection. ……………………………………………………………………… 59
Figure 3.4 Differentiation of PbTII cells during PcAS infection. ………………………………... 60
Figure 3.5 PbTII cells differentiate into regulatory cells during PcAS infection. ………………... 61
Figure 3.6 IFNγ+ PbTII cells migrate to the liver. ………………………………………………... 62
Figure 3.7 PbTII cells develop into memory cells after acute PcAS infection. ………………….. 63
Figure 3.8 PbTII cell expansion and Th1/Tfh differentiation during P. yoelii 17XNL and P. berghei
ANKA blood-stage infection. …………………………………………………………………….. 65
Figure 4.1 Sorting strategy for PbTII cells. ………………………………………………………. 76
Figure 4.2 Single-cell mRNA-sequencing of activated antigen-specific PbTII CD4+ T cells. …... 77
Figure 4.3 Computational delineation of Th1 and Tfh differentiation trajectories. ……………… 79
Figure 4.4 Bifurcation of T cell fates is accompanied by changes in transcription, proliferation and
metabolism. ……………………………………………………………………………………….. 81
Figure 4.5 Unique gene expression signatures corresponding with Th1 and Tfh differentiation. ... 83
Figure 4.6 IL-10/IFNγ co-producing PbTIIs begin to emerge from Th1 cells late in pseudotime. . 84
Figure 4.7 Chemokine signals underlying Th fate commitment. ………………………………… 86
Figure 4.8 Bifurcation of PbTII cells into Th1 and Tfh effector cells. …………………………... 87
Figure 4.9 B cells are essential for Tfh responses in PbTII cells during PcAS infection. ……….. 88
Figure 4.10 Sorting strategy for myeloid cells. …………………………………………………… 90
Figure 4.11 Principal Component Analysis of cDCs from naïve and infected mice. ……………. 91
Figure 4.12 Differential gene expression between single splenic CD8α+ and CD8α- cDCs. ……. 92
Figure 4.13 cDCs influence Th bifurcation in uncommitted PbTII cells. ………………………... 94
Figure 4.14 Differentially-expressed genes between single naïve and day 3 PcAS-infected cDCs. 95
Figure 4.15 Expression of immune-related molecules by myeloid cells. …………………….. 96-98
Figure 4.16 Principal Component Analysis of Ly6Chi monocytes from naïve and infected mice.100
Figure 4.17 Ly6Chi monocytes display similar functional capacity as cDCs. ……………………101
xv
Figure 4.18 Differentially-expressed genes between single Ly6Chi monocytes from naïve and day 3
PcAS-infected mice. ………………………………………………………………………………102
Figure 4.19 Kinetics of CXCL9 expression by myeloid cell populations. ………………............. 103
Figure 4.20 Figure 4.20 Ly6Chimonocytes support Th1 responses. …………………………….. 104
Figure 4.21 PbTII differentiation is influenced by chemokine-producing cells. ...……………… 105
Figure 5.1 PbTII responses are partially modulated by MyD88- and TRIF-mediated signalling, but
further dependent on IRF3. ………………………………………………………………………. 113
Figure 5.2 IRF3 promotes early protective Th1 responses during blood-stage Plasmodium infection.
……………………………………………………………………………………………………. 115
Figure 5.3 Phenotypic characterisation of Irf3-/->WT bone marrow chimeric mice. …………… 116
Figure 5.4 Requirements for IRF3 in early activation of PbTII cells. …………………………… 118
Figure 5.5 Activation kinetics of conventional dendritic cells during PcAS infection. …………. 120
Figure 5.6 Inflammatory monocytes express MHCII in an IRF3-dependent manner. …………... 122
Figure 5.7 IRF3 limits Plasmodium-specific antibody responses. ………………………………. 124
Figure 5.8 IRF3 limits Plasmodium-specific antibodies GC B cells and Tfh cell differentiation.. 125
Figure 5.9 IRF3 within B cells dampens maturation and GC B cell responses during infection… 127
Figure 5.10 IRF3 limits humoral immune responses during Py17XNL infection. ……………… 129
Figure 5.11 IRF3 impairs resolution of PbA infection in mice. …………………………………. 130
xvi
Abbreviations
AID Activation-Induced Deaminase
APC Antigen-Presenting Cell
bp Base pair
Bcl6 B cell lymphoma 6
BLIMP-1 B-Lymphocyte-Induced Maturation Protein 1
BSA Bovine Serum Albumin
cDC conventional Dendritic Cell
ChIP-seq Chromatin immunoprecipitation followed by sequencing
CRISPR-Cas9 Clustered, Regularly Interspaced, Short Palindromic Repeat-Cas9
CSP Circumsporozoite Protein
CXCL C-X-C motif Chemokine Ligand
CXCR C-X-C motif Chemokine Receptor
CyTOF Mass cytometry
DNA Deoxyribonucleic Acid
DT Diphtheria Toxin
DTR Diphtheria Toxin Receptor
DZ Dark Zone
EAE Experimental Autoimmune Encephalomyelitis
ECM Experimental Cerebral Malaria
ELISPOT Enzyme-Linked ImmunoSPOT
ERCC External RNA Control Consortium
ESC Embryonic Stem Cell
EU European Union
FACS Fluorescence-Activated Cell Sorting
FDC Follicular Dendritic Cell
GC Germinal Centre
GPI Glycosylphosphatidylinositol
GPLVM Gaussian Process Latent Variable Model
HIV Human Immunodeficiency Virus
Hz Haemozoin
ICOS Inducible T-cell Costimulator
ICOS-L Inducible T-cell Costimulator Ligand
xvii
Ig Immunoglobulin
i.p. intraperitoneal
IRF Interferon Regulatory Factor
ISG Interferon Stimulated Genes
i.v. intravenous
L Litre
LAG3 Lymphocyte-Activation Gene 3
LZ Light Zone
MACS Magnetic-Activated Cell Sorting
MAVS Mitochondrial Anti-Viral Signalling protein
MBC Memory B Cell
MHC Major Histocompatibility Complex
MHCI MHC Class I
MHCII MHC Class II
μg Microgram
mg Milligram
μL Microlitre
mL Millilitre
MSP Merozoite Surface Protein
MyD88 Myeloid Differentiation primary response gene 88
NK Natural Killer
OMGP Overlapping Mixture of Gaussian Processes
PALS Periarteriolar Lymphoid Sheath
PbA Plasmodium berghei ANKA
PBMC Peripheral Blood Mononuclear Cell
PC Principal Component
PCA Principal Component Analysis
PcAS Plasmodium chabaudi chabaudi AS
PCR Polymerase Chain Reaction
PD-1 Programmed Death 1
PfEMP1 Plasmodium falciparum Erythrocyte Membrane Protein 1
PfRh5 Plasmodium falciparum Reticulocyte binding protein 5 homologue
PfSPZ Plasmodium falciparum Sporozoite
p.i. post-infection
pMHCII peptide bound Major Histocompatibility Complex II
xviii
pRBC parasitised Red Blood Cell
PRR Pattern Recognition Receptor
p-S6 Phosphorylated ribosomal protein S6
Py17XL Plasmodium yoelii 17X Lethal
Py17XNL Plasmodium yoelii 17X Non-Lethal
RAG Recombination Activation Gene
RBC Red Blood Cell
Rorγt RAR-related orphan receptor gamma thymus-specific
ROS Reactive Oxygen Species
scRNAseq single-cell Ribonucleic Acid sequencing
STING Stimulator of Interferon Genes
T-bet T-box Expressed in T cells
TCR T Cell Receptor
TI IFN Type 1 Interferon
TLR Toll-like Receptor
Treg T regulatory
Th T helper
Tfh T follicular helper
Tr1 T regulator 1
1
Chapter One:
Literature review
The human body is constantly at risk of infection from micro-organisms, such as the
protozoan parasite species, Plasmodium, the causative agent of malaria. Whether infection causes
disease depends on a delicate balance between pathogenicity of the organism and defence
mechanisms employed by the body, including those mediated by the immune system (Parkin and
Cohen 2001). Understanding the body’s response to infection is therefore of critical importance to
tip the balance towards a favourable outcome for the host.
The immune system encompasses a vast array of cells with the collective goal of defending
the body against disease. Broadly speaking, the immune system can be divided into two arms based
on the speed and specificity with which it responds. The first arm is the innate immune system,
which is rapid in its response, but displays a limited capacity to distinguish between threats. It
includes physical and chemical barriers, as well as varied cell types, for example phagocytic cells
that engulf particulate matter, and other cells specialised in the rapid production of soluble factors.
The highly conserved nature of this immune response across evolutionarily-distant phyla, including
the simplest of animals, demonstrates its necessity for survival. The second arm of the immune
system is the adaptive immune system, which generally takes longer than the innate immune system
to mount an effective response, and is more specifically targeted towards the immune challenge
presented. The adaptive immune system is also comprised of numerous cell types, the most
important and prevalent of which are T cells and B cells. A key feature of the adaptive response is
that it confers 'immunological memory', so that secondary infections are dealt with more effectively,
via a faster and stronger host adaptive immune response. Although different cell types of the innate
and adaptive immune systems exhibit unique and individual behaviours, in practice, highly complex
interactions between these cells must occur for an effective immune response to infection to be
mounted. Indeed, vaccine design and immune therapies rely on these complex interactions.
Malaria remains a significant global health concern; at least in part due to a limited
understanding of how to induce host immune responses that provide long-lasting protection. This
thesis seeks to determine novel cellular and molecular mechanisms controlling adaptive immune
responses during malaria, principally those mediated by CD4+ T helper cells. This literature review
will provide a detailed exploration of the field of malaria immunology. It will highlight gaps in
knowledge regarding adaptive immune responses to malaria parasites that may be filled by novel
approaches and technologies employed in this thesis.
2
1.2 Malaria
Malaria is the disease resulting from infection with the protozoan parasite, Plasmodium. It
remains a leading cause of global mortality, with an estimated 214 million cases and 438,000 deaths
in 2015, 90% of which occurred in sub-Saharan Africa. Children under the age of 5 are particularly
at risk of severe symptoms (WHO 2015). There are five species of Plasmodium known to infect
humans: P. vivax, P. falciparum, P. malariae, P. ovale and P. knowlesi, with P. falciparum causing
the majority of deaths. Symptoms of malaria include fever, fatigue, anaemia, nausea and sweating.
However, more severe complications such as respiratory distress, metabolic acidosis and coma can
also occur during P. falciparum infection. Despite the significant global health burden posed by
malaria, there are still no effective vaccines or immune therapies for generating long-lasting,
Plasmodium-specific immunity.
Part of the difficulty in generating immunity to malaria may be linked to the complex life-
cycle of the Plasmodium parasite. Plasmodium parasites are spread to humans when an infected
female Anopheles mosquito takes a blood meal (Figure 1.1). Transmitted parasites (sporozoites)
migrate through the skin to the liver, where they infect hepatocytes. After a single round of
replication, parasites spread to the bloodstream and infect erythrocytes. Here, they undergo asexual
replication, producing many daughter parasites (merozoites) from every infected red blood cell
(RBC). All of the clinical symptoms associated with malaria occur during the blood-stage of
infection. Furthermore, parasite burden during this stage is currenty the most accurate predictor of
patient prognosis (Dondorp, Desakorn et al. 2005). During P. falciparum infection, parasitised
RBCs (pRBCs) can sequester in soft tissues such as the brain, kidney, liver and lung, which may
perturb blood flow and promote severe symptoms as mentioned above (Carter and Mendis 2002).
Some merozoites give rise to the sexual-stage parasites (gametocytes), which migrate to peripheral
blood vessels of the skin, and await the opportunity to be taken up by a new mosquito taking a
blood meal. If gametocytes are successfully taken up by another mosquito, they undergo sexual
reproduction within the midgut. The resulting sporozoites move to the salivary glands and are
transferred to a new human host when the infected mosquito takes another blood meal.
3
Figure 1.1 Life cycle of Plasmodium spp. The parasites (sporozoites) are transmitted to a human
host via the bite of an infected female Anopheles mosquito. Sporozoites migrate through the skin
and take up residence in hepatocytes. Here, they undergo asexual reproduction to produce blood-
stage parasites (merozoites). Merozoites enter the blood stream and infect RBCs. Inside RBCs,
merozoites hijack host machinery to undergo further multiplication, causing rupture of the RBC
when it has reached capacity. The released merozoites infect new RBCs to continue multiplying, or
alternatively, become the sexual-stage parasite (gametocytes). Gametocytes migrate to the dermis
where they may be taken up by mosquitoes, undergo sexual reproduction and continue the life cycle
(Long and Zavala 2016).
4
1.2.1 Progress towards a successful malaria vaccine
Large-scale interventions in endemic regions have contributed to the decline of global
mortality due to malaria by 48% between 2000 and 2015 (WHO 2015). These interventions include
the use of insecticide-treated bed nets, indoor residual spraying, chemoprevention in highly-
susceptible groups including pregnant women and young children, and use of rapid diagnostic tests
(Steketee and Campbell 2010, WHO 2015). However, insecticide and antimalarial resistance are an
increasing threat to the control of this disease. Thus, it is generally accepted that inducing long-
lasting immunological protection in at-risk individuals, either naturally or by vaccination, will be
necessary for the eradication of malaria (Moorthy, Good et al. 2004).
Over 100 years ago the German microbiologist Robert Koch was the first to observe
naturally-acquired immunity to symptomatic malaria in individuals living in endemic areas
(Stanisic, Mueller et al. 2010). In Papua New Guinea, where individuals are exposed to hundreds of
infectious mosquito bites each year, young children and transmigrants had higher detectable
parasite burdens than local adults (Stanisic, Mueller et al. 2010). From this he concluded that
protective immunity develops slowly after many years of exposure. Further observations from the
field showed that countries with high transmission rates, such as Kenya and Gambia, have the
lowest incidence of cerebral malaria or severe malaria (Mbogo, Snow et al. 1993, McElroy, Beier et
al. 1994). These observations support the argument that implementing control measures to prevent
the transmission of infection could contribute to poorer outcomes for some individuals infected with
Plasmodium (Snow, Omumbo et al. 1997). Therefore, inducing clinical immunity to curtail the
symptoms of malaria in people living endemic areas is of absolute necessity to reduce the burden of
malaria on world health.
While naturally-acquired immunity is considered 100% effective against severe disease and
death (Doolan, Dobano et al. 2009), it requires multiple infections over a number of years to
develop and is easily lost in the absence of continual re-infection. Thus, considerable effort has
been devoted to the development of a malaria vaccine that induces long-term protective immunity.
In the 1940s, immunity to malaria was induced when ducks and monkeys were vaccinated with
killed P. lophurae and P. knowlesi respectively (Freund, Sommer et al. 1945). In the 1960s, rodents
were also protected after immunization with irradiated sporozoites (Nussenzweig, Vanderberg et al.
1967). Subsequently, protection was demonstrated in humans. However, this was only achieved
after large numbers of bites from irradiated infectious mosquitoes (Clyde 1975). In the 1980s, the
circumsporozoite (CSP) protein was discovered as a major component of the sporozoite coat, which
5
demonstrated its promise as an alternative vaccination target (Dame, Williams et al. 1984, Enea,
Ellis et al. 1984).
The current most advanced vaccine candidate, RTS,S, is based on the CSP protein combined
with the hepatitis B surface antigen to target the liver stage of disease. RTS,S is given alongside the
adjuvant, AS01, a combination of mono-phosphoryl lipid A (MPL, a toll-like receptor 4 agonist),
QS21 (a derivative of Quill A) and lipids (Stoute, Slaoui et al. 1997, Kester, Cummings et al. 2009).
Results from phase III clinical trials of RTS,S were modest, with an efficacy of approximately 50%
over 12 months in children aged 5-17 months (Olotu, Fegan et al. 2013). Furthermore, efficacy
waned during subsequent years, reaching only 0.4% by the fourth year and declining most rapidly
in children with high exposure to infection. However, since the application of this vaccine is
considered useful in conjunction with current vector control measures, the European Medicines
Agency’s Committee for Medicinal Products for Human Use recently adopted a positive scientific
opinion for its use outside the European Union (EU) (Kaslow and Biernaux 2015).
A combination vaccine approach, in which a range of Plasmodium antigens expressed at
different stages of infection are targeted, could offer a way forward. Hence, the discovery of other
candidate vaccines is still an area of intense research (Seder, Chang et al. 2013, Reddy, Pandey et
al. 2014, Ishizuka, Lyke et al. 2016). Progress in this venture is slow, since it is still unclear what
characteristics new vaccines should have and how their effectiveness should be evaluated. This
necessitates continued studies into the immune mechanisms mediating protection to Plasmodium
infection (Riley and Stewart 2013).
1.3 Immunity to malaria
1.3.1 Experimental models of malaria
Studies of the immune response to Plasmodium infection have benefitted from field
observations, clinical trials and experimental models. Although human studies are desirable, they
have many limitations, including lack of access to relevant tissues and the difficulty in
demonstrating causation (Langhorne, Buffet et al. 2011). For these reasons animal models can be
useful. Four mouse models of Plasmodium infection are routinely used for modeling the various
manifestations of human malaria. Plasmodium berghei ANKA (PbA) is typically used to mimic
severe and cerebral malaria as seen during P. falciparum infection of humans (Renia, Howland et
al. 2012). C57BL6/J mice infected with PbA experience cerebral complications such as seizures,
6
paralysis, and coma, and typically succumb to the infection after approximately 6-10 days (Hunt,
Golenser et al. 2006). P. chabaudi chabaudi AS (PcAS) infection is non-lethal, similar to human P.
vivax and P. falciparum infections (Stephens, Culleton et al. 2012), and establishes a recrudescent
infection (Achtman, Stephens et al. 2007) as seen in human P. vivax and P. ovale infections
(Imwong, Snounou et al. 2007). Finally, two strains of P. yoelii, a lethal P. yoelii 17 YM (Py17XL)
strain that causes hyperparasitemia and subsequent anaemia, and P. yoelii 17X nonlethal
(Py17XNL) strain that models slow-resolving infection (Amante and Good 1997).
1.3.2 Requirement for antibody-mediated protection
Antibodies have a well-established role in protection against natural Plasmodium infection.
Cohen and MacGregor first observed this in 1960 when they transferred purified antibodies from
naturally-immune adults of West Africa into partially immune children, resulting in rapidly
decreased parasitemia and alleviated symptoms (Cohen, McGregor et al. 1961). More recent
support for the association between Plasmodium-specific antibodies and naturally-acquired
immunity was provided by a prospective study in which antibody levels were measured in the
serum of young Malian children each year until young adulthood, when clinical immunity is
typically observed (Crompton, Kayala et al. 2010). Antibody levels rose each subsequent year of
exposure to infection up until young adulthood, when it plateaued at a high level (Crompton,
Kayala et al. 2010). However, in the absence of infection, naturally-acquired antibody titres are
easily lost, particularly in young children (Akpogheneta, Duah et al. 2008). During experimental
malaria, antibody mediated protection is most convincingly demonstrated in scenarios where mice
lack B cells, such as JHD mice, which fail to control Py17XNL infection (van der Heyde, Huszar et
al. 1994). Similar results were seen in Aicda-/- mice with mature B cells that cannot undergo
antibody class-switching (Butler, Moebius et al. 2012).
Protective antibody responses are likely generated against antigens expressed on the surface
of merozoite or parasite-derived antigens on the surface of pRBCs. A meta-analysis of pool data
from three studies on merozoite proteins determined a dose-associated response of antibodies
against merozoite surface protein 1-19 (MSP-119), by showing a 15% reduction in symptomatic P.
falciparum infections per doubling of the antibody levels in individuals (Fowkes, Richards et al.
2010). Similarly, risk of symptomatic infection dropped 54% in people with measurable IgG to
MSP-3-Ct (Fowkes, Richards et al. 2010). Parasite antigens expressed on the surface of RBC (also
known as variant surface antigens; VSAs) that could be targets for antibodies include P.
falciparum erythrocyte membrane protein 1 (PfEMP1) (Leech, Barnwell et al. 1984), repetitive
interspersed family (RIFIN) proteins (Cheng, Cloonan et al. 1998, Fernandez, Hommel et al. 1999),
7
sub-telomeric variable open reading frame (STEVOR) proteins (Kaviratne, Khan et al. 2002,
Blythe, Yam et al. 2008, Niang, Yan Yam et al. 2009), surface-associated interspersed gene family
(SURFIN) proteins (Winter, Kawai et al. 2005) and P. falciparum Maurer’s cleft two
transmembrane (PfMC-2TM) proteins (Sam-Yellowe, Florens et al. 2004, Lavazec, Sanyal et al.
2006). The best studied, PfEMP1, was first identified in the sera of infected aotus monkeys and is
now known to be involved in the adherence of pRBCs to endothelial cells. Due to the high
variability of PfEMP1 and the many other antigens expressed on iRBCs, it is difficult to show
PfEMP1-specific antibody responses in humans. However, using recombinant PfEMP1, a study in
Papua New Guinea demonstrated that the magnitude of anti-PfEMP1 responses was limited and
variant specific in young children, but in adulthood, serum antibodies were capable of recognising
at least 20 different variants, indicating that the PfEMP1-specific antibody repertoire increases with
age (Barry, Trieu et al. 2011). Antibodies against merozoite surface antigens or parasite-derived
antigens on the RBCs could provide protection by blocking the invasion of free blood-stage
parasites into new RBCs, opsonising merozoites for phagocytosis, and antibody-dependent cellular
inhibition (Blackman, Heidrich et al. 1990, Perraut, Mercereau-Puijalon et al. 1995, Bull, Lowe et
al. 1998), however this remains to be determined.
1.3.3 Requirement for CD4+ T cell responses
T cells are another key component of the adaptive immune response, and have also been
associated with improved outcomes during Plasmodium infection. Adults co-infected with
Plasmodium and Human Immunodeficiency Virus (HIV), which infects and destroys CD4+ T cells,
were hospitalised with clinical malaria twice as often than those with malaria alone (Whitworth,
Morgan et al. 2000). Additionally, individuals receiving multiple subclinical injections of P.
falciparum acquired a level of immunity that was attributed to cellular immunity on the basis of
increased production of a prototypical CD4+ cytokine, IFNγ, and absence of detectable
Plasmodium-specific antibodies throughout the study (Pombo, Lawrence et al. 2002). Serum levels
of IFNγ have also been positively associated with protection against re-infection in field studies
(Deloron, Chougnet et al. 1991). Furthermore, IFNγ production as determined by Enzyme-linked
ImmunoSpot (ELISPOT) assay of ex vivo cultures of lymphocytes was associated with improved
protection against malaria during clinical trials for RTS,S (Sun, Schwenk et al. 2003, Kester,
Cummings et al. 2009).
In mouse models of infection, the involvement of CD4+ T cells in protection against blood-
stage Plasmodium infection is most clearly evidenced by increased parasite burden and mortality in
T cell-depleted mice, a phenotype that can be rescued by adoptive transfer of unfractioned or
8
purified immune splenic cells (Weiss, Sedegah et al. 1993). Mice genetically deficient in IFNγ
(Amani, Vigario et al. 2000, Su and Stevenson 2000) or the IFNγ receptor (Ifnγr-/-) (Favre, Ryffel et
al. 1997) also fail to control infection and succumb to hyperparasitemia. In animal vaccination
studies conducted by Pinzon-Charry et al., a killed blood-stage parasite vaccine with the adjuvant,
CpG-oligodeoxynucleotides induced protective CD4+ T cells in mice (Pinzon-Charry, McPhun et
al. 2010). Even at very low doses (103 pRBCs), this vaccine induced strong proliferation of parasite-
specific CD4+ T cells within the spleen and increased serum IFNγ, IL-12, IL-10 and TNF-α levels.
At the time of rechallenge, vaccinated mice were completely protected from the high mortality and
severe disease experienced by control mice that received killed parasites alone. Cell-depletion
studies ruled out the involvement of CD8+ T cells and NK cells that can also produce IFNγ.
Importantly, the role of antibodies was also discounted due to low titres induced by vaccination and
the failure of passive transfer of immune sera to protect naive mice from infection (Pinzon-Charry,
McPhun et al. 2010). Experiments performed in SCID mice, demonstrated that transfer of enriched
splenic CD4+ T cells controlled primary PcAS infections, although this was insufficient to
completely eliminate parasites, indicating that humoral immunity is likely required for final
resolution of infection (Meding and Langhorne 1991).
1.3.4 Mechanisms of immune evasion
The adaptive immune system clearly has the capacity to mount protective immune responses
against Plasmodium infection. However, protective immunity requires many intermittent infections
to acquire and is easily lost. The difficulty in maintaining clinical protection is hypothesised to be
partly due to parasite evasion mechanisms. One means by which Plasmodium parasites can evade
antigen-specific adaptive immune responses is via antigen diversity. For example, as previously
mentioned, PfEMP1, a parasite-derived adhesion molecule expressed on the surface of pRBCs, is
involved in sequestration of pRBCs and immune evasion. Therefore, PfEMP1 is targeted by host
antigen-specific antibodies to block sequestration. However, PfEMP1 is encoded by the var gene,
which has over 60 antigenically and functionally distinct variants within a single parasite genome
(Smith, Chitnis et al. 1995, Su, Heatwole et al. 1995). Therefore, switching var gene expression can
prevent binding of antigen-specific antibodies and enable continued sequestration.
Numerous studies have also reported immunomodulation by Plasmodium infection.
Reduced numbers of circulating innate immune cells have been observed in human patients infected
with P. falciparum and P. vivax, at least partially due to cellular apoptosis (Woodberry, Minigo et
al. 2012, Pinzon-Charry, Woodberry et al. 2013). Innate cells are critical for priming adaptive
responses. Therefore, their clearance could have knock-on effects on long-lived immune responses.
9
Apoptosis of antigen-specific T cells has also been observed during experimental Plasmodium
infection (Xu, Wipasa et al. 2002). Additionally, inappropriate activation of T cell inhibitory
pathways, such as those mediated by high expression of PD1 and LAG3, may also contribute to
functional exhaustion of T cells as observed in children exposed to P. falciparum infection in Mali
(Butler, Moebius et al. 2012). Furthermore, PD1+ LAG3+ CD4+ T cells have been associated with
poorer antibody and memory B cell responses during infection (Illingworth, Butler et al. 2013).
Blocking these inhibitory receptors can result in better control of parasitemia in mice (Butler,
Moebius et al. 2012, Hafalla, Claser et al. 2012, Horne-Debets, Faleiro et al. 2013). These potential
immune evasion mechanisms highlight the dynamic relationship between host immune cells and
parasites, thus adding another layer of complexity to the induction of protective immune responses
to malaria.
1.4 T cell-mediated immunity
1.4.1 Development of antigen-specific T cells within the thymus
The adaptive immune system is adept at recognising different pathogens and responding
accordingly. Antigen specificity is provided through the expression of unique surface-bound
receptors on adaptive immune cells, as postulated in the clonal selection theory first described by
Burnet in 1957 (Burnet 1957). CD4+ and CD8+ T cells express unique T cell receptor (TCR)
complexes composed of variable disulphide-linked α and β TCR chains non-covalently associated
with a number of invariant CD3 polypeptides. Generation of TCRs begins in the thymus with the
CD4-CD8- (DN) thymocyte derived from a common hematopoietic progenitor cells. The DN
thymocyte undergoes rearrangement at the Vβ gene locus leading to expression of a functional Vβ
chain paired with a non-variant pre-Vα chain (Groettrup, Ungewiss et al. 1993). This drives
proliferation of the thymocyte, up-regulation of both CD4 and CD8 (DP) and cessation of
rearrangement at the Vβ locus. The end of Vβ rearrangement is termed allelic exclusion and results
in almost all T cells expressing a single Vβ variant (Casanova, Romero et al. 1991). The DP T cell
then undergoes rearrangement at the α locus until a TCR is created that is competent for positive
selection through recognition of major histocompatibility complex (MHC) molecules expressed by
local antigen presenting cells (APCs). If the DP T cell expresses a Vα chain that does not contribute
to recognition, it may still be expressed alongside the next iteration (Borgulya, Kishi et al. 1992).
For this reason, almost 30% of all T cells express two Vα variants (Padovan, Casorati et al. 1993).
10
90% of DP cells will only generate 'useless' TCRs that cannot successfully bind MHC molecules,
and undergo cell death (Klein, Kyewski et al. 2014).
In the event of a TCR successfully recognising an MHC molecule, the affinity of the TCR
for 'self-peptide' bound to the MHC molecule determines the fate of the T cell. If affinity is high,
the T cell is deemed 'self-reactive' and promptly deleted. T cells with moderate affinity may
progress to become natural T regulatory cells. Lastly, T cells with low affinity for self antigen
migrate out of the thymus and join the naïve T cell repertoire. In a study by Liu and Bosselut,
longer interactions between the peptide-MHC (p-MHC) complex and the TCR of these low affinity-
binders was shown to be constitutive for CD8+ T cell development, regardless of the MHC class
type (Liu and Bosselut 2004). The significance of positive selection by recognition of self-peptide
was evident from a study by Mandl et al. who showed that the affinity of CD4+ T cells for self-
peptide bound to MCH molecules was positively associated with its affinity for foreign bound
antigen (Mandl, Monteiro et al. 2013).
The resulting naïve T cell repertoire of the human body has the capacity to recognise an
estimated 109 different antigens, making them one of the most diverse populations of cells in the
body (Davis and Bjorkman 1988). However, this high diversity within the naive T cell repertoire
comes at a cost to the number of each clone that can be accommodated. In fact, the frequency of
naïve CD4+ T cells specific to any given antigen is estimated to be only 20 to 200 cells per mouse
(Moon, Chu et al. 2007) or 1 to 10 per million CD4+ T cells in humans (Jenkins, Chu et al. 2010).
Clonal expansion of these rare clones occurs in secondary lymphoid organs when a TCR recognises
a peptide bound to a MHC molecule, of which there are two classes. MHC class I (MHCI)
molecules are expressed by all nucleated cells and are recognised by CD8+ T cells. On the other
hand, MHC class II (MHCII) molecules are expressed by specialised APCs, including DCs,
macrophages and B cells, and are recognised by CD4+ T cells. Upon recognition of cognate
antigens, expansion of T cells must be vigorous to provide a protective response to acute disease
(Buchholz, Schumacher et al. 2016). Studying the development of antigen-specific T cell responses
in vivo is of high interest, but is confounded by the low frequency with which clones exist within
the entire T cell pool.
1.4.2 Studying antigen specific T cell responses
The ‘gold standard’ for circumventing the problem of low antigen-specific T cell
frequencies is the use of peptide-bound MHC multimers or TCR transgenic mice expressing clonal
populations of T cells with proven antigen specificity. Peptide-bound MHC multimers are a soluble
form of MHC molecules with bound antigen (Nepom 2012). The MHC multimer commonly
11
consists of a streptavidin core bound to four biotin-conjugated MHC molecules and tagged with a
fluorochrome for easy flow cytometry-based detection of bound T cells. Peptide-bound MHCI
tetramers were first applied to study CD8+ T cells 20 years ago. One example of their early
application was in determining the frequencies and functions of antigen-specific CD8+ T cells
among peripheral blood mononuclear cells (PBMCs) of HIV patients (Altman, Moss et al. 1996).
Since then, the system has been applied to MHCII tetramers for studying CD4+ T cell responses to a
wide variety of diseases, including type 1 diabetes, coeliac disease, pemphigus vulgaris, rheumatoid
arthritis, multiple sclerosis, and uveitis (Danke, Koelle et al. 2004, Danke, Yang et al. 2005,
Mallone, Kochik et al. 2005, Oling, Marttila et al. 2005). However, MHC tetramer design requires
prior knowledge of peptide sequences, which in conjunction with MHC molecules, bind to T cell
clones of interest (Nepom 2012).
The second major approach for studying antigen-specific T cell responses in vivo is the use
of TCR transgenic T cells. TCR transgenic T cell-expressing mice are created by culturing
immortalised T cells with antigen-loaded APCs. Responding cells are selected for and their α and β
TCR chains sequenced. These sequences are used to create cDNA, which is then cloned into
expression vectors and injected into blastocysts to generate transgenic founder mice (Mueller,
Heath et al. 2002). The first TCR transgenic mouse was developed in the late 1980's towards the
minor histocompatibility HY complex and was used to study negative selection of T cells
(Kisielow, Bluthmann et al. 1988). Subsequent transgenic mice were used to study positive
selection (Hogquist, Jameson et al. 1994). TCR transgenic cells have been instrumental in observing
CD8+ T cell exhaustion in mice with persistent LCMV infection (Moskophidis, Lechner et al.
1993), and in showing that initial encounters with APCs trigger memory programming (Kaech and
Ahmed 2001). Similarly, LCMV-specific CD4+ T cells have been used to demonstrate the
requirement for TCR signal strength in CD4+ T cell differentiation (Williams, Ravkov et al. 2008)
and a role for CD4+ T cells in rescuing exhausted CD8+ T cells (Aubert, Kamphorst et al. 2011).
TCR transgenic T cells have not only informed T cell biology, but also their interactions
with other immune cells and contribution to immune responses. Proliferation of MHCI-restricted
TCR transgenic CD8+ T cells were used to measure antigen presentation during acute and
recrudescent HSV-1 infection, leading to the identification of CD103+ dermal DCs as dominant
APCs in this model (Mueller, Heath et al. 2002, Bedoui, Whitney et al. 2009). PbA parasites
transgenically modified to express the model protein OVA, recognized by OVA-specific TCR
transgenic CD4+ (OTII) or CD8+ (OTI) cells have revealed a requirement for DCs in inducing CTL
cells (Lundie, de Koning-Ward et al. 2008) and protective CD4+ T cells during Plasmodium
infection (Haque, Best et al. 2014) respectively. A more biologically relevant MHCI-restricted TCR
12
transgenic T cell-expressing mouse that harbors CD8+ T (termed PbTI) cells responsive to a
Plasmodium derived antigen has been generated and was able to protect recipient mice against liver
stage Plasmodium infection (Lau, Fernandez-Ruiz et al. 2014).
Only one TCR transgenic system to date has been used for studying Plasmodium-specific
CD4+ T cells in vivo (Stephens, Albano et al. 2005). The authors of this paper generated CD4+ T
cells reactive to Plasmodium MSP-1 protein (Stephens, Albano et al. 2005). These cells were useful
in determining the role for DC subsets in antigen-presentation during malaria (Sponaas, Cadman et
al. 2006). However, a significant caveat of this reagent was that a second Vα chain was transcribed
alongside the transgenic Vα chain, which may have confounded results. Furthermore, the genetic
background of these transgenic mice (BALB/c) has few available knock-out strains, thus limiting its
application for immunological studies. Currently, no other reagent exists for studying Plasmodium-
specific CD4+ T cells in vivo. This lack of appropriate tools has hampered efforts to understand
many aspects of CD4+ T cell responses during malaria.
1.4.3 Antigen presentation to CD4+ T cells during malaria
DCs are generally regarded as the most proficient APC, and as suggested above, have been
linked to priming T cells during Plasmodium infection. DCs can be divided into two main subsets:
plasmacytoid dendritic cells (pDCs), which express low levels of MHCII and the co-stimulatory
integrin CD11c in steady state, and classical dendritic cells (cDCs), which express high MHCII and
CD11c. pDCs have a key role in the production of type I interferons (TI IFN), which are
particularly important for protection against viral infection. On the other hand, cDCs are superior at
interacting with T cells due to their capacity to phagocytose antigen, upregulate MHCII, express co-
stimulatory molecules such as CD86, CD40 and CD80, as well as produce chemo-attractant
molecules (Villadangos and Schnorrer 2007, Segura and Villadangos 2009, Reizis, Bunin et al.
2011, Joffre, Segura et al. 2012). In secondary lymphoid tissues, in which T cell priming occurs,
cDCs can be subdivided into two main groups based on their differential expression of CD8α and
CD11b (Dudziak, Kamphorst et al. 2007). CD8α+CD11b- cDCs play a unique role in resistance to
certain viral infections due to their ability to process non-replicating antigens for presentation by
MHCI (termed cross-presentation), particularly to CD8+ T cells (den Haan and Bevan 2002, Iyoda,
Shimoyama et al. 2002, Allan, Smith et al. 2003). In contrast, CD8α-CD11b+ cDCs, which also
express Sirpα and Clec4a4 (also known as DCIR2), are more adept at presenting antigen to and
activating CD4+ T cells, with limited capacity for eliciting CD8+ T cell activation (Dudziak,
Kamphorst et al. 2007)
13
The requirement for cDCs in initiating T cell responses during Plasmodium infection has
been demonstrated in a number of studies. During liver-stage infection, depletion of CD11c-
expressing cells resulted in reduced activation of CD8+ T cells (Jung, Unutmaz et al. 2002), which
are required for killing infected hepatocytes expressing Plasmodium antigen in a contact-dependent
manner (Cockburn, Amino et al. 2013, Cockburn, Tse et al. 2014). During blood-stage infection,
the spleen is a major site of both parasite clearance and developing immune responses (Grun, Long
et al. 1985, Chotivanich, Udomsangpetch et al. 2002). The number of cDCs within the spleen
increases considerably during blood-stage infection, as does expression of MHCII, CD40 and CD80
(Perry, Rush et al. 2004). Here, cDCs act as APCs for CD8+ T cells as well, with CD8α+ DCs the
most prominent APC (Lundie, de Koning-Ward et al. 2008). In addition, co-culture of naïve CD4+
T cells with cDCs harvested at day 6 of infection with Py17XNL has been shown to induce T cell
activation and expression of IFNγ, TNFα and IL-2 (Perry, Rush et al. 2004). Moreover, depletion of
cDCs during PbA infection perturbs CD4+ T cell responses, resulting in alleviated immune
pathology within the brain (deWalick, Amante et al. 2007). While both cDC populations are
capable of priming CD4+ T cells during in vivo PcAS infection, ex vivo experiments indicate that
CD8α- cDCs may be more effective than their CD8α+ counterparts (Sponaas, Cadman et al. 2006).
With respect to the involvement of other APCs in T cell responses to blood-stage malaria, a study
by Sponaas et al showed a population of Ly6C+CD11bhi monocytes were generated in the bone
marrow during infection, migrated to the spleen and upregulated MHCII. However, monocytes
sorted from the spleens of day 8 PcAS infected mice displayed limited capacity to induce
proliferation or cytokine production from naïve CD4+ T cells in vitro, suggesting these cells do not
play a significant role in priming naïve CD4+ T cells (Sponaas, Freitas do Rosario et al. 2009).
1.4.4 Differentiation of CD4+ T cells
Activated CD4+ T cells differentiate into a spectrum of T helper cells that provide
specialised responses to different immune challenges. Diversity in CD4+ T cell responses was first
reported in the early 1970’s, but it was not until a seminal study by Mosmann and Coffman in 1986
that CD4+ T cells were subdivided into helper populations (Mosmann, Cherwinski et al. 1986). In
this study, T cell clones were categorised into two subsets termed T helper 1 (Th1) and T helper 2
(Th2), based on patterns of cytokine production. Other Th subsets have since been defined (Figure
1.2). It is generally believed that the differentiation programs of these subsets are predominantly
governed by signals derived from antigen-presenting cells (APC) and the microenvironment at the
time of activation (Coquet, Rausch et al. 2015). However, inherent factors such as the balance of
transcription factor expression or TCR affinity may also contribute to fate decision (Tubo and
Jenkins 2014, Weinmann 2014).
14
Th1 cells are characterised by secretion of IFNγ and TNFα and are associated with
inflammatory responses to intracellular pathogens. Their differentiation is driven by IFNγ and
expression of the master transcription factor T-bet (encoded by Tbx21) (Szabo, Kim et al. 2000,
Szabo, Sullivan et al. 2003). Th1 cells also contribute to the pathogenicity of organ-specific
autoimmune diseases, such as autoimmune type 1 diabetes and multiple sclerosis (MS), as
demonstrated in a mouse model of MS, experimental autoimmune encephalomyelitis (EAE) (Szabo,
Sullivan et al. 2003, Christen and von Herrath 2004, Sospedra and Martin 2005). Th17 cells express
IL-17A, IL-22, IL-21 and the transcription factor RORγt. Like Th1 cells, Th17 cells contribute to
autoimmune diseases including EAE (Sospedra and Martin 2005, Kang, Wang et al. 2013), but can
also provide protection against extracellular pathogens (Curtis and Way 2009). Another population
of Th cells that produce IL-22, but not IL-21 or IL-17A, are termed Th22 cells (Duhen, Geiger et al.
2009). Th22 cells have been isolated from the skin of patients with psoriasis, atopic eczema (AE)
and allergic contact dermatitis (ACD) (Eyerich, Eyerich et al. 2009). Th2 cells are defined by
secretion of IL-4, IL-5 and IL-13 and expression of the transcription factor GATA3. Th2 responses
are induced during helminth infection and provoke production of IL-10 and IL-13, which have a
passive anti-inflammatory effect (Chen, Liu et al. 2012). Th2 cytokines have also been
demonstrated in allergic inflammation such as asthma (Robinson, Hamid et al. 1992). Th9 cells
produce the canonical cytokine IL-9, which promotes production of mucus during airway
inflammation (Kaplan, Hufford et al. 2015). T follicular helper cells (Tfh) were first identified in
human tonsils in the early 2000's and were noted for high expression of the B cell zone-homing
marker (CXCR5) (Breitfeld, Ohl et al. 2000, Kim, Rott et al. 2001, Chtanova, Tangye et al. 2004).
They are now further distinguished by expression of Programmed cell Death Protein-1 (PD1),
Inducible T cell Co-Stimulator (ICOS) and the master transcription factor Bcl-6, and secretion of
IL-21 (Crotty 2011). Differentiation of Tfh cells is promoted by IL-6 and IL-21 (Eto, Lao et al.
2011). Tfh cells are critical for germinal centre reactions, including the differentiation of antigen-
specific B cells into memory or plasma cells and antibody production during T cell dependent B cell
responses (Crotty 2011).
T regulatory cells (Tregs), as previously mentioned, are essential in maintaining peripheral
tolerance to self-antigens and limiting chronic inflammation by regulating the response of other Th
cell subsets. Tregs are characterised by expression of the key transcription factor Forkhead box P3
(FOXP3), CD25, and production of IL-10 and TGF-β (Wing and Sakaguchi 2014). Their
development is driven by recognition of self-antigens, and IL-2 and TGF-β. The importance of
Tregs in central tolerance is demonstrated in mice and humans deficient in Foxp3, who exhibit
hyperactive T helper responses and overproduction of inflammatory cytokines (Brunkow, Jeffery et
15
al. 2001, Ochs, Ziegler et al. 2005). A subset of Tregs differentiates within the thymus, and is
therefore named thymus-derived Tregs (tTregs). However, the differentiation of Tregs can also be
induced in the periphery (pTregs) (Abbas, Benoist et al. 2013). A third, Th1-like, regulatory subset
that produces IL-10, but does not express CD25 or FOXP3 has been classified as T regulatory 1
(Tr1) cells (Groux, O'Garra et al. 1997).
Despite categorisation of T helper cells into subsets there is likely plasticity between them
(Zhu and Paul 2010). Some defining surface markers and cytokines are shared between subsets,
such as IL-22 expression by both Th-17 and Th-22 cells. This crossover has led to scepticism in the
field about whether these are unique bona fide T helper subsets (Ahlfors, Morrison et al. 2014).
Furthermore, individual cells differentiating toward one subset may display patterns of expression
resembling another subset. It has been proposed in a study by Nakayamada et al that differentiating
Th1 cells first transition through a Tfh-like phenotype, by expressing Bcl6 and IL-12 (Nakayamada,
Kanno et al. 2011). Early expression of Tfh markers by pre-Th1 cells is likely initiated by the
activation of STAT4, but this induces transcription of Tbx21 to commit the cells to the Th1 fate
(Nakayamada, Kanno et al. 2011).
16
Figure 1.2 CD4+ T helper cell differentiation. CD4+ T cells are primed through recognition of
antigen bound to MHCII molecules presented by APCs. Under the guidance of external cues,
including cytokines, as well as internal signals, primed CD4+ T cells differentiate into a spectrum of
T helper cells, including T helper 1 (Th1), Th2, Th17, T regulatory (Treg), Th9 and T follicular
helper (Tfh) cells (Russ, Prier et al. 2013).
17
1.4.5 T helper responses provide protection during Plasmodium infection
Th1 responses have long been known to contribute to protective immune responses to
blood-stage Plasmodium infection. Transfer of IFNγ-secreting CD4+ T cells into athymic
Py17XNL-infected mice conferred protection, as manifested by suppressed growth parasite number
and improved resolution of the infection (Amante and Good 1997). Similarly, Plasmodium-specific
IFNγ+ Th1 cells, but not control OVA-specific CD4+ cells, allowed for resolution of PcAS infection
in CD4+-depleted mice (Taylor-Robinson and Phillips 1994). During PbA infection, enhanced
IFNγ+ T-bet+ CD4+ T cells in mice lacking Type I IFN signalling were associated with better control
of infections, including lower morbidity and mortality (Haque, Best et al. 2011, Haque, Best et al.
2014). In human infection, expansion of IFNγ-producing CD4+ T cells was observed during drug-
induced clearance of P. falciparum (Mewono, Agnandji et al. 2009). Additionally, a positive
correlation between serum IFNγ levels and the outcome of infection has fuelled confidence in an
association between Th1 cells and protective immunity (Deloron, Chougnet et al. 1991, Sun,
Schwenk et al. 2003, Kester, Cummings et al. 2009). However, since IFNγ is also produced by
other immune cells, including CD8+ T cells, natural killer (NK) cells, NK T cells and γδ T cells
(Schlub, Sun et al. 2011, Villegas-Mendez, Greig et al. 2012), it is not clear whether IFNγ-secreting
CD4+ T (Th1) cells play the major protective role in humans. A possible mechanism by which Th1
cells provide protection is by IFNγ- and TNFα- mediated activation of innate immune cells, such as
macrophages and natural killer (NK) cells (Taylor-Robinson and Phillips 1998). These cells could
respond by secreting reactive oxygen species (ROS) that directly kill infected erythrocytes (Clark,
Hunt et al. 1987, Taylor-Robinson and Phillips 1998). However, a prolonged proinflammatory Th1
response can also contribute to immunopathology, as demonstrated by resistance to experimental
cerebral malaria (ECM) of PbA infected Tbx21-/-mice (Oakley, Sahu et al. 2013).
An important aspect of clinical immunity is the ability to suppress potentially harmful
inflammatory responses once the infection has been cleared. The number of CD4+ FOXP3+ CD127lo
T cells was higher in healthy Gambian individuals living in rural regions experiencing high seasonal
malaria transmission, compared to individuals living in urban areas with low transmission (Finney,
Nwakanma et al. 2009). These Tregs expressed an effector memory phenotype, and suppressed
cytokine production by CD4+ T cells exposed to Plasmodium antigen (Finney, Nwakanma et al.
2009). Of particular interest was the constant ratio between T-bet+ CD4+ T cells and Treg cells in
individuals during the transmission and non-transmission seasons, suggesting that increased Th1
responses to Plasmodium infection was balanced with a proportionate Treg response. The balance
of inflammation and immunosuppression can also be observed in the outcomes of the two strains of
P. yoelii infection. Depletion of CD25+ Treg cells in BALB/c mice with a monoclonal antibody
18
enabled complete resolution of an otherwise lethal Py17XL infection (Hisaeda, Maekawa et al.
2004). However, depletion of CD25+ Treg cells during Py17XNL infection did not affect either the
parasitemia or the outcome of infection (Hisaeda, Maekawa et al. 2004).
Regulatory mechanisms provided by IL-10-producing Tr1 cells are also present during
Plasmodium infection. IL-10 and IFNγ co-producing cells were observed in stimulated PBMCs
from acutely infected children from The Gambia, Malia and Uganda (Walther, Jeffries et al. 2009,
Jagannathan, Eccles-James et al. 2014, Portugal, Moebius et al. 2014). To demonstrate the function
of Tr1 cells, Couper et al. transferred Il10-/- or wild-type (WT) CD4+ T cells into Rag1-/- mice,
which lack T or B cells, and infected mice with P. yoelii (Couper, Blount et al. 2008). While all
mice eventually succumbed to infection, mice receiving Il10-/- T cells experienced lower
parasitemia, but more severe pathology associated with greater numbers of circulating IFNγ+ CD4+
T cells (Couper, Blount et al. 2008). This data suggests that Tr1 cells have a role in balancing
immune-mediated clearance of parasites with immunopathology.
The role of Tfh cells in the class switching of B cells and production of antibodies make
them another obvious target for enhancing the immune response to Plasmodium (Perez-Mazliah and
Langhorne 2014). Before the characterisation of Tfh cells, PcAS, a model for chronic infection was
observed to have biphasic Th responses. While Th1 cells were observed early during blood-stage
infection, a population of IFNγ- CD4+ T cells were shown to be necessary for B cell responses
(Langhorne, Gillard et al. 1989). This observation coincided with the appearance of an IL-4-
producing CD4+ T-cell population at this later time of infection in both humans and mice
(Langhorne, Gillard et al. 1989, Troye-Blomberg, Riley et al. 1990). These data were interpreted as
an early activation of Th1 cells that controlled parasitemia, followed by a Th2 response that assisted
in activating B cell responses to clear infection (Langhorne, Meding et al. 1989, von der Weid and
Langhorne 1993). However, the frequency of CD4+ T cells able to help B cells to produce
Plasmodium-specific antibodies was much higher than the frequency of IL-4-producing CD4+ T
cells (Langhorne, Gillard et al. 1989). Furthermore, control of PcAS infection and production of
specific IgG responses was possible even in the complete absence of IL-4 (von der Weid, Kopf et
al. 1994). The identification of Tfh cells, specialising in B cell help, provided the answer to this
puzzle. In recent murine studies, therapeutic blockade of PD1 and LAG3 boosted the CD4+ T cell
response and improved parasite clearance in Py17XNL-infected mice (Butler, Moebius et al. 2012).
Further assessment showed that the blockade resulted in a 7-fold enhancement in Tfh numbers and
50-fold enhancement in plasmablast B cells (Butler, Moebius et al. 2012). IL-21-producing cells
have also been identified in people living in malaria-endemic areas, and these have been associated
with increased levels of IgG (Mewono, Matondo Maya et al. 2008, Mewono, Agnandji et al. 2009).
19
Tfh cells exhibit heterogeneity in their phenotype and behaviour during Plasmodium
infection. In Malain malaria-exposed children, a population of circulating memory PD-1+ CXCR5+
Tfh cells possessed phenotypic and functional characteristics of GC Tfh cells (Obeng-Adjei,
Portugal et al. 2015). These cells had a marked downregulation of Bcl6 permitting their exit from
secondary lymphoid organs. Furthermore, longitudinal studies in the same children showed that
expression of CXCR3 was preferentially induced during acute infection and skewed the response of
these cells to more of a Th1 phenotype (Obeng-Adjei, Portugal et al. 2015). These circulating
CXCR3+ Tfh cells had reduced ability to support antibody production by B cells compared to their
CXCR3- counterparts. This could explain the absence of correlation between Tfh responses and
plasma cell numbers and antibody titres or breadth in these children (Obeng-Adjei, Portugal et al.
2015).
1.4.6 CD4+ T cell memory to Plasmodium infection
After the initial wave of antigen-specific proliferation in response to antigen and subsequent
clearance of infection, the number of reactive T cells drops back to levels approximately 100-1000
fold higher than the initial frequency (Buchholz, Schumacher et al. 2016). The remaining cells can
last for the life-time of the host and provide a minimum 1 day advantage in responses to re-infection
(Schlub, Sun et al. 2011). CD4+ T memory cells can be divided into central memory cells, which
are positive for the cell adhesion molecule CD44 and the secondary lymphoid homing molecule
CD62L, and effector memory cells, which are positive for CD44 but negative for CD62L.
Currently, the kinetics of CD4+ memory T cell responses to Plasmodium infection in humans is
unknown. However, in a follow-up study to the Madagascan malaria epidemic of 1987, memory
CD4+ T cell responses to simple peptide epitopes from the Pf155/RESA antigen persisted in the
absence of reinfection for at least 5 years, although both the frequency and magnitude of the
responses were lower than those detected in the same individuals 3 years previously (Migot,
Chougnet et al. 1993).
In experimental studies, MSP-1-specific CD4+ T cells differentiated into effector and central
memory (TEM and TCM) cells during PcAS infection (Stephens and Langhorne 2010). Furthermore,
transfer of CD4+ T cells from immunized mice provided protection against PbA and PcAS infection
even in the absence of B cells, suggesting that memory CD4+ T cells can provide a degree of
protective immunity via a mechanism independent of the humoral response (Grun and Weidanz
1981, Tsuji, Romero et al. 1990, Langhorne 1994). In contrast and as previously mentioned, several
reports from experimental infections suggested that Plasmodium infection may lead to functional
deletion or modulation of activated CD4+ T cells, leading to defective memory responses
20
(Hirunpetcharat and Good 1998, Xu, Wipasa et al. 2002). This has also been hypothesised to be due
to normal contraction of effector cells, which is necessary to regulate inflammatory responses and
thus prevent pathology (Langhorne, Ndungu et al. 2008). The exact reason why T cell memory
responses are not consistently induced in mice and humans remains to be elucidated.
1.4.7 CD8+ T cell during Plasmodium infection
Plasmodium-specific CD8+ T cells contribute to both protection and immunopathogy during
Plasmodium infection. The first scenario occurs during the pre-erythrocytic stage of infection. Upon
infection with sporozoites, CD8+ T cells are primed by CD8α+cDCs in the skin draining lymph
nodes (Chakravarty, Cockburn et al. 2007, Radtke, Kastenmuller et al. 2015). They then migrate to
the liver and destroy infected hepatocytes expressing parasite-derived antigens bound to MHCI
molecules (Chakravarty, Cockburn et al. 2007, Cockburn, Amino et al. 2013). The significance of
CD8+ T cells in generating protection is evident from β2-microglobulin knock-out mice (β2m-/-;
deficient of MHCI expression) that fail to generated protection after attenuated P. berghei
sporozoite challenge (White, Snyder et al. 1996). This protection is likely mediated by a
combination of effector mechanisms including perforin-associated direct killing and pathways
involving IFNγ and TNFα (Butler, Schmidt et al. 2010, Cockburn, Amino et al. 2013).
CD8+ T cells take on a more sinister role during the erythrocytic-stage of severe P.
falciparum infection. Parasite-infected RBCs can sequester in brain, resulting in cerebral malaria.
Studies of the mouse model of cerebral malaria, PbA, have demonstrated that antigen-specific
CD8+ T cells migrate to brain in response to the production of chemokines such as CXCL10 by
local cells (Nitcheu, Bonduelle et al. 2003). Here they target endothelia cells expressing parasite
antigens with secreted IFNγ, perforin and granzyme B, with the latter two being essential for CD8+
T cell pathogenicity (Nitcheu, Bonduelle et al. 2003, Haque, Best et al. 2011). In support of the
involvement of CD8+ T cells in this pathogenicity, mice depleted of CD8+ T cells are immune to
cerebral symptoms of PbA infection, but susceptibility is restored upon adoptive transfer of PbTI
cells (Lau, Fernandez-Ruiz et al. 2014). Given the ethical considerations, it is impossible to explore
the development and mechanism of human CM. However, post-mortem studies of the brains of
Malawian children with CM, have shown that, just as in ECM, small numbers of CD8+T cells can
be found in brain capillaries (Dorovini-Zis, Schmidt et al. 2011). Likewise, a positive association
between CXCL10 expression and CM has been found in the brains of Ghanaian children (Armah,
Wilson et al. 2007). Further studies into the development of ECM, which can be supported by
clinical observations, are still required for developing CM interventions.
21
1.5 Humoral immunity
1.5.1 Antibodies
Antibodies, Y-shaped effector proteins of B cells, are protective against many infections,
including malaria (Chapter 1.3.2). Antibodies can be divided into five classes or isotypes- IgG,
IgM, IgA, IgD, and IgE, with IgG further divided into IgG1, IgG2a/c, IgG2b and IgG3. The base of
the “Y”, the Fc (crystallisable fragment) region, is common within each isotype and determines the
function of the antibody by binding to specific Fc receptors. The arms of the “Y” are called
fragment antigen-binding (Fab) regions and confer antigen specificity. Isotype expression changes
during maturation and response of B cells. For instance, naïve B cells express only surface bound
IgD and IgM, while activated B cells secrete IgG, IgE and IgA, each with more defined roles.
Maturation of B cells occurs in lymphoid tissues such as the spleen.
1.5.2 Micro-architecture of the spleen
Under steady-state conditions, the spleen consists of white pulp and red pulp that can be
visualised macroscopically. Closer examination reveals that white pulp is further divided into B cell
follicles and adjacent T cell zones (Figure 1.3). The B cell follicle contains follicular B cells
(IgMmedIgDhiCD21medCD23hi) and follicular dendritic cells (FDCs). FDCs express the CXCR5
ligand, CXCL13, which acts as a major chemoattractant for B cells and Tfh cells, and may facilitate
the movement of these cells into the follicle (Pereira, Kelly et al. 2010, Victora and Nussenzweig
2012). The T cell zone, also known as the periarteriolar sheath (PALS), contains mostly T cells,
which interact with passing APCs and B cells (Cesta 2006). Blood enters the white pulp through a
central arteriole and disperses via a conduit system through which only small antigenic molecules
can pass(Nolte, Belien et al. 2003). The white pulp is surrounded by the red pulp, which is highly
vascular and consists of various APCs and other immune cells. Red pulp filters the blood for dead
cells and larger foreign material (Nolte, Belien et al. 2003). The area between the red and white
pulps is termed the marginal zone. Different subsets of macrophages, DCs and marginal zone B
cells (IgMhiIgDlowCD21hiCD23low) reside here (Kumararatne, Bazin et al. 1981, Martin and Kearney
2002).
22
Figure 1.3 Architecture of the spleen. The spleen is divided into red and white pulps. Red pulp
contains an array of immune cells and specialises in filtering the blood. The white pulp areas are
subdivided into B cell follicles and neighbouring T cell zones. These are supplied with blood
through a central arteriole and conduit network, and are the foci of antibody production during
infection (Batista and Harwood 2009).
1.5.3 Germinal centre reactions
In the follicle, B cells are activated when they recognise either soluble or bound antigens
presented by APCs via surface immunoglobulins (Ig) that serve as antigen-specific B cell receptors
(BCRs) (Batista and Harwood 2009). This initiates proliferation and differentiation of B cells.
Activated B cells can become extrafollicular plasmablasts, which move out of the follicle and
provide rapid antibody production for early control of infection, or they can remain in the follicle
and initiate germinal centre (GC) reactions. GC B cells are identified by their expression of Fas, η-
glycolylneuraminic acid (ligand of the antibody GL-7), the transcription factor Bcl-6, reduced
expression of CD38 and affinity for peanut agglutinin (Rose, Birbeck et al. 1980, Oliver, Martin et
al. 1997, Naito, Takematsu et al. 2007). GCs begin to develop within follicles approximately 6 days
after antigen exposure (Jacob, Kelsoe et al. 1991). A GC is divided into two distinct regions, the
Dark Zone (DZ) and Light Zone (LZ) (Figure 1.4). The DZ is proximal to the T cell zone and
23
consists almost exclusively of GC B cells. GC B cells in the DZ receive signals from Tfh cells that
migrate to the border of T cell zones and B cell follicles under the direction of CXCR5 (Arnold,
Campbell et al. 2007). In the DZ, GC B cells proliferate and undergo BCR diversification, in which
the enzyme activation-induced deaminase (AID) deaminates cytidine residues in the variable
regions (Batista and Harwood 2009, Dominguez-Sola, Victora et al. 2012, Meyer-Hermann, Mohr
et al. 2012). GC B cells then migrate to the LZ, which is proximal to the marginal zone. Here they
experience clonal selection, whereby B cells with varying BCR affinities compete for antigen
presented by FDCs. Higher-affinity cells are selectively expanded, while lower-affinity cells are
eliminated by apoptosis (Aguzzi, Kranich et al. 2014). Approximately 30% of positively selected
GC B cells return to the DZ to repeat the cycle of somatic hypermutation and selection in a process
termed 'cyclic re-entry', resulting in the progressive improvement of antigen specificity within the
GC B cell pool (Victora, Schwickert et al. 2010). Alternatively, high-affinity GC B cells
differentiate into plasma cells under the control of B-lymphocyte-induced maturation protein 1
(BLIMP-1) and subsequently increase their synthesis and secretion of antibodies (Shaffer, Lin et al.
2002).
Figure 1.4 Germinal centre. The germinal centre is divided into two areas, the light and dark
zones. Frozen spleen section stained with CD35 (Follicular DCs (FDCs), IgD (B cell mantel), and
GFP-expressing germinal centre (GC) B cells. T cell zone is unstained and sits below the germinal
centre. White dashed line shows the division between zones (Victora and Nussenzweig 2012).
24
1.5.4 B cell memory
GC B cells typically undergo apoptosis due to high expression of the death receptor Fas and loss of
expression of the anti-apoptotic molecule Bcl-2 (Liu, Joshua et al. 1989). However, GC B cells can
also differentiate into long-lived antigen-producing plasma cells and quiescent memory B cells
(MBCs) to contribute to immunological memory. There are no common markers for MBCs in mice
other than class switching from IgD. In a study by Tomayako et al, higher expression of CD80,
PDL2 and CD73 was observed on MBCs relative to naïve cells (Tomayko, Steinel et al. 2010).
However, there was extensive heterogeneity within the expression of these markers (Tomayko,
Steinel et al. 2010). In humans, CD27 marks a population of antigen-experienced B cells that are
regarded as MBCs (Sanz, Wei et al. 2008). Longitudinal studies have identified the presence of
long-term MBCs and antibodies specific to Plasmodium in individuals from Thailand and
Madagascar years after infection with P. falciparum (Migot, Chougnet et al. 1995, Wipasa,
Suphavilai et al. 2010). In a prospective study, MBCs specific to two P. falciparum antigens,
AMA1 and MSP1, increased in frequency in responses to acute infection, but then decrease to just
above pre-infection levels following a 6-month period of reduced exposure. The MBC compartment
expanded in a gradual, stepwise fashion after multiple infections in subsequent malaria seasons.
This was compared to the stable antigen-specific MBC population generated in response to tetanus
immunisation to conclude that the Plasmodium-specific MBC compartments does not simply occur
with age, but requires repeated antigen exposure. In line with this, the proportions of individuals
with memory B cells induced after natural exposure or vaccination against various viruses is
typically 60-100% (Nanan, Heinrich et al. 2001, Amanna, Carlson et al. 2007), the range of
individuals in low to moderate endemic regions with antibodies to a given Plasmodium antigen only
reaches 30-60% (Dorfman, Bejon et al. 2005, Weiss, Traore et al. 2010, Wipasa, Suphavilai et al.
2010, Nogaro, Hafalla et al. 2011). Furthermore, in fatal malaria cases, there are significant changes
in splenic architecture, including breakdown in the marginal zone, loss of B cells and reduced
formation of germinal centres (Urban, Hien et al. 2005). This suggests that B cell responses in
malaria patients are compromised and may lead to short-lived clinical protection to malaria
observed in the field.
25
1.6 Innate immunity
1.6.1 Innate immune detection of Plasmodium infection
Malaria is a highly inflammatory disease, known to induce cyclic bursts of fever in infected
individuals (Prakash, Fesel et al. 2006). This inflammation is clear evidence of the visibility of
Plasmodium parasites by the innate immune system. Foreign antigen is identified by innate immune
cells through pattern-recognition receptors (PRRs) expressed on the cell surface or within the
cytoplasm. Among the known Plasmodium antigens recognised by innate cells, are
Glycosylphosphatidylinositols (GPIs) that can be detected by macrophages through surface-bound
Toll-like receptor (TLR) 2 and TLR4 (Krishnegowda, Hajjar et al. 2005). Similarly, malarial
pigment, hemozoin (Hz) has been reported to trigger TLR9-signalling (Coban, Ishii et al. 2005).
When cultured in vitro with human peripheral blood monocytes, Hz purified from the blood of P.
falciparum infected humans resulted in the production of proinflammatory cytokines, chemokines
and nitric oxide (Sherry, Alava et al. 1995, Coban, Ishii et al. 2005). In addition, Hz has been
reported to activate the NALP3 inflammasome of macrophages (Griffith, Sun et al. 2009, Shio,
Eisenbarth et al. 2009). However, the immunogenicity of hemozoin is debatable given observations
by Parroche et al. that hemozoin itself is immunologically inert, but is coated with Plasmodium
DNA that can be recognised through TLR9 (Parroche, Lauw et al. 2007). Recently, Sharma et al.
reported that AT-rich Plasmodium DNA was detected through the intracellular Stimulator of
Interferon Genes (STING) signalling pathway in humans (Sharma, DeOliveira et al. 2011).
Furthermore, using PbA-infected mice, the downstream effector molecules TBK1, interferon
regulatory factor 3 (IRF3) and IRF7 were also implicated in Plasmodium detection. Given that the
innate immune system can clearly detect Plasmodium infection, it seems likely that innate-
signalling pathways may play a role in controlling, and possibly distorting adaptive immune
responses during malaria. However, only one report has provided evidence of this, with MyD88, an
signalling adaptor molecule for surface bound TLRs, promoting IFNγ and TNFα expressing CD4+
T cells during Plasmodium infection(Franklin, Rodrigues et al. 2007).
1.6.2 Interferon regulatory factors
IRFs are a family of nine (IRF1-9) transcription regulators, highly conserved in mice and
humans. IRFs were first identified as transcriptional regulators of type 1 interferons (TI IFNs) and
interferon-stimulated genes (ISGs), but have now been linked with many facets of innate and
adaptive immunity. For example, IRF1, IRF4, IRF5 and IRF8 induce the expression of pro-
inflammatory cytokines in response to PRR activation (Tsujimura, Tamura et al. 2004, Negishi,
26
Ohba et al. 2005, Takaoka, Yanai et al. 2005, Negishi, Fujita et al. 2006). These cytokines can, in
turn, skew the adaptive immune response. For example, IRF1 biases the response towards Th1
differentiation, as demonstrated by defective IFN-γ production and increased IL-4 production in
Irf1-/- mice compared to IRF1 sufficient controls (Taki, Sato et al. 1997). Similarly, Leishmania
infection of Irf4-/- mice elicited decreased differentiation into IFNγ-producing Th1 cells compared
to heterozygous controls (Lohoff, Mittrucker et al. 2002). On the other hand, IRF1, IRF2, IRF4 and
IRF8 have been implicated in the development of hematopoietic cells, including DCs, NK, CD8+ T
and B cells (Matsuyama, Kimura et al. 1993, Ogasawara, Hida et al. 1998, Lu, Medina et al. 2003,
Suzuki, Honma et al. 2004, Tamura, Tailor et al. 2005).
With regards to the role of IRFs in malaria, a whole genome transcriptional array conducted
on splenic CD4+ T cells from PbA-infected mice showed prominent up- and down-regulation of
genes encoding components of type 1 (IFN-α/β) and type 2 (IFN-γ) interferon pathways (Haque,
Best et al. 2011). While the importance of type 2 interferons during malaria is established, the
significance of TI IFNs required further investigation. Mice unresponsive to TI IFN signalling
(Ifnar1-/-) had 10-fold higher levels of serum IFN-γ and significantly more IFN-γ-positive Th cells
during PbA infection compared to mice capable of TI IFN signalling (Haque, Best et al. 2011). This
suggested a role for TI IFNs in suppressing the development of the Th1 response. IRF7 and IRF3
are key transcription factors regulating the expression of TI IFNs, thus their involvement in immune
responses to Plasmodium infection was also investigated. Indeed, IRF7 was demonstrated to be
essential of the suppressive role of TI IFNs (Edwards, Best et al. 2015). However, the same was not
seen of IRF3 (Edwards, Best et al. 2015), highlighting a disconnection between the function of
IRF3 and IRF7 during Plasmodium infection.
1.6.3 Interferon Regulatory Factor 3
IRF3 is typically associated with production of TI IFNs in response to viruses. IRF3 is
constitutively expressed in the cytosol of most cells and activated downstream of a number of cell
membrane or cytosolic nucleic acid detection receptors (Figure 1.5) (Cavlar, Ablasser et al. 2012).
Phosphorylation of IRF3 by kinases such as TBK1 results in its translocation to the nucleus where it
facilitates the expression of TI IFNs and ISGs (Fitzgerald, Rowe et al. 2003, Tarassishin, Bauman et
al. 2013). IRF3, in association with TBK1, has been shown to be important in B cell responses to
CpG (Oganesyan, Saha et al. 2008). Additionally, activated IRF3 mediates apoptosis of virus-
infected cells in an IFN- and p53-independent way (Weaver, Ando et al. 2001).
27
Figure 1.5 Innate signalling pathways converging on Interferon regulatory factor 3 (IRF3).
Pathogen products such as DNA or dsRNA act as ligands for receptors expressed on the cell
surface, in the cytosol and in endosomes, notably TLRs, mitochondrial antiviral-signalling protein
(MAVS/IPS-1) and the DNA sensors, DDX41 and DAI. These activate specific adaptor molecules,
which in turn interact with kinases. The kinase TBK1 phosphorylates cytosolic IRF3 resulting in its
translocation to the nucleus, thereby facilitating its action as a transcription factor for type 1
interferons and other interferon-stimulated cytokines.
Since IRF3 appears to be a convergence point for several PRR-signalling pathways, it is
ideally situated to influence adaptive immune responses. IRF3 has been reported to suppress Th1
responses during viral and bacterial co-infection (Negishi, Yanai et al. 2012), but drive Th1 and
Th17 responses in the central nervous system during EAE (Fitzgerald, O'Brien et al. 2014). During
liver-stage PbA infection of mice, IRF3 has been reported by two independent studies to be a driver
of TI IFN responses (Liehl, Zuzarte-Luis et al. 2014, Miller, Sack et al. 2014). Whether IRF3 is also
involved in shaping adaptive immune responses to blood-stage malaria is currently unknown.
28
1.7 Thesis aims
This thesis aims to explore cellular and molecular mechanisms that modulate Plasmodium-
specific CD4+ T helper responses during experimental blood-stage malaria.
Specifically it aims to:
1. Determine whether a newly developed Plasmodium-specific CD4+ T cell can be effectively
used to track T helper responses.
2. Resolve the process of Th1 and Tfh cell differentiation to gain molecular insight into
mechanisms controlling Th fate decision-making.
3. Investigate whether innate immune signalling pathways can influence Th1 and Tfh-
dependent immune responses during infection.
1.7.1 Thesis outline
The materials and methods used throughout this thesis are described in Chapter 2.
The importance of CD4+ T helper cells for protection against malaria is well established.
However, the molecular and cellular mechanisms underlying their emergence in vivo remain poorly
delineated. A novel Plasmodium-specific TCR transgenic mouse was recently generated by
Professor Bill Heath and Dr Daniel Fernandez Ruiz (Doherty Institute, University of Melbourne),
but its response during in vivo Plasmodium infection was uncharacterised. In Chapter 3, CD4+ T
cells from this transgenic mouse (termed PbTII cells) are tested for their utility in tracking Th
responses in vivo. PbTII cells are shown to proliferate during experimental malaria in a cDC-
dependent manner. In addition, PbTII cells are demonstrated to differentiate into Th1 and Tfh
effector cells, and also regulatory and memory populations.
The bifurcation of PbTII cells into two Th subpopulations offered a unique opportunity to
study the process of fate 'decision-making' of a clonal population during in vivo infection. To this
end, in Chapter 4, single-cell RNA sequencing (scRNAseq) is applied to PbTII cells during the
first week of PcAS infection. By applying a combination of modelling algorithms to the
transcriptomic data, the process of Th1 and Tfh differentiation is resolved. While Cxcr5 is the only
chemokine receptor associating with Tfh fate decision, a number of chemokine receptors, including
Cxcr3, correlate with the Th1 fate decision. ScRNAseq analysis of myeloid populations at the time
of PbTII bifurcation, revealed expression of CXCR3 ligands not only by cDCs, but also
29
Ly6Chiinflammatory monocytes. For the first time, the requirement for inflammatory monocytes in
Th1 responses is confirmed on a functional level.
Given that PRR can detect Plasmodium infection and induce innate immune responses, it is
possible that these influence Th fate decision. In Chapter 5, the first side-by-side comparison of
endosomal and cytosolic PRRs is performed using the PbTII cells. Minor opposing roles for TLR
adaptor molecules, MyD88 and Trif are observed. However, a critical role for the downstream
transcription factor IRF3 in promoting PbTII accumulation, and furthermore, in their differentiation
towards Th1 cells is demonstrated. This requirement corresponded with a role for IRF3 in MHCII
expression by Ly6Chi inflammatory monocytes. Conversely, IRF3 is observed to suppress Tfh
differentiation, GC B cell responses and resulting Plasmodium-specific antibody production in a B
cell-intrinsic mechanism.
Chapter 6 summarises the findings outline in each of the results chapters, their relationship
with each other and how they contribute to a wider scientific understanding of CD4+ T cell
responses during malaria. Finally, future directions of this project will be discussed.
30
Chapter Two:
Materials and methods
2.1 Materials
2.1.1 Mice
Strain Description Reference
C57BL/6J Inbred animal expressing MHC class II (MHCII)
IA(b)
Australian Resource
Centre (Canning
Vale, Western
Australia)
B6.SJL-Ptprca These congenic mice express the leukocyte
surface antigen CD45.1 (also referred to as
Ly5.1) Ptprca (protein-tyrosine phosphatase,
receptor type c, a allele). This maker is used to
distinguish between cells from these mice and
those from WT C57BL/6J mice, which express
CD45.1/Ly5.2.
Australian Resource
Centre (Canning
Vale, Western
Australia)
B6.129S7-
Rag1tm1Mom(Rag1
-/-)
Mice lack mature T and B cell populations due
to a mutation in the recombination activation
gene (RAG) 1. The original mutation was made
in the 129-derived AB1 ES cell line. The
C57BL/6J strain was generated by backcrossing
mice carrying the mutation to C57BL/6J inbred
mice 10 times.
(Mombaerts,
Iacomini et al. 1992)
LysMCre x iDTR F1 generation of LysMCre and iDTR breeding
generating a mouse in which a diphtheria toxin
receptor (DTR) is expressed off the lysozyme M
promoter, such that lysozyme M expressing
Generated in-house
31
myeloid cells can be depleted upon diphtheria
toxin (DT) administration.
CD11c-DOG Mice in which DTR, ovalbumin (OVA) and GFP
are expressed off the CD11c promoter allowing
for depletion of CD11c expressing cells upon
administration of DT.
(Hochweller,
Striegler et al. 2008)
Irf7-/- This mouse was generated by homologous
recombination of an Irf7 gene-targeting construct
in E14-1S cells, and their microinjection into
C57BL/6 blastocysts. A homozygous line was
generated by intercrossing heterozygous mice.
(Honda, Yanai et al.
2005)
Irf3-/- An Irf3 gene-targeting vector was isolated from
the C57BL/6N genomic library and
electroporated into CCE embryonic stem cells
(ESCs). Positive cells were injected into
C57BL/6J blastocysts. Irf3-/- mice were
generated by intercrossing heterozygous mice.
(Sato, Suemori et al.
2000)
Myd88-/- The Myd88 gene was disrupted by homologous
recombination in E14.1 embryonic stem cells
with a targeting vector containing neomycin
resistance gene. Clones with homologous
recombination were microinjected into C57BL/6
blastocysts. Homozygous knock-out mice were
born at Mendelian ratio.
(Adachi, Kawai et al.
1998)
Trif-/- A targeting vector was generated by replacing
the Trif-encoding gene with a neomycin-
resistance gene cassette. This was transfected
into ESCs. Homologous recombinants were
micro-injected into C57BL/6 mice and
heterozygous progenies were intercrossed in
order to obtain a homozygous line.
(Yamamoto, Sato et
al. 2003)
Casp1−/−Casp111 Mice were obtained by backcrossing (Kayagaki, Warming
32
29mt/129mt (Casp1/1
1-/-)
NOD/ShiLtJ Casp1/11 double knockout to
C57BL/6 for more than 10 generations.
et al. 2011)
Mavs-/-(Ips1-/-) A targeting vector was designed to disrupt two
exons harboring the CARD-like domain of IPS-
1. Homozygous knock-out mice were born at
expected Mendelian ratio.
(Kumar, Kawai et al.
2006)
B6(Cg)-
Tmem173tm1.2Cam
b/J
A targeting vector covering the Mpys locus was
transfected into J<8A3.N1 ESCs. Positive clones
were injected into C57BL/6J blastocysts.
Heterozygous mice were intercrossed to achieve
a homozygous line.
(Jin, Hill et al. 2011)
Tlr3-/- To generate these mice, the first exon of the Tlr3
gene was replaced with a neomycin-resistance
cassette flanked by two loxP sites. Chimeric
mice were generated by microinjecting
embryonic stem cells from three positive clones
into C57BL/6 blastocysts. Male chimeric mice
were mated with female and mutation was
confirmed by southern blot.
(Alexopoulou, Holt
et al. 2001)
OTII
MHC class II-restricted, αβTCR transgenic mice,
which express CD4+ T cells that are specific for
the OVA323–339 determinant. This mouse is on
a Rag1-/- background eliminative the expression
of endogenous TCRs.
(Barnden, Allison et
al. 1998)
μMT KO These mice were generated by targeted
disruption of the gene encoding the
immunoglobulin (Ig) u-chain constant region of
IgM. Since IgM is the first immunoglobulin
expressed by pre-immature B cells, homozygous
mutation of this gene results in B cell deficiency.
(Kitamura, Roes et
al. 1991)
PbTII x CD45.1
(PbTII)
MHCII-restricted T cell receptor (TCR)
transgenic PbTII mice were generated using
TCR genes isolated from a IA(b)-restricted
(Fernandez-Ruiz
DL, Ghazanfari et al.
2016)
33
hybridoma originally derived from a T cell line
isolated from a C57BL/6 mouse infected with
blood-stage P. berghei ANKA. Female PbTII
mice were crossed with male B6.SJL-Ptprca.
Mice were maintained as a heterozygous line and
phenotyped by flow cytometry assessment of
Vα2 and Vβ12 transgenes by CD4+ T cells.
2.1.2 Parasites
(Stabilates stored at -80◦C)
Parasite Description Reference
P. berghei ANKA
(PbA)
A transgenic PbA line (231c1l) expressing
luciferase and GFP under the control of the
ef1-α promoter. Lethal experimental model.
C57BL/6 mice succumb to cerebral malaria
after approximately 1 week of infection.
(Franke-Fayard, Janse et al.
2005)
P. chabaudi
chabaudi AS
(PcAS)
A model of resolving infection. C57Bl/6J
mice resolve infection with a standard dose
within 15 days.
(Stephens, Culleton et al.
2012)
P. yoelii 17X non-
lethal (Py17XNL)
Model of resolving infection. C57Bl/6J mice
resolve infection with a standard dose by day
30.
(Amante and Good 1997)
2.1.3 Infections
Consumable/Reagent Source
5ml tubes Greiner Labortechnik (Frickenhausen,
34
Germany)
30mL tubes Sarstedt (Pookara, Australia)
Haemocytometer Pacific Laboratory Product (Blackburn, VIC,
Aus)
Immersion oil Merck (Darmatadt, Germany)
CliniPure Haem Kwik Fixative Grale Scientific (Ringwood, VIC, Aus)
CliniPure Haem Kwik Stain No 1 Grale Scientific (Ringwood, VIC, Aus)
CliniPure Haem Kwik Stain No 2 Grale Scientific (Ringwood, VIC, Aus)
Heparin 5000 IU in 5mL Pfizer (New York, NY, USA)
Trypan Blue 0.4% Thermo Fischer Scientific
Sodium chloride 0.9% Baxter (Toongabbie, NSW, Aus)
1mL Syringe Terumo (Tokyo, Japan)
26 G needle Terumo (Tokyo, Japan)
2.1.4 Harvesting tissues
Consumable/Reagent Source
1mL Insulin syringe and 18 gauge needle Terumo (Tokyo, Japan)
10mL tubes Sarstedt(Pookara, Aus)
1.5mL eppendorf tube VWR (Radnor, PA, USA)
2.1.5 Processing spleens
Consumable/Reagent Source
Petri dishes Greiner Labortechnik (Frickenhausen,
35
Germany)
Falcon Yellow 100uM Nylon Strainer Fischer Scientific (Waltham, MA, USA)
Deoxyribonuclease 1 100mg Worthington Biochemical
Corporation(Lakewood, NJ, USA)
5ml syringe Terumo (Tokyo, Japan)
Collagenase Type 4 100mg Worthington Biochemical Corporation
(Lakewood, NJ, USA)
2.1.6 Cell transfer
Consumable/Reagent Source
MS columns Miltenyi Biotec (Bergisch Gladbach,
Germany)
LS columns Miltenyi Biotec (Bergisch Gladbach,
Germany)
Octomagnant Miltenyi Biotec (Bergisch Gladbach,
Germany)
CD4 (L3T4) Microbeads Miltenyi Biotec (Bergisch Gladbach,
Germany)
CD11b Microbeads Miltenyi Biotec (Bergisch Gladbach,
Germany)
MACS stand Miltenyi Biotec (Bergisch Gladbach,
Germany)
Vacuum-driven filter 500mL Merck Millipore (Darmstadt , Germany)
36
2.1.7 In vivo cell depletions
Consumable/Reagent Source
Diptheria toxin from Corynebacterium
diptheriae
Sigma Aldrich Pty Ltd (St Louis Missouri,
USA)
anti-CD4 depleting monoclonal antibody
(clone GK5.1)
BioXCell (West Lebanon, NH, USA)
anti-CD20 depleting (clone 5D2) Genentech (South San Francisco, CA, USA)
2.1.8 Flow cytometry reagents and materials
Consumable/Reagent Source
CELLSTAR Falcon tube (50mL) Greiner Labortechnik (Frickenhausen,
Germany)
18 G needle Terumo (Tokyo, Japan)
Falcon Centrifuge tubes (5mL) Corning (Corning, NY, USA)
RBC Lysis Buffer Sigma Aldrich Pty Ltd (St Louis Missouri,
USA)
Pipette 5mL Sarstedt (Pookara, Aus)
Pipette 10mL Sarstedt (Pookara, Aus)
Pipette 25mL Sarstedt (Pookara, Aus)
Corning Costar U bottom 96-well plates Sigma Aldrich Pty Ltd (St Louis Missouri,
USA)
BD FACS lysing solution BD Biosciences (Franklin Lakes, NJ, USA)
Foxp3 Staining Buffer Set eBioscience (San Diego, CA, USA)
Sucrose Chem-supply (Gillman, SA, Aus)
37
Ionomycin calcium salt from Streptomyces
conglobatus powder
Sigma Aldrich Pty Ltd (St Louis Missouri,
USA)
Phorbol 12-myristate 13-acetate (PMA) Sigma Aldrich Pty Ltd (St Louis Missouri,
USA)
Brefeldin A (BFA) Sigma Aldrich Pty Ltd (St Louis Missouri,
USA)
Dulbecco's Phosphate buffered saline (dPBS) Sigma Aldrich Pty Ltd (St Louis Missouri,
USA)
Percoll Sigma Aldrich Pty Ltd (St Louis Missouri,
USA)
2.1.9 Antibodies and dyes
Antibody/Dye Clone Source
Rat α mouse CD4-BV605 RM4-5 BD Biosciences (Franklin
Lakes, NJ, USA)
Hamster α mouse TCRb-APCCy7 H57-597 Biolegend (San Diego, CA,
USA)
Hamster α mouse CD69- PE H1.2F3 Biolegend (San Diego, CA,
USA)
Biotin Rat α mouse CXCR5 2G8 BD Biosciences (Franklin
Lakes, NJ, USA)
Rat α mouse Vα2-FITC B20.1 Biolegend (San Diego, CA,
USA)
Rat α mouse CXCR6- PE SA051D1 Biolegend (San Diego, CA,
USA)
Rat α mouse Vβ12-TCR PerCP-
eFluor710
MR11-1 eBioscience (San Diego, CA,
USA)
Hamster α mouse CD279 (PD-1)- APC-
eFluor 780
J43 eBioscience (San Diego, CA,
USA)
38
Rat α mouse CD279 (PD-1)-APC 29F.1A12 Biolegend (San Diego, CA,
USA)
Rat α mouse ICOS-PE 7E.17G9 eBioscience (San Diego, CA,
USA)
Mouse α mouse CD45.1-FITC A20 Biolegend (San Diego, CA,
USA)
Mouse α mouse CD45.1-Alexa Fluor
700
A20 Biolegend (San Diego, CA,
USA)
Streptavidin- BV605 Biolegend (San Diego, CA,
USA)
Streptavidin-PercpCy5.5 Biolegend (San Diego, CA,
USA)
Streptavidin-PeCy7 Biolegend (San Diego, CA,
USA)
Mouse α-mouse CD45.2-Alexa Fluor
700
104 Biolegend (San Diego, CA,
USA)
Hamster α mouse CD11c-APC N418 Biolegend (San Diego, CA,
USA)
Hamster α mouse CD11c- PercpCy5.5 N418 eBioscience (San Diego, CA,
USA)
Rat α mouse MHCII(I-A/I-E)-Pacific
Blue
M5/114-15.3 Biolegend (San Diego, CA,
USA)
Rat α mouse MHCII(I-A/I-E)-APC M5/114-15.3 Biolegend (San Diego, CA,
USA)
Rat α mouse Ly6C-FITC HK1.4 Biolegend (San Diego, CA,
USA)
Rat α mouse Ly6G-PE 1A8 Biolegend (San Diego, CA,
USA)
Rat α mouse B220-APCCy7 RA3-6B2 Biolegend (San Diego, CA,
USA)
Hamster α mouse TCRβ-BV605 H57-597 BD Biosciences (Franklin
Lakes, NJ, USA)
Hamster α mouse TCRβ-APCCy7 H57-597 Biolegend (San Diego, CA,
USA)
39
Rat α mouse CD8a-PECy7 53-6.7 Biolegend (San Diego, CA,
USA)
Rat α mouse CD172a (Sirpα)-FITC P84 Biolegend (San Diego, CA,
USA)
Rat α mouse CD11b-PercpCy5.5 M1/70 Biolegend (San Diego, CA,
USA)
Rat α mouse CD11b-BV421 M1/70 Biolegend (San Diego, CA,
USA)
Rat α mouse CD86-PE GL1 Biolegend (San Diego, CA,
USA)
Hamster α mouse CD80-PE 16-10A1 Biolegend (San Diego, CA,
USA)
Rat α mouse CD40-PE 1C10 eBioscience (San Diego, CA,
USA)
Rat α mouse CD38- Pacific Blue 90 Biolegend (San Diego, CA,
USA)
Rat α mouse B220-Alexa Fluor 700 RA3-6B2 Biolegend (San Diego, CA,
USA)
Rat α mouse CD138-BV605 281-2 Biolegend (San Diego, CA,
USA)
Rat α mouse CD80-PercpCy5.5 16-10A1 Biolegend (San Diego, CA,
USA)
Rat α mouse CD73-PE TY/23 BD Biosciences (Franklin
Lakes, NJ, USA)
Rat α mouse CD19-FITC 6D5 Biolegend (San Diego, CA,
USA)
Rat α mouse GL7-eFluor660 GL-7 eBioscience (San Diego, CA,
USA)
Hamster α mouse CD95 (FAS)- PeCy7 Jo2 BD Biosciences (Franklin
Lakes, NJ, USA)
Rat α mouse CD23-APC B3B4 Biolegend (San Diego, CA,
USA)
Rat α mouse CD21/CD35-PercpCy5.5 7E9 Biolegend (San Diego, CA,
USA)
40
Rat α mouseIFNγ-BV421 XMG1.2 Biolegend (San Diego, CA,
USA)
Rat α mouseIFNγ-PeCy7 XMG1.2 Biolegend (San Diego, CA,
USA)
Mouse α human/mouse Tbet-eFluor660 eBio4B10 eBioscience (San Diego, CA,
USA)
Mouse α mouse Bcl2-Alexa Fluor 647 BCL/10C4 Biolegend (San Diego, CA,
USA)
Rat α human/mouse RoRγT-APC AFKJS-9 eBioscience (San Diego, CA,
USA)
Rat α mouse FOXP3-Alexa Fluor 647 MF-14 Biolegend (San Diego, CA,
USA)
Rat α mouse IL-17A- BV605 TC11-18H10.1 Biolegend (San Diego, CA,
USA)
Rat α human/mouse GATA3-PerCP-
eFluor 710
TWAJ eBioscience (San Diego, CA,
USA)
Rat α mouse IL-10-BV421 JES5-16E3 Biolegend (San Diego, CA,
USA)
Rat α mouse IL-4-PE 11B11 BD Biosciences (Franklin
Lakes, NJ, USA)
Rabbit α human/mouse TCF-1- PE CD63D9 Cell Signaling Technology
(Danvers, MA, USA)
Hamster α mouse CXCL9-PE MIG-2F5.5 Biolegend (San Diego, CA,
USA)
Rat α rat/mouse Ki67-PE SolA15 eBioscience (San Diego, CA,
USA)
Mouse α human/mouse Bcl6-
PercpCy5.5
K112-91 BD Biosciences (Franklin
Lakes, NJ, USA)
Mouse α human/mouse Bcl6-PE K112-91 BD Biosciences (Franklin
Lakes, NJ, USA)
Hamster α mouse CD183 (CXCR3)- PE CXCR3-173 Biolegend (San Diego, CA,
USA)
Syto-84 Life Technologies (Carlsbad,
CA, USA)
41
Hoechst 33342 Sigma Aldrich Pty Ltd (St Louis
Missouri, USA)
CellTrace Violet ThermoFisher Scientific
(Massachusetts, USA)
Zombie Aqua Dye Biolegend (San Diego, CA,
USA)
2.1.10 Plasmodium-specific ELISA
Reagent Source
Corning Costar Flat bottom 96-well plates Greiner Labortechnik (Frickenhausen,
Germany)
OPD Sigma Aldrich Pty Ltd (St Louis Missouri,
USA)
Tween 20
Sigma Aldrich Pty Ltd (St Louis Missouri,
USA)
Streptavidin-HRP BD Biosciences (Franklin Lakes, NJ, USA)
Anti-IgM, total IgG, IgG1, IgG2b and IgG3 Jackson ImmunoResearch (West Grove, PA,
USA)
2.1.11 Single-cell RNA sequencing (scRNAseq)
Reagent Source
C1™ IFC for mRNA seq (5-10 μm) Fluidigm (San Fransisco, CA, USA)
C1™ Single-Cell Auto Prep Reagent Kit for
mRNASeq
Fluidigm (Fransisco, CA, USA)
42
Clontech SMARTer® Kit Designed for the
C1™ System, 10 IFCs
Takara Bio USA (formally Clontech)
(Mountain View, CA, USA)
Nextera XT DNA Sample Preparation Kit Illumina, (San Diego, CA, USA)
Nextera XT DNA Sample Preparation Index
Kit (96 indices, 384 samples)
Illumina (San Diego, CA, USA)
ArrayControl™ ERRC RNA Spikes Life Technologies (Carlsbad, CA, USA)
AMPure XP beads Beckman Coulter (Brea, CA, USA)
2.1.12 Media and stock solutions
RPMI/PS:- 10mL penicillin; 1L RPMI prepared in-house by QIMRB core services
PBS:- Prepared in-house by QIMRB core services
FACS Buffer:- Bovine serum albumin (BSA) (Life Technology) 100g/L; 10%w/v Sodium Azide
1ml/L; 0.5M EDTA in PBS pH8 (Sigma)10ml/L; 1L PBS; filtered and de-gassed through 0.2μm
bottle-top filter at 4oC for 20 minutes.
MACS Buffer:- BSA 100g/L; 0.5M EDTA 10ml/L; 1L PBS; filtered and de-gassed through 0.2um
bottle-top filter at 4oC for 20 minutes.
Fetal Calf Serum (FCS):- Fetal calf serum (Bovogene) was heat inactivated at 56oC for 1 hour.
FACS Block:- Generated in-house by harvesting supernatant of 120/G8 hybridoma to block against
Fc receptor.
4% PFA:- Paraformaldehyde powder (MP Biomedicals, USA) 4g/100mL; PBS 100mL; added
~20μL NaOH while gently heating and stirring until powder dissolves. Add HCL until pH is 7.
Aliquots of this were stored at -20oC until use. 1-2% PFA was made with the addition of PBS just
prior to use.
1.6% saline:- 0.16g saline; 100mL sterile milli-Q water
12% saline:- 1.2g saline; 100mL sterile milli-Q water
33% Percoll:- 1:3 v:v of Percoll in PBS
43
ELISA coating buffer:-1 L PBS; 1.59g Na2CO3; 2.93g NaHCO3; adjust pH to 9.6; filtered
ELISA blocking buffer:- 1 L PBS; 1% BSA; 0.05% Tween 20; filtered
ELISA wash buffer:- 05mL Tween20; 1L PBS.
PcAS and Py17XNL antigens:- prepared in house
2.2 Methods
2.2.1 Mice and ethics
Mice used for single-cell RNAseq experiments were maintained under specific pathogen-
free conditions at the Wellcome Trust Genome Campus Research Support Facility (Cambridge,
UK). These animal facilities are approved by and registered with the UK Home Office. All
procedures were in accordance with the Animals (Scientific Procedures) Act 1986. The protocols
were approved by the Animal Welfare and Ethical Review Body of the Wellcome Trust Genome
Campus.
All other C57Bl/6, Rag1-/-, Irf7-/-, Irf3-/-, Myd88-/-, Trif-/-, Casp1/11-/-, Mavs-/-, Tmem173-/-,
Tlr3-/-, CD11c-Cre, LysMCre x iDTRand μMT mice (all on a C57BL/6J background) were
maintained in-house at QIMR Berghofer Medical Research Institute. PbTII mice were maintained
as crosses with B6.SJL-Ptprca mice at QIMR Berghofer Medical Research Institute, and typed for
the presence of the PbTII TCR by flow cytometric assessment of peripheral blood CD4+ T cells for
co-expression of Vα2 and Vβ12.Animal procedures here were approved and monitored by the
QIMR Berghofer Medical Research Institute Animal Ethics Committee (approval no. A02-633M)
in accordance with Australian National Health and Medical Research Council guidelines.
All mice were female unless otherwise stated and used at 8-12 weeks of age.
44
2.2.2 Adoptive transfer of Plasmodium-specific CD4+ T (PbTII) cells
Spleens from PbTII mice were aseptically removed and collected into a 10mL
polypropylene tube containing 10mL of RPMI/PS. Spleens were mechanically homogenised
through a 100μm strainer with a 5mL syringe and transferred back into original 10mL tube. Cells
were pelleted by centrifuge at 1200rpm for 7 minutes at room temperature. The supernatant was
discarding before lysis of erythrocytes with 5mL of RBC lysis buffer for 5 minutes at room
temperature. The lysis buffer was quenched by topping up the tube with freshly made ice-cold
MACS buffer, and cells were pelleted as before, but at 4oC. The supernatant was discarded. Cells
were resuspended in 400μL of MACS buffer and 100μL of CD4+ microbeads and incubated for 15
minutes on ice and in the dark. In this time, the octomagnet was attached to the MACS stand and an
MS column was attached to the magnet. The column was equilibrated with 1mL of MACS buffer.
Cells were washed with MACS buffer, centrifuged as before and the supernatant discarded. Cells
were resuspended in 1mL MACS buffer. Using a 1mL pipette, cells were carefully passed through a
100μM cell strainer suspended above the MS column. The column was washed three times with
0.5mL of MACS buffer, allowing each wash to completely flow through before the addition of the
next. After the final wash, the column was removed from the magnet and placed in a new 10mL
tube. 1mL of MACS buffer was added to the column then, using force, cells were eluted from the
column with a plunger. Cells were washed with RPMI/PS, centrifuged and the supernatant
removed. Enriched cells were resuspended in 1mL RPMI/PS and counted with a haemocytometer.
10μL of cell suspension was stained for expression of CD4, TCRβ, Vα2 and Vβ12 and assessed by
flow cytometric methods for purity of enriched cells (purity typically >80% CD4+TCRβ+). Cells
were diluted to the desired concentration in RPMI/PS and injected into mice via a lateral vein using
a 1mL syringe and 18-gauge needle.
2.2.3 CellTrace violet labelling of cells
Cells were washed twice in PBS and resuspended in 1mL of PBS per 107 cells. 1μL of 1mM
CellTrace™ Violet dye in PBS was added for each 1mL of cell suspension. Cells were incubated at
37oC in the dark for 15 minutes. Cells were washed twice in RPMI/PS before being counted with a
45
haemocytometer and purity assessed by flow cytometry as above. Cells were resuspended in
RPMI/PS and injected via a lateral tail vein.
2.2.4 Infections
Plasmodium chabaudi chabaudi AS (PcAS), Plasmodium yoelii 17XNL (Py17XNL) and
Plasmodium berghei ANKA (PbA) infected red blood cells (obtained from frozen stocks) were
passaged through a C57Bl/6J mice prior to being used. Mice were infected intravenously via a
lateral tail vein with 1x104 (Py17XNL) or 1x105 (PcAS and PbA) freshly prepared parasitised RBC
(pRBC) in 200μL RPMI. Blood parasite burden (parasitemia) was measured from thin blood smears
obtained from tail bleeds. Alternatively, parasitemia was measure by taking one drop of blood from
the tail into 250μL of RPMI containing 5U/mL heparin sulphate and stained with 5μM Syto84 to
detect RNA, and 10ug/mL Hoechst33342 to detect DNA, for 30 minutes in the dark and at room
temperature. Staining was quenched with 10x initial volume of RPMI and samples were analysed
immediately by flow cytometry, using a BD FACS Canto II Cell Analyser (BD Biosciences) and
FlowJo software (Treestar, CA, USA).
2.2.5 In vivo cell depletion
2.2.5.1 CD4+ T cells
Depletion of CD4+ T cells was achieved by administering mice with 0.1mg of anti-CD4 depleting
monoclonal antibody (clone GK5.1) or an isotype control in 200μL 0.9% saline (Baxter) by
intravenous (i.v.) injection, one day prior to infection.
2.2.5.2 CD11c+ dendritic cells
Depletion of conventional CD11c+ dendritic cells was achieved using CD11c-DOG mice. Mice
were administered 160ng of DT (Sigma Aldrich) in 200μL of 0.9% saline (Baxter).
46
2.2.5.3 LysM+ monocytes/macrophages
Cellular depletion in LysMCre x iDTR mice was performed by intraperitoneal (i.p.) injection of
10ng/g DT (Sigma-Aldrich) in 200μL 0.9% saline (Baxter) per mouse at 3 day post-infection.
Control mice were given saline only.
2.2.5.3 B cell depletion
For B cell depletion, anti-CD20 (Genentech) or isotype control antibody was administered in a
single 0.25mg dose via i.p. injection in 200μL 0.9% saline (Baxter), 7 days prior to infection.
2.2.6 Euthanasia
Mice were sacrificed by asphyxiation with 80:20 mix of CO2:O2 and doused with 80% ethanol.
2.2.7 Processing tissues
2.2.7.1 Spleens
Spleens were collected into 10mL of RPMI/PS. When assessing myeloid cell populations,
spleens were incubated in Deoxyribosnuclease and collagenase for 25 minutes with constant
agitation. A cell suspension was created by homogenising each spleen through a 70μm cell strainer
with a 5mL syringe. RBCs were lysed with RBC lysing buffer (Sigma) for 5 minutes at room
temperature and splenocytes were washed once in RPMI/PS. Cell numbers were calculated from a
haemocytometer with Trypan Blue exclusion (Sigma-Aldrich). Following processing of tissue,
approximately 1/20th of total splenocytes diluted in 200μL of RPMI was transferred into a U-
bottomed 96-well plate.
47
2.2.7.2 Blood
Whole blood was harvested via cardiac bleed using a 26-gauge insulin syringe with needle
into a lithium/heparin tube for plasma or into Eppendorf’s containing 250μL of 1000ug heparin in
RPMI/PS for flow cytometry. Each blood sample was pelleted at 1200rpm for 5 minutes in a bench-
top centrifuge. The supernatant of was removed with a 1mL pipette. Samples were stained as
described below and then washed twice with FACS buffer. Red blood cells were lysed with BD
FACS Lysing solution for 7 minutes at room temperature, while mechanically disrupting the pellet
by pipetting up and down. Samples were washed twice as before.
2.2.7.3 Liver
Mice were perfused by injecting d-PBS through the heart. Livers were collected into 5mL of
PBS. Livers were digested in deoxyribosnuclease and collagenase for 25 minutes with constant
agitation before being homogenised through mesh. Liver cells were transferred into a new 50mL
FALCON tube, topped up to 50mL with cold PBS/2% FCS and pelleted for 7 minutes at 1200 rpm.
The supernatant was removed and the cells were washed again in 40mL of PBS/2% FCS. After
removing the supernatant, cells were resuspended in 25mL of 33% Percoll in PBS. Cells were spun
at room temperature for 12 minutes at 1700 rpm and with the brake off. Carefully, the top layer and
supernatant were removed from the pellet with a Pasteur pipette. RBCs were lysed with RBC lysing
buffer for 5 minutes at room temperature and cells were washed once in RPMI/PS. Cell were made
up to 200μL in RPMI/PS and a fraction taken for cell count by haemocytometer with Trypan Blue
exclusion. The remaining liver cells were transferred to a 96-well plate for staining.
2.2.7.4 Bone marrow
Hind limbs were removed from mice and collected into 25mL of RPMI/PS. Working
aseptically, tissue was removed from limbs to leave only femurs. The ends of bones were removed
with a scalpel. Using an 18-gauge needle and 10mL syringe filled with RPMI/PS, bone marrow was
flushed from the femurs in a new 50mL FALCON tube containing 10mL of RPMI/PS. Cells were
pelleted at 1200rpm for 10 minutes. Red blood cells were lysed with 5mL of lysis buffer for 5
minutes. Cells were washed twice with RPMI before being counted with a haemocytometer and
diluted to the appropriate concentration in RPMI/PS.
48
2.2.8 Bone marrow chimeric mice
Bone marrow (BM) chimeric mice were generated by injecting 2x106 syngenic BM cells
freshly harvested from the femurs of Ptprca (CD45.1) Irf3-/-, or μMT mice (described in section
2.2.7.4) into lethally irradiated (11Gy (137Cs source)) WT or Irf3-/- recipient mice via a lateral tail
vein. Recipient mice were treated with Baytril (100μg/mL enrofloxacin) in drinking water 7 days
prior to and 4 weeks following irradiation. At six weeks post-transplantation, engraftment was
assessed by flow cytometry. BM was allowed to reconstitute for 8 weeks following transplantation
before mice were used for experiments.
2.2.9 Flow cytometry
2.2.9.1 Live/Dead stain
Samples were washed twice by topping up wells to 200μL with PBS, centrifuging at
1200rpm for 4 minutes at room temperature, removing supernatant by quickly flicking the plate and
resuspending cells by gently vortexing. Cells were stained with 50μL of zombie dye diluted at
1:400 in PBS for 15 minutes in the dark and at room temperature. Samples were washed twice with
cold FACS buffer as before but at 4oC.
2.2.9.2 Surface stain
Fc receptors were blocked by incubating cells in 100μL of FACS block for 10 minutes on
ice. The plate was centrifuged, the block removed by quickly flicking and cells resuspended by
gently vortexing. The samples were stained 50μL of surface monoclonal antibodies made up in
FACS buffer for 20 minutes on ice. Cells were washed twice with cold FACS buffer.
2.2.9.3 Secondary antibody stain
Secondary antibody diluted in FACS buffer was added to each sample and incubated on ice
for 15 minutes. Cells were washed twice further.
49
2.2.9.4 Intracellular stain with eBioscience Foxp3 intracellular kit
Approximately 200μL of a 5mL preparation of homogenised spenocytes were transferred
into a 96 well U-bottom plate. Cells were pelleted by centrifuge for 4 minutes at 1200rpm. To each
sample, 200μL of 10μg/mL BFA, 10% FSC in RPMI/PS was added. For IL-10/IFNγ restimulation,
25ng/ml of PMA and 500ng/ml Ionomycin was also added to BFA cocktail. Cells were incubated
for 3 hours at 37oC. Cells were pelleted and washed twice with RPMI/PS, and surface stain was
performed as above. Following surface staining, cells were fixed and permeabilised by adding
100μL of freshly made Fix/perm solution and incubated on ice for 30 minutes, according to the
eBioscience Foxp3 intracellular staining protocol. Cells were washed twice with Perm buffer.
Intracellular antibodies diluted in Perm buffer were added and incubated for 1 hour on ice. Cells
were washed twice as before.
2.2.9.5 Detection of apoptosis
Following surface staining of samples, cell surface display of phosphatidylserine was
detected using the Annexin V-PE apoptosis Detection Kit I (BD Biosciences).
2.2.10 FACS acquisition
Samples were fixed in 2% paraformaldehyde and transferred into 5ml polypropelene FACS
tubes for acquisition on a BD LSR Fortessa Cell Analyser (BD Biosciences), MoFlo XDP
(Beckman Coulter) or a FACS Aria II (Becton Dickinson) instrument. Data were analysed using
FlowJo software (Tree Star).
2.2.11 ELISA analysis of Plasmodium-specific immunoglobulins in serum
Costar EIA/RIA 96-well flat bottom plates were coated overnight at 4oC with100μL/well of
2.5μg of soluble whole parasite lysate/ml in bicarbonate coating buffer. Wells were washed three
times (all washes in 0.005% Tween in PBS) and then blocked for 1hr at 37oC with 1% BSA in PBS
(Blocking buffer). Wells were washed three times and 100μL of sera diluted to 1/400, 1/800, 1/1600
50
or 1/3200 was added before being incubated for one hour at 37oC. Following six washes, wells were
incubated in the dark with biotinylated anti-IgM, total IgG, IgG1, IgG2b and IgG3 for one hour at
room temperature. Unbound antibodies were washed off (six times) prior to incubation with
streptavidin HRP in the dark for 30 minutes at room temperature. Wells were washed six times and
developed with 100μL of OPD for 3-5 minutes in the dark before termination with an equal volume
of 1M HCl. Absorbance was determined at 492nm using a Biotek synergy H4 ELISA plate reader
(Biotek, USA). Data were analysed using Gen5 software (version 2) and GraphPad Prism (version
6).
2.2.12 Single-cell mRNA sequencing
Activated PbTII T cells were sorted as CD4+ TCRβ+ CD4+ and CD69+ and/or divided at least
once as measured using the CellTrace proliferation dye. Dendritic cells were sorted as lineage
negative, CD11chi and MHCIIhi. Naive dendritic cells were further sorted as CD8α+ and CD11b- or
CD8α- and CD11b+. Inflammatory monocytes were identified as lineage negative, CD11bhi, Ly6Chi
and Ly6Glo.
Single cell capture and processing was performed using the Fluidigm C1 system as in
(Mahata, Zhang et al. 2014). The cell suspension obtained from sorting (made to 5000 cells/3μL)
was loaded on to the Fluidigm C1 platform using small–sized capture chips (5-10μm cells). 1 μL of
a 1:4000 dilution of External RNA Control Consortium (ERCC) spike-ins (Ambion, Life
Technologies) was included in the lysis buffer. Reverse transcription and preamplification of cDNA
were performed using the SMARTer Ultra Low RNA kit (Clontech). The sequencing libraries were
prepared using Nextera XT DNA Sample Preparation Kit (Illumina), according to the protocol
supplied by Fluidigm (PN 100-5950 B1). cDNA from each sample were barcoded (Illumina).
Libraries from up to 96 single cells were pooled and purified using AMPure XP beads (Beckman
Coulter). Pooled samples were sequenced on an Illumina HiSeq 2500 instrument, using paired-end
100-base pair reads. Depth was 1-6 million reads per cell.
51
2.2.13 Processing scRNAseq data and quality control
Reads were mapped to the Mus musculus genome (Ensembl version 38.75) concatenated
with the ERCC sequences, using GSNAP (version 2014-05-15_v2) with default parameters. Gene
expressions were quantified from the samples using Salmon (version 0.4.0) (Patro 2015). For
quality control of the single-cell data the number of input read pairs, and the amount of
mitochondrial gene content were assessed. Samples with fewer than 100,000 reads or more than
35% mitochondrial gene content, as well as cells where the number of genes detected was less than
100 + 0.008 * (mitochondrial content) were considered as failed. These were removed from further
analysis, and the remainder of the samples were taken as individual single cells. For expression
values, the Transcripts Per Millions (TPM's) estimated by Salmon (Patro 2015) included ERCC
spike-ins. Thus, for analysis of the cells, ERCC's were removed from the expression table and
TPM's scaled so they again summed to a million. This generated endogenous TPM values,
representing the relative abundance of a given gene within a cell. Also, genes were filtered for
expression in at least three cells at minimum level of 1 TPM prior to analysis, unless stated
otherwise.
2.2.14 Statistics
Single-cell RNAseq reads were analysed using R and RStudio software. Comparison
between two groups was performed using non-parametric Mann-Whitney tests. Comparisons
between multiple groups were performed using a one-way ANOVA or Two-way ANOVA with
Tukey's test for multiple comparisons. Graphs with individual points show median value, and bar
graphs display mean values ± SEM. p<0.05 was considered significant (p<0.05=*, p<0.01=**,
p<0.001=***, p<0.0001=****). All statistical analyse was performed using GraphPad Prism 6
software (San Diego, CA, USA).
52
Chapter Three:
Assessing the utility of Plasmodium-specific TCR transgenic CD4+ T
cells for studying T helper responses during experimental blood-stage
malaria
3.1 Abstract
Antigen-specific T helper cell responses have well-established roles in immunological
protection against malaria in humans and experimental mice. However, studying these responses in
vivo has proven difficult, partly due to an absence of appropriate Plasmodium-specific reagents.
Here, a newly generated MHCII-restricted TCR transgenic CD4+ T cell line was tested for its utility
in studying Plasmodium-specific T helper cell responses during blood-stage infection. CD4+ T cells
from PbTII TCR transgenic mice (PbTII cells) proliferated in response to multiple Plasmodium
strains, in a manner dependent on cDCs and MHCII. Furthermore, PbTII cells differentiated into
both Th1 and Tfh cells, but not other Th subsets, within the same animals during the first week of
infection. Moreover, the PbTII Th response closely resembled the endogenous polyclonal response.
Finally, PbTII cells also displayed Tr1, and effector and central memory phenotypes during the later
stages of infection. Therefore, PbTII cells represent a unique in vivo tool, with extensive
applications for studying Plasmodium-specific CD4+ T cell responses.
53
3.2 Introduction
Epidemiological studies and in vivo modelling have implicated CD4+ Th cell responses and
high-affinity Plasmodium-specific antibodies in the control of pRBCs (Weiss, Sedegah et al. 1993,
Whitworth, Morgan et al. 2000, Pombo, Lawrence et al. 2002). Th1 cells, defined by expression of
the transcription factor, T-bet, and secretion of the cytokine, IFNγ (Luckheeram, Zhou et al. 2012),
are generated during blood-stage Plasmodium infection (Suss, Eichmann et al. 1988), and can
control pRBC numbers (Pinzon-Charry, McPhun et al. 2010). More recently, Plasmodium infection
of mice has been reported to elicit anti-parasitic Tfh cells (Butler, Moebius et al. 2012, Perez-
Mazliah, Ng et al. 2015), which are defined by expression of the transcription factor Bcl6, the
cytokine IL-21, and cell-surface receptors CXCR5, ICOS and PD1 (Schaerli, Willimann et al. 2000,
Nurieva, Chung et al. 2009, Crotty 2011). In other experimental systems, Tfh cells are known to
migrate into B cell follicles to instruct the formation and maintenance of germinal centres, and
thereby to drive high-affinity antibody production (Kerfoot, Yaari et al. 2011). A recent study by
Ryg-Cornejo et al, demonstrated that in a model of severe malaria, pro-inflammatory cytokines
perturbed Tfh responses resulting in weak GC reactions (Ryg-Cornejo, Ioannidis et al. 2015). The
critical importance of humoral immunity for controlling pRBC is demonstrated by the inability of
mice lacking B cells or the cellular machinery for immunoglobulin-class-switching to resolve
infection (van der Heyde, Huszar et al. 1994, Butler, Moebius et al. 2012). Furthermore, passive
transfer of Plasmodium-specific antibodies in humans can provide protection against severe disease
(Cohen, McGregor et al. 1961). However, there remains a substantial gap in our current
understanding of how Th cell responses are generated during Plasmodium infection.
Genetically-marked TCR transgenic T cells allow for in vivo tracking of antigen-specific T
cell clones in modified immune environments. A Plasmodium-specific TCR transgenic mouse line
that expressed CD4+ T cells reactive against the blood-stage protein MSP-1 was used to examine
requirements for cDC subsets in initiating CD4+ T cell responses in vitro co-culture experiments
during PcAS infection (Sponaas, Cadman et al. 2006). One caveat of this reagent, however, was
that it was developed on the BALB/c genetic background, in which few immunologically-related
gene knock-out mice are currently available. This limits opportunities for identifying T-cell
extrinsic mechanisms that control CD4+ T cell responses. For this reason, Professor Bill Heath, at
The Peter Doherty Institute, University of Melbourne, Australia, has worked towards generating
reagents for studying T cell responses in mouse models of Plasmodium infection. His laboratory
firstly developed transgenic PbA parasites that expressed peptides derived from the model antigen
chicken egg ovalbumin, for which OTI (CD8+) and OTII (CD4+) T cells could be used to study
54
antigen-specific T cell responses. While these reagents have been useful (Langhorne 1989, Lundie,
de Koning-Ward et al. 2008, Haque, Best et al. 2011), it was preferable to develop T cell lines that
respond to wild-type Plasmodium antigens. Thus, a CD8+ TCR transgenic line (termed PbTI) was
developed and recently used to determine roles for CD8+ T cells during liver-stage and blood-stage
infections (Lau, Fernandez-Ruiz et al. 2014). A similar CD4+ TCR transgenic reagent, termed
PbTII, had been generated by the Heath laboratory, but had yet to be tested in vivo.
In this chapter, PbTII cells were tested for their utility as reporters of Plasmodium-specific
CD4+ T cell responses during in vivo blood-stage infection. PbTII cells proliferated upon infection
in a manner dependent on MHCII-expressing cells and cDCs. At the peak of infection towards the
end of the first week, PbTII cells had simultaneously differentiated in the same animals into Th1
and Tfh effector cells. Their response resembled the endogenous polyclonal response, thus
highlighting their usefulness for studying CD4+ T cell responses in vivo. Furthermore, PbTII cells
exhibited regulatory and memory phenotypes during later stages of infection.
55
3.3 Results
3.3.1 Generation of Plasmodium-specific TCR transgenic CD4+ T (PbTII) cells
To address the lack of immunological tools for assessing CD4+ T cell responses in vivo, our
collaborators Prof. Bill Heath and Dr Daniel Fernandez-Ruiz at The Peter Doherty Institute
(University of Melbourne) generated a novel MHCII-restricted TCR-transgenic mouse line (termed
PbTII). This mouse was developed by first generating an IAb-restricted hybridoma (termed D73) by
fusing an immortalised cell line with T cells taken from the spleen of a PbA-infected mouse. Vα2
and Vβ12 transgenes cloned from D73 were then used to generate the MHCII-restricted PbTII mice.
More than 90% of splenic CD4+ T cells in PbTII mice co-expressed Vα2 and Vβ12 TCRs (Figure
3.1A). In order to track these cells once transferred into recipient C57Bl/6J (CD45.2) mice, the
PbTII mice were crossed with congenic CD45.1+ (Ptprca) mice (Figure 3.1A).
Figure 3.1 Gating strategy for sorted Plasmodium-specific CD4+ TCR transgenic (PbTII) cells.
(A) Representative plot of PbTII cells (Vα2+ Vβ12+ CD45.1+ CD4+ TCRβ+) MACS enriched from the
spleens of PbTII-expressing mice based on CD4+ expression. Flow-through of the MACS
enrichment is shown for comparison.
CD
45
.1
CTV
81.2 71.5
88.2 94.1
0.2530.0
CD
4
TCRβ
Vα
2
Vβ12
FS
C-H
FSC-A
SS
C-A
FSC-A
A
56
3.3.2 PbTII responses are specific for Plasmodium infection
Firstly, it was important to determine whether PbTII cells responded during Plasmodium
infection. To test this, increasing numbers of CellTrace™ Violet (CTV)-labelled PbTII cells, or 105
CTV-labelled OTII cells as a negative control, were transferred into wild-type C57BL/6J mice,
which were infected with PcAS or left naive. By 7 days post-infection (p.i.), which approximates to
the peak of parasitemia in this model, PbTII cells had proliferated extensively, as determined by
CTV dilution (Figure 3.2A). The absolute numbers of splenic PbTII cells retrieved at 7 days p.i.
were approximately 10-fold higher than the initial transfer dose of 103 or 104 PbTII cells (Figure
3.2A). At higher transfer numbers of 105 and 106 cells, the absolute number of splenic PbTII cells
was approximately equivalent to the number transferred (Figure 3.2A). In contrast, non-
Plasmodium-specific OTII cells were below the threshold of detection by 7 days p.i., suggesting
they had failed to respond to the infection (Figure 3.2A). Thus, PbTII cells proliferated during in
vivo PcAS infection, with lower numbers of transferred cells eliciting stronger proliferative
responses.
To determine if PbTII proliferative responses required cDCs in vivo, splenic PbTII cells
were enumerated in PcAS-infected CD11c-DTR recipient mice, which had received 104 PbTII cells
and were treated with diphtheria toxin (DT) to deplete CD11chi cells, or with control saline (Figure
3.2B). In addition, PbTII responses were examined in PcAS-infected, CD11cCre IAbf/f recipient mice
(104 PbTII cells transferred), in which CD11c+ cells lacked expression of the MHCII molecule, IAb,
compared to control IAbf/f littermates (Figure 3.2B). In both experimental systems, lack of cDCs or
MHCII-expression by CD11chi cells resulted in substantial reductions in splenic PbTII numbers
(Figure 3.2B). Together, these data strongly suggested that in vivo proliferation of PbTII cells
during PcAS infection was dependent upon cDC-mediated MHCII-restricted antigen presentation.
Finally, to explore the influence of PbTII cells on parasitemia, increasing numbers of PbTII
cells were transferred into PcAS-infected WT mice, and peripheral parasitemia was monitored until
the first peak of infection was controlled. No change in the kinetics of PcAS infection was observed
upon transfer of PbTII cells compared with infected mice receiving no PbTII cells, demonstrating
that PbTII cells did not influence the outcome of PcAS infection in WT mice (Figure 3.2C).
57
Figure 3.2 PbTII cells proliferate in an MHCII-dependent manner during PcAS infection. CTV-
labelled PbTII cells or non-specific control OTII cells were transferred at the indicated number into
C57Bl6/J mice that were left naïve or infected with PcAS. (A) Representative plots of total CD4+ T
cell population showing expansion of transferred cells and graphs depicting total numbers of
transferred cells in the spleen of mice at 7 days p.i.. (B)Numbers of PbTII cells (104 transferred) in
the spleens of DT treated CD11c-DTR or CD11cCreIAbfl/fl or appropriate control mice at 7 days p.i.
(n=5-6). (C) Kinetics of infection determined by proportion of parasitised red blood cells (pRBC).
(A) Data are a single experiment, or (B &C) representative of two independent experiments.
Graphs show mean with SEM. * p<0.05, **p<0.01.
D a y s p o s t - in fe c t io n
Pa
ras
ite
mia
(%
iR
BC
)
0 5 1 0 1 5
0
2 0
4 0
6 0
10
1 02
1 04
1 06
B
No
. P
bT
II (
x1
05)
WT
: D
T
CD
11c -D
TR
: D
T
IAbf /
f
CD
11cC
re I
Ab
f /f
0
5
10
C
Pb
TII
ce
lls
0
10
^5
10
^3
10
^4
10
^5
10
^6
10
^5
1 0 - 1
1 0 0
1 0 1
1 0 2
1 0 3
1 0 4
1 0 5
1 0 6
1 0 7
+ - + + + + +
- + + + + + -
- - - - - - +
P c A S
P b T II
O T II
No transfer
100,000PbTII cells
100,000 OTII cells
CD
45
.1
CTV
AF
SC
H
Liv
e/D
ea
d
SS
CA
CD
4FSCA FSCA
FSCA TCRβ
58
3.3.3 Th1 and Tfh are distinct effector subsets
CD4+ T cell clones have been reported to display preferential skewing towards certain Th
subsets (Tubo, Pagan et al. 2013). OTII cells, for example, preferentially differentiate into Tfh cells
over Th1 cells in response to LCMV infection (Tubo, Pagan et al. 2013). Thus, it was important to
determine whether PbTII cells differentiated into T helper cells, and the kinetics of this
differentiation. To enable tracking of PbTII cells at earlier time points, 106 CTV-labelled PbTII
cells were transferred into mice and splenic PbTII cell responses assessed at 1, 4 and 7 days p.i.
with PcAS (Figure 3.3A). PbTII cells proliferated extensively by 4 days p.i. as determined by the
loss of CTV and total numbers of splenic PbTII cells. Additionally, PbTII cells that had progressed
through more than 5 divisions up-regulated CXCR5 expression, a marker of Tfh differentiation, and
exhibited modest, direct ex vivo expression of IFNγ, a Th1 marker (Figure 3.3A). PbTII expansion,
as well as IFNγ and CXCR5 expression increased up to day 7 p.i. (Figure 3.3A).
Intra-clonal competition has previously been reported at transfer of higher numbers that can
affect the magnitude of the T cell responses (Foulds, Rotte et al. 2006, Badovinac, Haring et al.
2007, Bautista, Lio et al. 2009). Therefore, to characterise Th1 and Tfh responses further at peak
infection, 104 PbTII cells were transferred. Importantly, most PbTII cells expressed either IFNγ
(Th1) or CXCR5 (Tfh) at 7days p.i. (Figure 3.3B), in a manner similar to the polyclonal Th
response (Figure 3.3B). Of particular note, bifurcated PbTII cells, expressing either IFNγ or
CXCR5, also expressed canonical transcription factors T-bet or Bcl6 respectively (Figure 3.3C). To
determine the effect of intra-clonal competition on PbTII cell responses, PbTII cells were
transferred at numbers of 102, 104 or 106 into WT mice, where transfer 102 represents the most
physiologically relevant frequency in naïve mice (Moon, Chu et al. 2007). Proportions of Th1 or
Tfh cells within the PbTII population were equivalent for transfers of 102 or 104 cells, while transfer
of 106 PbTII cells elicited lower proportions of Th1 cells and Tfh cells (Figure 3.4A). The absolute
number of both effector populations was equally high upon transfer of 104 or 106 compared to 102
cells (Figure 3.4A) Thus, use of 104 PbTII cells was appropriated for assessing PbTII responses at
peak infection. Together, these data suggests that PbTII cells bifurcate into either Th1 or Tfh
effector cells, similar to the polyclonal response.
59
Figure 3.3 Plasmodium-specific TCR transgenic CD4+ T (PbTII) cells bifurcate into Th1 and Tfh
cells during PcAS infection. (A) CellTrace™ Violet (CTV)-labelled, CD45.1+ PbTII cells (106)
were transferred into WT mice (n=4) prior to infection with PcAS. Representative FACS plots of
CTV loss and IFNγ or CXCR5 expression, and numbers of splenic PbTIIs at indicated days p.i.. (B)
Representative FACS plots and summary graphs showing proportions of PbTII cells (CD45.1+
CD4+ TCRβ+ live singlets) and endogenous polyclonal CD4+ T cells (CD45.1- CD4+ TCRβ+ live
singlets) expressing IFNγ or CXCR5 in PcAS-infected mice 7 days p.i. (receiving 104 PbTII cells)
compared to naïve controls (106 PbTII cells). (C) Left: representative FACS plots (gated on
CD45.1+ CD4+ TCRβ+ live singlets) and a summary graph showing T-bet and Bcl6 expression by
splenic PbTII cells (CD45.1+) from naive and 7-day PcAS-infected mice (n=5). Right:
representative histograms of IFNγ and CXCR5 expression by T-bethi Bcl6lo (red), Bcl6hi T-betlo
(blue) PbTII cells compared to those from naive mice (grey). Data are representative of two
independent experiments. Statistics: Mann-Whitney U test; *** p<0.001; ****p<0.0001.
CXCR5
IFNγ
Naiv
eP
cA
SPbTIIB
0.4 0.3
2.16
0.4 0.2
3.0
7.3 1.5
17.6
25.8 2.9
27.6
Polyclonal
2.21
12.7
49.5
40.1
Bcl6
Tb
et
CXCR5
IFNγ
C
Na
ive
PcA
S
0 2 4 6 8
1 0 4
1 0 5
1 0 6
1 0 7
D a y s p o s t - in fe c t io n
Pb
TII
ce
lls
/sp
lee
n0
5
1 0
1 5
% o
f C
D4
+ T
ce
lls
***
****
P c A S - -+ +
IFN
+
CX
CR
5+
0
1 0
2 0
3 0
% o
f P
bT
II
***
P c A S - -+ +
IFN
+
CX
CR
5+
***
CXCR5
IFNγ
Naiv
eP
cA
S
0
2 0
4 0
6 0
% o
f P
bT
II
P c A S - -+ +
Tb
et+
Bc
l6+
**
Da
y 1
Da
y 4
CD
45
.1 0.3
1.4
7.0IF
Nγ
CX
CR
5
Day 7
CTV
A
60
Figure 3.4 Differentiation of PbTII cells during PcAS infection. PbTII cells were transferred at
the indicated doses into PcAS-infected WT mice. Proportions and absolute numbers of T-bet+ IFNγ+
(Th1) or CXCR5+ Bcl6+ (Tfh) splenic PbTII cells at day 7 p.i..
3.3.4 PbTII display the capacity to differentiate into T regulatory 1 cells
Regulatory responses by Tregs and Tr1 cells have been observed in human and experimental
malaria studies (Langhorne, Gillard et al. 1989, Amante, Stanley et al. 2007, Couper, Blount et al.
2008, Finney, Nwakanma et al. 2009, Walther, Jeffries et al. 2009, Berretta, St-Pierre et al. 2011).
Similarly, IL-4 positive Th-2 cells have been implicated in immune responses to malaria
(Langhorne, Gillard et al. 1989). Therefore, PbTII cells were assessed for their capacity to
differentiate into regulatory T cells and other Th subsets during PcAS infection. While
approximately 4% of the recipient polyclonal CD4+ T cells expressed FOXP3 at peak infection
(Figure 3.5A), no such FOXP3 expression was observed from the PbTII cells (Figure 3.5A).
Notably, however, after peak infection, ex vivo restimulation of PbTII cells resulted in co-
expression of IL-10 and IFNγ by approximately 5% of PbTII cells (Figure 3.5B), evidence of Tr1
effector function as seen from polyclonal CD4+ T cells in this infection (Montes de Oca, Kumar et
al. 2016). Finally, neither endogenous polyclonal CD4+ T cells nor PbTII cells expressed Th2
markers, IL-4+ and GATA3+, or Th17 markers, IL-17A and RORγT at peak infection (Figure 3.5C).
PcAS
Tb
et+
IF
N
+ (
%)
106
102
104
106
0
1 0
2 0
3 0**
N S
Bc
l6+C
XC
R5
+(%
)
106
102
104
106
0
2 0
4 0
6 0
8 0*
N S
PcAS
106
102
104
106
0 .0
0 .1
0 .2
1
2
3
4
Tb
et+
IF
N
+ (
x1
05)
*
*
N S
PcAS
106
102
104
106
0 .0
0 .5
1 .0
5
1 0
1 5
Bc
l6+ C
XC
R5
+(x
10
5)
*
*
N S
PcAS
61
Together, this demonstrates that during PcAS infection, PbTII cells have the capacity to
differentiate into Tr1 cells, but not Treg, Th2 and Th17 cell subsets.
Figure 3.5 PbTII cells differentiate into regulatory cells during PcAS infection. PbTII cells were
transferred into C57Bl/6J mice infected with PcAS (104/mouse) or left uninfected (106/mouse).
(A)Representative FACS plots (gated on CD4+ TCRβ+ live singlets) and proportion of Treg
(FOXP3+) cells within the PbTII (CD45.1+) or polyclonal CD4+ T cell population (CD45.1-) at 7
days p.i.. (B) Representative FACS plots (gated on CD45.1+ CD4+ TCRβ+ live singlets) and
summary graph of ex vivo restimulated IL-10 and IFNγ co-expression by splenic PbTII cells (106
transferred) in naive (n=2) or day 9-infected mice (n=6). (C) Representative FACS plots (gated on
CD45.1+ CD4+ TCRβ+ live singlets) of IL-4+ GATA3+ (Th2) and IL-17+ RORγt+ (Th17) splenic
PbTII cells at 7 days p.i. (n=6). Data show mean and SEM and are representative of two
independent experiments. Statistics: Mann-Whitney U test; *p<0.05.
CD45.1
FO
XP
3
GATA3
IL-4
0.010
RORγt
IL-1
7
0.030
Naive PcAS
0.323.54
Po
lyc
lon
al
Pb
TII
0
1
2
3
4
5
% F
OX
P3
+
*
A
C
Naive PcAS
IL-10
IFNγ
B1.484.78 6.8114.0
Na
ive
Pc
AS
0
2
4
6
8
% I
L-1
0+ I
FN
+
62
3.3.5 PbTII cells migrate to the liver and display a Th1 phenotype
Next, it was of interest whether effector PbTII cells could migrate to peripheral tissues such
as the liver, in which CD4+ T cell responses have previously been identified during blood-stage
malaria (Mastelic, do Rosario et al. 2012). Indeed, PbTII cells were observed in the liver at peak
infection, although roughly 100-fold fewer compared to the number within the spleen (Figure 3.6A
and Figure 3.3A). Of the PbTII cells within the liver, approximately 50% expressed IFNγ (Figure
3.6B). Conversely, no CXCR5 expression was detected (Figure 3.6B). Together, these data show
that PbTII cells can migrate to the liver, and display a Th1, but not Tfh effector phenotype.
Figure 3.6 IFNγ+ PbTII cells migrate to the liver. PbTII cells (106) were transferred into mice that
were infected with PcAS (n=4) or left naive (n=1). (A) Absolute numbers of PbTII cells in the liver
at day 7 p.i.. (B) Representative FACS plots (gated on CD45.1+ CD4+ TCRβ+ live singlets) and
proportions of IFNγ and CXCR5 expression by PbTII cells in the liver at day 7 p.i.. Numbers on
plots show proportion of PbTII population within respective quadrants. Data show mean with SEM
and are a single experiment.
Naiv
e
PcA
S
0
2
4
6
Pb
TII
(x
10
5)
IFNγ
CXCR5
PcA
SN
aiv
e
IFN
+
CX
CR
5+
0
2 0
4 0
6 0
% o
f P
bT
II
1.8 0.4
0.4
52.5 0.5
0.7
B
A
63
3.3.6 PbTII cells develop into memory cells after acute PcAS infection
Memory T cells have been associated with long-lasting protection against Plasmodium
infection in mice and humans (Grun and Weidanz 1981, Tsuji, Romero et al. 1990, Migot,
Chougnet et al. 1993, Langhorne 1994, Stephens and Langhorne 2010). However, it has been
challenging to definitively track memory T cell responses. To determine if PbTII cells survived
beyond the first week of infection, and could convert into memory phenotypes, PbTII cells were
assessed after peak parasitemia had been controlled. PbTII cells were detected in the spleens of WT
recipient mice by 37 days p.i. with PcAS (Figure 3.7A), and depending on the number of cells
transferred, exhibited both effector memory (CD62Llo CD44hi) and central memory (CD62Lhi
CD44hi) phenotypes (Figure 3.7B). Thus, PbTII cells exhibited the potential to form splenic
memory responses after acute PcAS infection.
Figure 3.7 PbTII cells develop into memory cells after acute PcAS infection. 104 or 106 PbTII
cells were adoptively transferred to C57Bl/6J mice (n=3-4) infected with PcAS. (A) Enumerated
splenic PbTII cells at 37 days p.i.. (B) Representative FACS plots of CD62L and CD44 expression
by recipient polyclonal CD4+ T cells (gated on CD45.1- CD4+ TCRβ+ live singlets) or PbTII cells
(gated on CD45.1+ CD4+ TCRβ+ live singlets) and summary graphs showing proportions of central
memory (CD62L+ CD44+) (TCM) and effector memory (CD62L-CD44+) (TEM) splenic PbTII cells.
Numbers in plots are proportion of population within respective quadrants. Data are a single
experiment.
Recipient CD4+
CD44
CD
62
L
104 106
14.6 29.2
53.6
0 18.9
81.1
0.73 33.3
65.3
B TCM TEM
A
Pb
TII
ce
lls
104
106
1 0 0
1 0 2
1 0 4
1 0 6
% C
D6
2L
+ C
D4
4+
104
106
0
2 0
4 0
6 0
% C
D6
2L
+ C
D4
4-
104
106
0
2 0
4 0
6 0
8 0
1 0 0
64
3.3.7 PbTII cells show cross-species reactivity to Plasmodium infection
Lastly, PbTII cells were assessed for their ability to respond to two other commonly used
rodent Plasmodium strains- Py17XNL and PbA. During Py17XNL infection, transfer of fewer than
105 cells did not give rise to a reliable PbTII response. Thus, 105 cells were determined to be the
optimal dose in this model. Similar to PbTII responses during PcAS infection, PbTII cells expanded
and bifurcated into IFNγ+ T-bet+ Th1 cells or CXCR5+ Bcl6+ Tfh cells in WT mice by day 11 of
Py17XNL infection, which was also seen in the endogenous polyclonal response (Figure 3.8A).
Finally, transfer of 106 PbTII cells was found to be the optimal transfer dose during PbA infection.
PbTII cells proliferated, and began to differentiate into Th1 cells, but not Tfh cells by day 4 p.i.
during PbA infection (Figure 3.8B), in accordance with polyclonal CD4+ T cell responses and
previous reports (Ryg-Cornejo, Ioannidis et al. 2015). These results together demonstrate the
reactivity of PbTII cells in several murine models of malaria, and furthermore highlight possible
differences in magnitude of Th responses mounted during infection with these three strains.
65
Figure 3.8 PbTII cell expansion and Th1/Tfh differentiation during P. yoelii 17XNL and P.
berghei ANKA blood-stage infection. (A) Representative FACS plots of polyclonal CD4+ T cells
(gated on CD45.1- CD4+ TCRβ+ live singlets) and PbTII cells (105 transferred) (gated on CD45.1+
CD4+ TCRβ+ live singlets), showing proportions expressing IFNγ or CXCR5, as well as absolute
numbers of splenic PbTII cells 11 days p.i. with Py17XNL, compared to uninfected WT mice. (B)
Representative FACS plots of polyclonal CD4+ T cells (gated on CD45.1- CD4+ TCRβ+ live
singlets) and PbTII cells (106 transferred) (gated on CD45.1+ CD4+ TCRβ+ live singlets), showing
proportions expressing IFNγ or CXCR5, as well as absolute numbers of splenic PbTIIs 4 days p.i.
with PbA. Data pooled from two independent experiments. Statistics: Mann-Whitney U test;
*p<0.05; **p<0.01; ****p<0.0001.
Py1
7X
NL
Na
ive
Polyclonal PbTII
IFNγ
CXCR5
0.29 0
0.9
0.1 0.1
1.9
0.9 0.1
10.1
3.28 0.1
19.3
0
2
4
1 0
2 0
% o
f p
op
ula
tio
n
**
*
P y 1 7 X N L - - -+ + + - +
IFN
+
CX
CR
5+
IFN
+
CX
CR
5+
*
Polyclonal PbTII
0 .0 1
0 .1
1
1 0
1 0 0
% I
FN
+**
P b A - -+ +
**
IFNγP
bA
NK
AN
aiv
e
CXCR5
Polyclonal PbTII0.31 0.3
0.2
0.1 0
0.3
0.85 0
0.8
7.2 0.1
0.6
Polyclonal PbTII
B
Naiv
e
Py17X
NL
0
1 0
2 0
3 0
Pb
TII
(x
10
5)
****
Naiv
e
PbA
NK
A
0
1 0
2 0
3 0
Pb
TII
(x
10
5)
**
A
66
3.4 Discussion
Antigen-specific CD4+ T helper responses protect against blood-stage Plasmodium infection
in humans and experimental mice. However, studying the emergence of these responses in vivo is
difficult due to the low frequency of antigen-specific T cells in the naive repertoire, and that T cell
priming occurs in the spleen, which is not easily visualised in humans. Murine TCR transgenic T
cells are therefore a powerful reagent, as they allow for in vivo tracking of T cell priming and
differentiation. Moreover, their responses to manipulation of the external immune environment can
be assessed via transfer into genetically altered recipient mice. Unfortunately, few TCR transgenic
reagents have been available for assessing CD4+ T cell responses during Plasmodium infection.
Here, the utility of a recently developed Plasmodium-specific TCR transgenic CD4+ T cell line for
following T helper responses during in vivo blood-stage malaria was investigated.
Adoptively transferred PbTII cells proliferated extensively, and differentiated into two T
helper subsets- Th1 and Tfh cells, during PcAS infection. The response of PbTII cells was critically
dependent on MHCII-expressing CD11c+ cells. This is consistent with previous in vivo and ex vivo
studies showing important roles for cDCs in priming CD4+ T cells during Plasmodium infection
(deWalick, Amante et al. 2007, Sponaas, Freitas do Rosario et al. 2009, Haque, Best et al. 2014).
While IL-17A and IL-17F-producing Th17 cells and IL-4-producing Th2 have been identified
during experimental blood-stage Plasmodium infection (Langhorne, Gillard et al. 1989, Keswani
and Bhattacharyya 2014), whether these subsets have a significant role in protective immunity has
not been demonstrated. Here, no evidence of Th2 of Th17 differentiation was observed from PbTII
cells or endogenous polyclonal CD4+ T cells at peak infection. Thus, in the spleen during PcAS
infection at least, these subsets do not appear to contribute to immune responses.
Although experimental malaria and field studies have reported the involvement of Treg cells
in immune responses to infection (Hisaeda, Maekawa et al. 2004, Finney, Nwakanma et al. 2009),
PbTII cells did not express FOXP3 at peak infection. Since a subset of FOXP3+ Tregs develop in
the thymus from moderate affinity of their TCR for self-antigen, it is not surprising that PbTII cells,
with forced expression of a Plasmodium reactive TCR, display limited capacity to become
regulatory cells. Interesting, however, PbTII cells did have the capacity to co-produced the
regulatory cytokine IL-10 and the proinflammatory cytokine IFNγ+, a phenotype that has been
termed 'Tr1' and has also previously been observed in human and experimental malaria (Couper,
Blount et al. 2008, Walther, Jeffries et al. 2009). This population appeared to emerge from the
IFNγ+ populations at a time point after the emergence of the Th1 response, suggesting that it could
represent a continuation from the Th1 phenotype. A study by Cardone et al. has proposed that CD46
67
expression mediates the switch from the Th1 phenotype to a Tr1 phenotype in purified human CD4+
T cells (Cardone, Le Friec et al. 2010). However the relationship between Th1 and Tr1 cells has not
been demonstrated within a clonal population or in vivo. Thus, these observations from PbTII cells
offer the prospect of exploring whether Tr1 cells do emerge from Th1 cells during in vivo infection.
After the acute infection, PbTII cells displayed both TCM and TEM phenotypes within the
spleen. Memory T cells contribute to long-term immunity to malaria (Grun and Weidanz 1981,
Tsuji, Romero et al. 1990, Langhorne 1994), but are also hypothesised to be functionally deleted or
modulated during Plasmodium infection (Hirunpetcharat and Good 1998, Xu, Wipasa et al. 2002).
PbTII cells would be useful for examining how these populations of memory T cells develop, and
also how their development can be boosted in the future to improve long-term protection by
vaccines or other immune-interventions. In addition to circulating TEM and lymphoid-resident TCM
populations (Sallusto, Geginat et al. 2004), another tissue resident memory T cells (TRMs) have been
shown to reside in peripheral tissues. The best described TRMs are CD8+ and have been shown to
provide local immune responses in the skin (Mackay, Rahimpour et al. 2013), ganglia (Gebhardt,
Wakim et al. 2009), intestinal mucosa (Kim, Reed et al. 1997), brain (Wakim, Woodward-Davis et
al. 2010) and thymus (Hofmann, Oschowitzer et al. 2013). CD4+ TRMs have also been described in
the skin (Glennie, Yeramilli et al. 2015), genital tract (Iijima and Iwasaki 2014) and lungs (Teijaro,
Turner et al. 2011). In the liver, CD44hi antigen-specific CD8+ TRMs were identified in mice at 45-
days after immunization with irradiated P. yoelii sporozoites (Tse, Cockburn et al. 2013). These
memory cells displayed differential gene expression compared with antigen-specific memory CD8+
T cells in the spleen, suggesting they represented a distinct population from central memory T cells.
Whether an equivalent tissue-resident CD4+ T cell population exists within the liver is unknown.
Here, PbTII cells are also shown to exist within the liver during blood stage-infection. A large
proportion exhibited a Th1 phenotype, but none differentiated into Tfh cells, in alignment with the
role of Tfh cells in germinal centre formation within secondary lymphoid organs (Crotty 2011).
Given the ideal localisation of liver-resident TRMs to contribute to memory responses against liver-
stage infection (Tse, Cockburn et al. 2013), assessing PbTII memory responses in the liver would be
of high interest, specifically for vaccine development targeting liver-stage of infection.
A particularly interesting observation from these data was that adoptive transfer of PbTII
cells did not modulate the kinetics of the infection. A possible explanation is that PbTII cells are not
involved in the clearance of pRBCs. However, this does not seem likely given the strong Th1
response of PbTII cells at peak infection and the demonstrated contribution of Th1 responses in
clearance of pRBCs (Taylor-Robinson and Phillips 1994, Amante and Good 1997, Haque, Best et
al. 2011, Haque, Best et al. 2014). Another explanation could be that endogenous CD4+ T cells in
68
WT mice infected with PcAS are already adequate for the number of macrophages to phagocytose
the pRBCs (Clark, Hunt et al. 1987, Taylor-Robinson and Phillips 1998)and for the number of B
cells that contribute to resolution of infection (Butler, Moebius et al. 2012). In order to test this
hypothesis, further experiments could include transfer of PbTII cells into Rag1-/- mice that do not
have endogenous T or B cell responses. PbTII cells would not be expected to differentiate into Tfh
cells in the absence of B cells within this system (Kerfoot, Yaari et al. 2011), but it would allow for
functional assessment of Th1 PbTII cells. Alternatively, PbTII cells could be transferred into CD40
ligand-deficient mice, in which endogenous T cells lack the ability to receive co-stimulatory signals
and can therefore not undergo activation (Grewal, Foellmer et al. 1996).
Here, increasing doses of PbTII cells were tested for their responses compared with an
approximately physiologically relevant number of 102 PbTII cells (Moon, Chu et al. 2007).
Compared to 102 transferred cells, 104 resulted in similar PbTII cell responses by peak PcAS
infection; however transfer of 106 PbTII cells resulted in reduced expansion and proportions of T
helper populations. This suggests that transfer of 104 cells is a practical method for studying
physiologically relevant responses during PcAS infection. At transfer doses in the order of 106 cells,
however, PbTII cells experienced intra-clonal competition, possibly due to processes such as
competition for contact with APCs or for physical room within the spleen. This phenomenon of
intra-clonal competition has been observed within multiple TCR transgenic cells (Langhorne,
Gillard et al. 1989, Langhorne and Simon 1989). It was particularly interesting that the Th1
response was impaired to a greater extent at higher PbTII transfer doses than the Tfh response,
suggesting that Tfh cells are more impartial to clonal competition. This observation is consistent
with the concept that Tfh differentiation is the default pathway for activated CD4+ T cells(Crotty
2014). A study by Eto et al. provides support for this idea by showing that unlike other
differentiation of Th subsets, which require the presence of a key cytokine, Tfh differentiation can
be induced by multiple redundant signals during viral challenge (Eto, Lao et al. 2011). A highly
reliable Tfh response is biologically conceivable given that subsequent GC development and
affinity maturation are central processes of the adaptive immune response.
By using a single T cell clone, these data have provided the evidence that the magnitude of
Th responses for a given TCR is different between models. The optimal responses were observed
upon the transfer of 106, 104 and 105 cells respectively for PbA, PcAS and Py17XNL infections.
However, a direct comparison between the Th responses induced by these different strains cannot
be definitively performed since the parasite antigen triggering PbTII cells, and whether this antigen
differs between Plasmodium strains, has not yet been determined. Nevertheless, relative to
endogenous CD4+ T cell responses, it can be inferred that the greater the endogenous Th response,
69
the fewer PbTII cells required. TCR transgenic cells can exhibit some preference in their
differentiation toward a particular Th subset (Tubo, Pagan et al. 2013). This was not the case with
PbTII cells, since they could bifurcate into both Th1 and Tfh cells during in vivo Py17XNL and
PcAS infections, in a manner that closely resembled the endogenous polyclonal responses. During
PbA infection, PbTII cells gave rise to Th1 cells before the animals succumbed to disease 7-9 days
after infection. As with the endogenous polyclonal response, CXCR5-expressing PbTII cells failed
to develop in this model. The absence of a polyclonal Tfh response during PbA infection has been
reported recently (Ryg-Cornejo, Ioannidis et al. 2015). Although the antigen to which PbTII cells
respond is yet to be determined, the cross-reactivity of this line suggests that the target epitope is
expressed by at least three common rodent infective strains. Whether PbTII cells also respond to
human infective Plasmodium species such as P. falciparum, or to other life stages of the parasite,
such as the liver-infective sporozoite stage, will be of future interest. Further studies will be
required to determine the exact antigen recognized by PbTII cells.
In conclusion, the utility of a novel TCR transgenic tool for studying Plasmodium-specific
CD4+ T cell responses during experimental blood-stage malaria has been demonstrated. PbTII cells
proliferated in a cDC- and MHCII-dependent manner. They developed into Th1 and Tfh cells, Tr1
cells and later TEM and TCM cells. Therefore, this reagent provides an opportunity for examining
multiple aspects of CD4+ T cell biology during experimental models of malaria in mice.
70
Chapter Four:
Single-cell RNA-sequencing resolves a CD4+ T helper cell fate
bifurcation
4.1 Abstract
CD4+ T helper cells are critical for immunity to blood-stage Plasmodium infection. During
experimental malaria in mice T helper 1 (Th1) and T follicular helper (Tfh) subsets emerge, which
have both been associated with better infection outcomes. In vitro experimentation and
mathematical modelling have proposed asymmetric cell division and internal stochastic events as
possible mechanisms controlling T cell differentiation fates. However, molecular mechanisms
controlling this process in vivo remain unclear. In Chapter 3, TCR transgenic PbTII cells were
shown to concurrently differentiate, or bifurcate, into Th1 or Tfh effector cells during infection.
Here, to study this process at molecular resolution, a single-cell RNAseq (scRNAseq) approach was
adopted. Emerging Th cells entered a state of high cell-cycling after initial priming, in which they
expressed markers of both Th1 and Tfh subsets. This occurred prior to a commitment to a
differentiated, and possibly terminal, Th1 or Tfh effector state. Furthermore, expression of
chemokine receptors prior to bifurcation suggested that CD4+ T cells were receptive to chemokine-
expressing cells at this point. While B cells were shown to sustain PbTII Tfh responses, additional
scRNAseq analysis of myeloid populations supported roles for cDCs and Ly6Chi inflammatory
monocytes in interacting with un-committed, activated PbTII cells. Depletion of Ly6Chi monocytes
after PbTII activation, and prior to bifurcation, demonstrated their support of Th1 but not Tfh
responses. In summary, Plasmodium-specific CD4+ T cells do not commit to an effector state until
several days after initial activation, before which they are indistinguishable at the transcriptional
level. In particular, activated PbTII cells required support from B cells and myeloid populations to
sustain commitment to Tfh and Th1 effector states respectively.
71
4.2 Introduction
CD4+ T cells exhibit substantial functional diversity in response to many immune
challenges, including blood-stage Plasmodium infection. Naive CD4+ T cells are activated upon
recognition of antigenic peptides presented by MHCII molecules on the surface of APCs. They
proceed to undergo clonal proliferation and differentiate into a range of T helper (Th) cell subsets,
classified according to their expression of cytokines, transcription factors and surface molecules. T
cells typically display skewed effector phenotypes in response to an immune challenge. For
example, intracellular infections induce differentiation of TNFα- and IFNγ- producing Th1 cells,
whereas helminth infections and allergy are characterised by the emergence of IL-4-, IL-5- and IL-
13- secreting Th2 cells. As discussed in Chapter 3, two subsets concurrently emerge during
Plasmodium infection: Th1 cells, which are considered important for macrophage-mediated
clearance of infected red blood cells (Clark, Hunt et al. 1987, Taylor-Robinson and Phillips 1998),
and Tfh cells, which assist in the production of high-affinity antibodies (Perez-Mazliah, Ng et al.
2015). While Th1 and Tfh cells are established to be protective during malaria, the molecular and
cellular mechanisms underlying their development are not fully understood.
Recent in vivo data suggested that the unique TCR of a single naïve CD4+ T cell imparts a
genetically programmed preference towards a particular Th fate (Tubo, Pagan et al. 2013). This
study performed limiting dilution-mediated single-cell adoptive transfer of naïve transgenic T cells
into mice, and showed that clonal cells gave rise to a limited range of effector subsets in response to
Listeria monocytogenes infection. However, extracellular factors such as exposure to cytokine
signals also profoundly influence the magnitude of the response, and skew differentiation towards
particular Th fates. For example, extracellular IFNγ can promote a Th1 response, while IL-4
promotes Th2 development. Additionally, the stochastic balance of several master transcription
factors known to be expressed in CD4+ T cells, such as Blimp1, T-bet and Bcl6, drive and stabilize
particularly Th fates (Szabo, Kim et al. 2000, Liu, Yan et al. 2012, Tubo and Jenkins 2014). This
supports a view of Th development as a choice between clearly distinct states. However, the
molecular relationship between Th subsets, particularly between Tfh and other Th fates remains
unclear in vivo.
Intra-vital microscopy has demonstrated that naïve CD4+ T cells make stable engagements
with cDCs during initial priming events in secondary lymphoid tissue (Celli, Lemaitre et al. 2007).
Thereafter, further pMHCII contact is required to sustain expansion of the responding T cell
population (Obst, van Santen et al. 2005). A recent study by Groom et al. suggested that
chemokines CXCL9 and CXCL10 facilitated interaction between adoptively-transferred antigen-
72
loaded cDCs and activated CXCR3+ CD4+ T cells in lymph nodes, and furthermore, were
associated with Th1 differentiation (Groom, Richmond et al. 2012). The generation of Tfh cells is
also a multi-step process. After the initial priming events, internal upregulation of Bcl6 drives the
expression of Tfh-associated genes, including CXCR5 to promote migration of pre-GC Tfh cells to
the T-B cell border of the follicle. Here, Tfh cells are critical for supporting GC formation and B
cells are imperative for sustaining Tfh effector cells, for example via ICOS:ICOSL signalling (Choi,
Kageyama et al. 2011). Whether interactions with different endogenous myeloid cells modulate the
decision of a primed T cell towards either Th1 or Tfh fates in vivo is yet to be explored.
Flow cytometry has been instrumental in studying CD4+ Th cells and their relationship with
disease. However, even the most advanced machines only allow for the simultaneous assessment of
15-20 parameters. Furthermore, this methodology depends almost completely on high-quality
antibodies, a reliance that tends to bias analyses towards better-known molecules. More recently, a
mass spectrometry-based flow cytometry method, CyTOF, has extended the number of assessable
parameters to ~50 (Newell and Davis 2014). CyTOF allowed for dissection of the relationship
between the CD8+ T cell phenotype, function and antigen-specificity by simultaneously assessing
several markers for each quality (Newell, Sigal et al. 2012). Similarly, this technique was applied to
murine myeloid cells taken from various tissues (Becher, Schlitzer et al. 2014). In this study,
machine-learning dimensional reduction of all parameters was used to cluster the cells in a semi-
unbiased way according to their similarity. Nevertheless, CyTOF still requires the generation of
antibodies against target molecules and is therefore poorly suited for the discovery of novel
molecules that control Th biology.
Single-cell genomics is a relatively new technique that possesses extraordinary potential for
studying cellular processes in many fields including immunology. The origins of single-cell
genomics stem from gene expression profiling of single cells using microarrays (Tang, Lao et al.
2011). However, the advent of next-generation sequencing has taken this field even further by
allowing for sequencing of mRNA from individual cells, a process termed single-cell RNA
sequencing (scRNAseq) (Tang, Barbacioru et al. 2009, Islam, Kjallquist et al. 2011, Ramskold, Luo
et al. 2012). In initial studies, technical and economical limitations restricted sequencing to only a
handful of cells (Lao, Tang et al. 2009, Tang, Barbacioru et al. 2009). However, continual
improvements in the efficient physical isolation of individual cells, amplification of the genome of
single cells to acquire sufficient material for downstream analyses, cost-effectiveness of this process
and development of computational and analytical approaches to make sure the data is fully
exploited and correctly interpreted, continue to drive more elaborate studies. ScRNAseq has begun
73
to provide novel information into the biology and response of immune cells that would never have
been possible with population-level methods.
A key area in which scRNAseq has provided new information is in cellular heterogeneity.
This was done to explore heterogeneity within CD11c+ mouse myeloid cells (Jaitin, Kenigsberg et
al. 2014), and within cells engaged in the tumour microenvironment (Kim, Lee et al. 2016).
Furthermore, scRNAseq allows for the identification of rare and potentially biologically important
cells, as demonstrated in a paper by Shalek et al., which showed that rare DCs respond to immune
stimuli early and drive the response of the core DC population via paracrine signalling (Shalek,
Satija et al. 2014). Another significant advantage of scRNAseq is the assessment of covariance of
genes. This means that if genes share similar or even inverse patterns of expression, it can be
reasoned that they are involved in related-biological processes, possibly leading to the identification
of novel gene interactions. For example, a subset of in vitro-induced Th2 cells were shown to
activate genes in the steroid synthesis pathway, and inhibit Th differentiation in a Cyp11a1 enzyme-
dependent manner (Mahata, Zhang et al. 2014). Due to the in-depth profile of cells provided by
scRNAseq, the description of other transcriptional features, such as splice variants (Shalek, Satija et
al. 2013) and allele-specific expression (Tang, Barbacioru et al. 2011) is also possible.
Studying immune processes, such as the response kinetics of T cells, has previously proven
difficult due to the extensive heterogeneity within even a clonal population of cells. Population-
level transcriptomic approaches such as RNAseq on pooled cell samples tend to mask heterogeneity
amongst responding cells. Instead, flow cytometry-based methods are commonly adopted to take
discrete 'snapshots' of a response through time. However, given the heterogeneity in the response
kinetics of individual cells in any snapshot, studying intermediate states is challenging. This issue
can be solved with single-cell RNAseq combined with computational analysis. In a study by
Gaublomme et al. scRNAseq data was used to model the transition of IL-17A+ Th17 cells through a
pre-Th1 effector state during acute EAE (Gaublomme, Yosef et al. 2015). To separate transitional
states and identify novel transcription factors mediating their development, the authors combined
dimensional reduction and unbiased clustering by Principal Component Analysis (PCA) with
annotation with known gene lists describing Th states. The model was then mined for novel genes
corresponding to different states. However, prior cell-sorting according to expression of the
canonical Th17 cytokine, IL-17A, limited this analysis to changes within an already differentiated
Th17-like cell population. This approach has not yet been applied to study the early processed of Th
differentiation in vivo.
74
Our collaborator, Dr Sarah Teichmann leads the single-cell genomics department at the
Wellcome Trust Sanger Institute, Hinxton, UK. Her team features computational biologists and
immunologists, who use single-cell genomic approaches to study aspects of T cell biology. An
example of the strength of this integrated approach was demonstrated by the development of
TraCeR, a computational method that determines full-length TCR sequences from sequencing data
for single T cells, thus allowing for assessment of clonality and paving the way for following the
development of effector responses from single clones (Stubbington MJT 2015). In another study, Dr
Teichmann's team integrated in-depth transcriptome profiling, bioinformatic data analysis and
functional validation via flow-cytometry and live-imaging of single-cells to demonstrate the
relationship between cell-cycling and differentiation of Th2 cells (Fujii, Kumazaki et al. 1996).
In this chapter, the single-cell genomics expertise of Dr Sarah Teichmann and Dr Tapio
Lonnberg, and computational knowledge of Valentine Svennson (Wellcome Trust Sanger Institute,
UK) were employed to resolve the concurrent emergence of Th1 and Tfh PbTII cells during
experimental malaria. PbTII cells entered a state of high cell-cycling and metabolic activity prior to
commitment to differentiation. In this state, they expressed a range of chemokine receptors,
suggesting that they were impressionable to signals from chemokine-expressing cells. ScRNAseq
analysis of myeloid cells predicted a role for inflammatory monocytes in "coaching" PbTII cells
towards a Th1 fate, likely via the CXCR3-signalling axis. This association was confirmed in vivo by
timed depletion of inflammatory monocytes.
75
4.3 Results
4.3.1 Unbiased separation of Th1 and Tfh effector cells
To study the concurrent differentiation of antigen-specific CD4+ T cell during in vivo blood-
stage Plasmodium infection, scRNAseq was performed on PbTII cells during PcAS infection. To
achieve this, CD4+ T cells were enriched from the spleens of PbTII mice, labelled with the
proliferation dye CTV (Figure 3.1A) and adoptively transferred into C57BL/6J mice before
infection with PcAS. A transfer dose of 106 cells per mouse was adopted to enable ease of
retrieving the cells at early time points of infection. At days 2, 3, 4 and 7 p.i., activated PbTII cells,
defined by expression of CD69 or dilution of CTV, were sorted by flow cytometry cell sorting
(FACS) (Figure 4.1A). Single cells were processed using the Fluidigm C1 platform, which allows
for automated cell lysis, reverse transcription of mRNA and pre-amplification of cDNA, thus
limiting technical variance. For quality control, External RNA Control Consortium (ERCC) spike-
in RNAs were added at a known concentration to each sample at the time of cell lysis. The cDNA
for each cell was harvested and further amplified via polymerase chain reaction (PCR), during
which unique barcodes were added. The cDNA libraries were pooled and cleaned for mRNA of a
minimum length of 100 base pairs (bp). The pooled cDNA libraries were subjected to 100 bp
paired-end Illumina Next-Generation sequencing. Unlike single-end sequencing, paired-end
sequencing allows for both ends of the reference gene to be sequenced, thus improving the quality
of the reads. Additionally, paired-end sequencing allows for detection of genomic rearrangement
and repetitive sequence elements, as well as gene fusions and novel transcripts (Fullwood, Wei et
al. 2009). Transcripts were mapped to the Mus musculus genome and normalised to the ERCC
spike-in measurements. Finally, cell filtering was performed to attain transcriptional data from only
high quality cells (Figure 4.2A).
Firstly, to determine whether this scRNAseq could characterise responding PbTII cells,
dimensionality reduction was performed using PCA on all reads for cells from day 7 p.i.. PCA uses
weighted combinations of each of the gene expression measurements to create composite
parameters that maximally represent the relationship of the cells with a minimal number of new
parameters. This analysis showed clear separation of two populations of PbTII cells along PC2 (Fig
4.2B). Using established makers of either effector fate, these two populations were shown to
correspond to Th1 or Tfh phenotypes (Fig 4.2C) as observed by flow cytometric assessments in
Chapter 3 (Fig 3.4B).
76
Figure 4.1 Sorting strategy for PbTII cells. (A) PbTII cells (CD45.1+ CD4+ TCRβ+) were
adoptively transferred into WT congenic (CD45.2+) recipient mice. At indicated days, early
activated (CD69+) and/or proliferated (CTVlo) PbTII cells were cell-sorted from spleens of PcAS
infected mice, or naïve PbTII cells (CD69loCTVhi) at the indicated days p.i..
FS
C-H
FSC-A
SS
C-A
FSC-A
CD
4
TCRβ
CD
69
CTV
CD
45.1
TCRβ
Day 2
Day 3
Day 4
Day 7
Uninfected day 7
A
77
Figure 4.2 Single-cell mRNA-sequencing of activated antigen-specific PbTII CD4+ T cells. (A)
Experimental setup. PbTII cells were transferred from a single donor to multiple recipients. n is the
number of recipient mice per time point. Also shown are the numbers of single cells from which
high-quality mRNAseq data was successfully recorded. (B) PCA of single PbTII cells at 7 days
post-infection with PcAS. The arrows represent the Pearson correlation with PC1 and PC2. Cell
size refers to the number of detected genes. The size of the data points also represents cell size.
“Th1 signature” and “Tfh signature” refer to cumulative expression of genes associated with Th1
or Tfh phenotypes (Hale, Youngblood et al. 2013). PC, Principal Component. (C) Expression of top
50 genes with largest PC2 loadings of day 7 cells (D). The genes were annotated as Th1- or Tfh-
associated based on public datasets (Marshall, Chandele et al. 2011, Liu, Yan et al. 2012, Hale,
Youngblood et al. 2013, Stubbington MJT 2015). PC, Principal Component. (B) and (D) were
generated by T. Lonnberg.
B C
A
76 78
78
4.3.2 Deducing concurrent Th trajectories during a Mixture of Gaussian Processes model
To assess overall heterogeneity within PbTII cells, PCA was then performed on the entire
PbTII cell dataset across all time points (Fig 4.3A). Although timepoint information was not used in
this analysis, cells clustered largely in accordance with the days at which cells were sorted (Fig
4.3A). This suggested that the gene expression variation between single PbTII cells could be used to
recreate the progression from a state of naivety through to terminal differentiation. To model the
dynamics of the differentiation of these cells, a temporal mixture model that builds on two
modelling approaches, a Gaussian Process Latent Variable Model (GPLVM) and an Overlapping
Mixtures of Gaussian Processes (OMGP) model, was developed and applied (Lawrence 2010).
GPLVM first reconstructed a progression trajectory (termed “psuedotime”) from the observed data,
thereby establishing an order for the cells (Figure 4.3B). Although this model used the sample time
as prior information, the inferred temporal ordering does not strictly adhere to these experimental
time points. For this reason, cells sorted at day 4 p.i. were mixed with some of the cells from day 3
and day 7 at either end of the day 4 pseudotime distribution (Fig 4.3B). This was consistent with the
idea that bulk assessments of cells at specific time points fail to take into account the heterogeneity
and differential kinetics of responses made by individual cells.
Next, OMGP was used to determine whether multiple independent trends could be occurring
(Lawrence 2010). Using this approach, two co-emerging trends or trajectories were identified
(Figure 4.3C). Cells following these alternate trajectories transcribed previously described Th1/Tfh
signature genes (Hale, Youngblood et al. 2013), indicating they corresponded to the emergence of
Th1 and Tfh cells (Fig 4.2C). To determine the time point at which these Th1 and Tfh trajectories
separated or 'bifurcated', they were followed backwards from the ends of the Th1 and Tfh trends,
where trend assignment was clear, to a point where trend assignments became completely
ambiguous. The point at which bifurcation initiated was amongst late day 4 p.i. cells relative to
pseudotime (Fig 4.3C). In a separate repeat experiment performed by Dr Tapio Lonnberg,
scRNAseq was performed on PbTII cells at day 0, 4 and 7 during PcAS infection. Consistent with
the original dataset, PbTII cells at day 7, but not day 4 p.i. were easily clustered into two
populations that corresponded with Th1 and Tfh gene signatures (data not shown). Furthermore,
bifurcating genes in the original dataset were also expressed by day 7 p.i. cells and were able to
independently separate Th1 and Tfh populations (data not shown). Together, this data demonstrates
that the process of pseudotime inference coupled with time series mixture modelling is effective at
modelling the co-development of two Th effector populations during infection and could likely be
applicable more generally for studying cellular processes in scRNAseq data.
79
Figure 4.3 Computational delineation of Th1 and Tfh differentiation trajectories. (A) Principal
component analysis of normalised mRNA expression data of single PbTII cells. (B) Unbiased
ordering of single PbTII cells using a Bayesian Gaussian Process Latent Variable Model and
assuming a 1-dimentional latent space (“pseudotime”). The blue line depicts the progress of
pseudotime. The text labels illustrate features of typical cells on that region of the pseudotime, and
are proved purely as a visual aid. (C) Inference of two simultaneous trends through pseudotime
using Overlapping Mixtures of Gaussian Processes (OMGP). The red and blue lines depict the
distinct trends, corresponding with characteristics of Th1 and Tfh differentiation, respectively. The
black dots correspond to the first instance when the two trajectories can be separated with
confidence. The colours of data points represent their relationship with the Th trends. (B) and (C)
were generated by V. Svensson and T. Lonnberg.
80
Next, PbTII cells at the point of bifurcation were characterised. Bifurcating PbTII cells
expressed the highest number of genes, indicative of high transcriptional activity, compared to those
at all other points in pseudotime (Fig 4.4A). These cells also expressed high levels of the cell-
cycling gene Mki67 (encoding Ki-67) (Fig 4.4B). High expression of Ki-67 before the emergence of
Th effector markers was confirmed on protein level by flow cytometry (Fig 4.4C). Cell cycle
activity was further supported by computational allocation of cells into cell cycle stages (Scialdone,
Natarajan et al. 2015), and flow cytometric confirmation of DNA content and cell size (Figure
4.4D-E). Bifurcating PbTII cells also had increased expression of genes associated with aerobic
glycolysis (data not shown), an indication of increased metabolic requirements being met by
glucose metabolism and increased mTORC1 activity. Consistent with this was the observed
elevated levels of ribosomal protein S6 phosphorylation (p-S6) at day 4 p.i. (Figure 4.4F). These
data suggested that PbTII cells entered an uncommitted state of high metabolic activity and cell-
cycling prior to a commitment to either Th1 or Tfh differentiation.
81
Figure 4.4 Bifurcation of T cell fates is accompanied by changes in transcription, proliferation
and metabolism. (A) The relationship of Th1-Tfh bifurcation point and the number of detected
genes per cell. (B) The expression level of the proliferative marker Ki-67 (encoded by the Mki67
gene) across pseudotime. (C) Representative FACS plots showing kinetics of CellTrace™ Violet
(CTV) dilution and Ki-67, IFNγ or CXCR5 expression, with summary graphs showing % of PbTII
cells expressing these markers (after 106 PbTII cells transferred) in uninfected (Day 0) and PcAS-
infected mice at indicated days post-infection (n=4 mice/time point, with individual mouse data
A B
C
D E F
Day 0 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
IFNγ
0 1 2 3 4 5 6 7
0
2 0
4 0
% I
FN
+
0 1 2 3 4 5 6 7
0
5 0
1 0 0
% K
i-6
7+
CTV
CTV
0 1 2 3 4 5 6 7
0
1 0
2 0
3 0
4 0
5 0
% C
XC
R5
+
CTV
CX
CR
5K
i-6
7
82
shown in summary graphs; solid line in summary graphs indicates results from third order
polynominal regression analysis). Data are representative of two independent experiments. (D)
Experimental and computational analysis of cell cycle speed of PbTII CD4+ T cells activated in
response to PcAS. The allocation of cells to cell cycle phases was performed by flow cytometry
using Hoechst staining and computationally using the Cyclone algorithm (Luscher 2012). The
relative cell-cycle speed was determined by measuring the fraction of cells in S, G2, or M phases.
(E) Cell size estimation using FSC (Forward Scatter) measurements of PbTII cells. (F) Cellular
metabolic activity of PbTII cells in naive mice (n=3) and at days 4 and 7 p.i. (n=6) as determined
by flow cytometric assessment of ribosomal protein S6 phosphorylation (p-S6). Flow cytometric
data are representative of two independent experiments. Statistics are one-way ANOVA and Tukey's
multiple comparisons tests ***p<0.001. NS, not significant. (A), (B) and (D) were generated by T.
Lonnberg.
4.3.3 Mechanisms underlying the differentiation of Th1 and Tfh cells
Molecular mechanisms possibly controlling Th1/Tfh fate decision were next explored. To
this end, the concordance of each gene with bifurcation was calculated as a 'bifurcation statistic'.
The relationship of genes with the direction of bifurcation was determined from the correlation
between their expression and trend assignment (Figure 4.5A). The overall pattern in gene
correlation was an up-regulation of gene expression during progression towards a Th1 fate (Figure
4.5A-B). Among the top genes contributing to the Th1 trend were established genes including Ifng
and Il18ra. In accordance with a recently published report by Shaw et al., Id2 was also among the
top genes associating Th1 commitment (Shaw, Belanger et al. 2016). However, novel genes were
also present including Gna15 and Mxd1, representing genes of interest for Th1 fate commitment.
Likewise, Tfh associated genes included established Tfh genes Cxcr5, Bcl6, IL21 and Tcf1 (encodes
TCF7) as previously reported (Choi, Gullicksrud et al. 2015, Xu, Cao et al. 2015). Novel genes
were also associated with the Tfh fate (Figure 4.5A-B). Assessment of transcription factor Id2
revealed that it continued to increase in expression until differentiation, suggesting that it could be
involved in stabilising fate commitment (Figure 4.5C). Interestingly, Tcf1 expression was high in
the naive state as expected, and was retained only in cells heading towards Tfh commitment. Using
flow-cytometry, the association between TCF7 protein expression and Tfh (CXCR5+) and naive
states, but not the Th1 state, was confirmed (Figure 4.5D).
83
Figure 4.5 Unique gene expression signatures corresponding with Th1 and Tfh differentiation.
(A)Identification of genes associated with the differentiation of Th1 or Tfh cells. For every gene, the
correlation of its expression with pseudotime (x-axis) and Tfh trend assignment (y-axis) are shown.
Statistical significance was determined using the bifurcating score. Genes satisfying the
significance threshold of FDR<0.002 are represented in colours according to the functional
classification of the genes. FDR, False Discovery Rate, estimated by performing the same analysis
with permuted data. (B) The genes with strongest association with Th1 (left) or Tfh (right)
differentiation. The genes were filtered using the bifurcation score as in (B). The genes were then
ranked in descending order of association with either Th1 or Tfh trend. (C) The expression of Id2
(upper panel) and Tcf7 (lower panel) across pseudotime. The curves represent the Th1 (red) and
Tfh (blue) trends when weighing the information from data points according to trend assignment.
The colour of the data points represents the strength of the relationship with the Th1 trend. (D)
Representative FACS plots (gated on CD45.1+ CD4+ TCRβ+ live singlets) showing TCF-1 (gene
product of Tcf7) expression in CXCR5+ (blue gate) and IFNγ+ (red gate) PbTIIs at 7 days post-
11.8 2.8
46.4
0 0
6.4
TCF-1
IFNγ+ CXCR5-
IFNγ- CXCR5+
IFNγ- CXCR5-
Isotype
CXCR5
Naive PcAS
IFNγ
IFN+
CX
CR
5+
0
5 0
1 0 0
1 5 0
2 0 0
TC
F-1
ex
pre
ss
ion
(Ge
om
Me
an
)
*
% o
f M
ax
D
A
C
B
84
infection (n=4) (isotype control shown in black in FACS histogram), compared to naïve PbTIIs
(grey gate) (n=1). Summary graph shows mean & standard deviations for geometric mean
fluorescence intensity of TCF-1 expression in gated PbTII populations. Statistics: Mann-Whitney U
test, *p<0.05. (A), (B) and (D) were generated by T. Lonnberg.
4.3.4 IFNγ and IL-10co-producing PbTII cells emerge from Th1 cells
Expression of the regulatory cytokine, Il-10, emerged after bifurcation and exhibited similar
kinetics and Th1 fate association as Ifnγ (Figure 4.6). Assessment of Ifnγ andIl-10 expression by
PbTII cells at day 7 p.i. revealed a population of co-producing cells, commonly referred to as Tr1
cells, emerging from Ifnγ+ cells (Figure 4.6).
Figure 4.6 IL-10/IFNγ co-producing PbTIIs begin to emerge from Th1 cells late in pseudotime. The expression of IFNγ (upper panel) and Il-10 (lower panel) across pseudotime. The curves
represent the Th1 (red) and Tfh (blue) trends when weighing the information from individual PbTII
cells according to trend assignment. Dot plot of Ifnγ and Il-10gene expression PbTIIs from day 7
p.i., with green box showing Il-10 producers as co-expressors of Ifnγ.Figure generated by T.
Lonnberg.
IFN
IL-10
IFN log(TPM+1)
IL-1
0 log
(TP
M+
1)
Pseudotime
Exp
ressio
n (
Log
10
TP
M)
85
4.3.5 PbTII cells are receptive to chemokine signals at bifurcation
Included in the top genes corresponding to either Th1 or Tfh trajectories were a number of
chemokine receptors. Among the highest ranked genes for the Th1 fate were Cxcr6, Ccr2, Ccr5,
Ccr4 and Cxcr3 (Figure 4.5A). In contrast, the only bifurcating chemokine receptor associated with
Tfh fate development was Cxcr5 (Figure 4.5A). When investigating the kinetics of chemokine
expression, two waves could be identified (Figure 4.7A). Cxcr6, Ccr2, and Ccr5 were among a late
wave, whose expression began after bifurcation and continued to increase with differentiation
(Figure 4.7A). The kinetics of CXCR6 expression and association with the Th1 phenotype was
confirmed on the protein level (Figure 4.7B-C). In contrast, Cxcr5, Cxcr3 and Ccr4 were among an
early wave, whose transcription and translation into protein peaked around the time of bifurcation
(Fig 4.7A and 4.7D). The difference in the timing of peak expression of these chemokine receptors
was reasoned to be due to differences in their function. For instance, while the late stage bifurcating
genes Cxcr6, Ccr2 and Ccr5 might be important for trafficking and effector function of CD4+ T
cells, earlier expression of Cxcr5, Cxcr3 and Ccr4 might be involved in cell-to-cell interactions that
promote differentiation of activated PbTII cells prior to bifurcation (Figure 4.8).
86
A
B
C
D 15.7 11.9
10.9
CXCR5
CX
CR
3
2.8 0.4
0.8
Naïve PcAS
Naiv
e
PcA
S
0
5
1 0
1 5
% C
XC
R3
+C
XC
R5
+
*
CTV 0 1 2 3 4 5 6 7
0
1 0
2 0
3 0
4 0
% C
XC
R6
+Day 0 Day 4 Day 5 Day 6 Day 7
CX
CR
6
T-bet+ Bcl6-
T-bet- Bcl6+
T-bet- Bcl6-
Day 0 Day 7
T-b
et
+B
cl6
+
0
5 0
1 0 0
1 5 0
2 0 0
CX
CR
6 e
xp
re
ss
ion
(Ge
om
Me
an
)
*
CXCR6 Bcl6
T-b
et
2.5
9.9
72.7
39.9
47.2
3.6
% o
f M
ax
87
Figure 4.7 Chemokine signals underlying Th fate commitment. (A) The expression kinetics of the
chemokine receptor genes Cxcr5, Cxcr3, Ccr4, Ccr2, Ccr5, and Cxcr6 across pseudotime. The
curves represent the expression patterns associated with the Th1 (red) and the Tfh (blue) trends. (B)
Representative FACS plots (gated on CD45.1+ CD4+ TCRβ+ live singlets) showing kinetics of
CellTraceTM Violet (CTV) dilution and CXCR6 expression, with summary graphs showing
proportion of PbTII cells expressing CXCR6 (after 106 PbTII cells transferred) in un-infected (Day
0) and PcAS-infected mice at indicated days p.i. (n=4 mice/time point, with individual mouse data
shown in summary graphs; solid line in summary graphs indicates results from third order
polynominal regression analysis). (C) Representative FACS plots (gated on CD45.1+ CD4+ TCRβ+
live singlets) showing CXCR6 expression in T-bethi (red gate) or Bcl6hi (blue gate) PbTII cells,
compared to naïve PbTIIs (grey) at 7 days p.i.. Summary graph shows mean & standard deviations
for geometric mean fluorescence intensity of CXCR6 expression in gated PbTII populations (n=4
mice). Data are representative of two independent experiments. Statistics: Mann-Whitney U test
*p<0.05. (A) was generated by T. Lonnberg.
Figure 4.8 Bifurcation of PbTII cells into Th1 and Tfh effector cells. A model summarizing the
expression patterns of Id2, Tcf7, and chemokine receptors during Th1-Tfh cell fate determination.
The size of the cell represents proliferative capacity and the colour of receptors and transcription
factors represent differences in expression level.
88
4.3.6 B cells support Tfh responses
Since CXCR5 drives migration and retention of Tfh cells in B cell areas (Breitfeld, Ohl et al.
2000, Kim, Rott et al. 2001, Chtanova, Tangye et al. 2004), the role of B cells in supporting Tfh fate
commitment in PbTII cells was explored. To this end, an anti-CD20 depleting antibody was used to
deplete B cells from mice prior to infection with PcAS. Tfh responses were significantly reduced in
B cell-depleted mice compared to control-treated mice (Figure 4.9). In contrast, Th1 cell
proportions were comparatively improved in B cell depleted mice (Figure 4.9). These data revealed
that B cells were crucial for Tfh differentiation, but not Th1 differentiation of PbTII cells.
Figure 4.9 B cells are essential for Tfh responses in PbTII cells during PcAS
infection.Representative FACS plots (gated on CD4+ TCRβ+ CD45.1+ live singlets) and summary
graphs of splenic PbTII cells, showing absolute and relative numbers exhibiting Tfh (Bcl6+
CXCR5+) and Th1 (T-bet+ IFNγ+) phenotypes in WT mice (receiving 104 PbTII cells) treated with
anti-CD20 monoclonal antibodies to deplete B-cells, or control IgG, and infected for 7 days with
PcAS. Naïve mice received 106 PbTII cells. Individual mice data are (n=5) shown in summary
graphs. Results are representative of two independent experiments. Mann-Whitney U test *p<0.05;
**p<0.01.
Bcl6
CX
CR
5
IgG αCD20 Naive
5.1 22.0 36.5
T-bet
IFNγ
4.6 17.4 3.3
0
20
40
60
% T
-bet+
IF
Ng+
*
IgG
αCD20
0
2
4
6
8
PbT
II c
ells
(x10
5)
0
5
10
15
20
% B
cl6
+ C
XC
R5
+
**
IgG
αCD20
0
2
4
6
8
10
Bcl6
+ C
XC
R5
+ (x 1
04)
**
IgG
αCD20
0
10
20
30
T-b
et+
IF
Ng+
cells
(x 1
04)
89
4.3.7 ScRNAseq assessment of myeloid cells during PcAS infection
Given that B cells were essential for Tfh commitment, it was hypothesised that myeloid cell
might provide alternative, competing support for Th1 commitment. Therefore, scRNAseq was
performed on splenic CD8α+ CD11b- cDCs, CD8α- CD11b+ cDCs, and Ly6Chi inflammatory
monocytes prior to the bifurcation of PbTII cells and from the same PcAS infected mice (Fig 4.1A
and Fig 4.10). This approach was particularly appropriate given the possibility that subsets of the
myeloid cell-types were providing unique signals to uncommitted PbTII cells.
Firstly, PCA of all cDCs separated naïve CD8α+ cells from their CD8α- counterparts along
PC2 (Fig 4.11). Differential gene expression analysis of these two naïve subsets, using the
algorithm Monocle (Trapnell, Cacchiarelli et al. 2014), showed generally higher expression of
genes within the CD8α- subset (Fig 4.12A-C). Among these were genes known to associate with
either subset, including Cd8α, Irf8, Clec4a4 and Sirpα. However, new associations were identified
including co-stimulatory molecule Cd80 with CD8α- cells and Cxcl9 with CD8α+ cells, suggesting
differences in the steady-state condition of these two subsets. While naïve CD8α+ and CD8α- cDCs
were easily discernible on the transcriptional level, no obvious clusters were evident amongst day 3
p.i. cDCs (Fig 4.11) suggesting a convergence of these cells during infection. Nevertheless, using
only differentially expressed genes between naïve CD8α+ and CD8α- cDCs, day 3 p.i. cDCs were
clustered into two approximately equal clusters, as per the mixing ratio of CD8α+ to CD8α- prior to
processing and sequencing (Fig 4.12D). These results demonstrate the un-biased separation of naïve
cDCs by single-cell transcriptomics, and a general convergence at a transcriptomic level upon
activation, as previously reported (Jaitin, Kenigsberg et al. 2014).
90
Figure 4.10 Sorting strategy for myeloid cells.Representative FACS plots showing sorting strategy
for CD8α+ and CD11b+ cDCs, and Ly6Chi inflammatory monocytes from the spleens of naive and 3-
day PcAS-infected mice.
FS
C-H
FSC-A
SS
C-A
FSC-A
B220
FSC-A
TC
Rβ
FSC-A
Ly6
C
CD11b
Ly6G
Ly6C
CD
11c
MHCII
CD
8α
CD11b
6.62
2.56
7.55
15.7
59.6
25.9
84.2
78.9
Day 3
Naive
Day 3
Naive
CD8α+/CD8α-
cDC
Ly6Chi
monocyte
91
Figure 4.11 Principal Component Analysis of cDCs from naïve and infected mice. Principal
Component Analysis (PCA) of mRNA reads (filtered by minimum expression of 100 TPM in at least
2 cells) from 131 single splenic naïve CD8α+ and CD8α- and mixed day 3 PcAS-infected cDCs.
PC1-PC6 shown. Axis labels show proportional contribution of respective PC.
92
Figure 4.12 Differential gene expression between single splenic CD8α+ and CD8α- cDCs. (A)
Results of differential gene expression analysis between naïve splenic CD8α+ and CD8α- cDCs, for
all genes expressed in greater than 2 cells. (B) Complete list of differentially-expressed genes
between naïve CD8α+ and CD8α- cDCs, which were expressed in >10 cells of either subset with a
qval <0.2 as determined in (A). (C) Heatmap of naïve cDCs ordered by PC2 (Figure 4.10) and
expression of genes from (B) ordered by PC2 loading in (Figure 4.10). (D) Heatmap examining
hierarchical clustering of mixed CD8α+ CD11b- and CD8α- CD11b+ day 3-infected cDCs (cell-
sorted and mixed at a ratio of 50:50 prior to scRNAseq) using differentially expressed genes from
(B) ordered by PC2 loading shown in (Figure 4.10).
93
PCA conducted on all genes in cDCs also separated naïve cells from day 3 p.i. cells along
PC6 (Figure 4.11 and 4.13A). To explore genes contributing to changes in these cDC states,
differential expression analysis was performed on naïve versus day 3 p.i. cDCs. This identified 30
differentially expressed genes, 29 of which were upregulated during infection (Figure 4.13B and
4.14). Among these upregulated genes were interferon-related transcription factors Irf1 and Stat1,
and CXCR3 ligands Cxcl9 and Cxcl10. Notably, expression patterns varied for individual genes.
For example Stat1 and Irf1 were both expressed in naïve cells, but further upregulated during
infection (Figure 4.13C and 4.15). Cxcl9 was expressed in naïve CD8α+ cells and also upregulated
during infection. On the other hand, Cxcl10 was not expressed in naïve cells, but was expressed
upon infection (Fig 4.13C and 4.15). These results showed that cDCs experienced up-regulation of
several genes during infection but little down-regulation, and furthermore, suggested that cDCs
were capable of interacting with CXCR3+ T cells via expression of Cxcl9/10 as previously reported
(Groom, Richmond et al. 2012).
94
Figure 4.13 cDCs influence Th bifurcation in uncommitted PbTII cells. (A) Principal Component
Analyses of mRNA reads (filtered by minimum expression of 100 TPM in at least 2 cells) of 131
single splenic CD8α+ and CD11b+ CD8α- cDCs from a naïve mouse, and mixed cDCs from a day
3-infected mouse, showing PC combinations best separating populations cells. (B) Volcano plots
showing fold-change and confidence for differentially expressed genes between naïve and infected
cDCs- genes filtered on expression in >10 cells; genes satisfying qval<0.05 are represented in
colours according to functional classification displayed (Full list is included as Figure 4.13). (C)
Expression heatmaps for significantly (qval<0.05) differentially expressed genes in (B): cells and
genes are ordered according to PC6 score and loading respectively as in (A).
95
Figure 4.14 Differentially-expressed genes between single naïve and day 3 PcAS-infected cDCs.
List of differentially-expressed genes, expressed in >10 cells (qval<0.05) between naïve and day 3-
infected cDCs. Mean TPM fold-change in gene expression is relative to naïve levels.
Gene name Log2(Fold Change) qval
Pianp -7.262625898 1.14E-37
Tgtp1 4.359998594 4.84E-11
Tgtp2 2.78069932 1.68E-10
Ifi47 3.557446068 4.23E-10
Kdm6b 4.254218426 1.22E-09
Actb 1.621695106 1.01E-07
Igtp 4.003078626 1.43E-07
AC124762.1 3.062289012 3.69E-07
Gm15427 -0.977819831 1.51E-06
Stat1 2.491431703 1.92E-06
U6 -3.307885729 8.27E-06
Snora31 0.926874728 9.92E-06
Nlrc5 2.091145817 1.43E-05
Gm12250 5.431395825 1.61E-05
Zbp1 4.871392677 5.59E-05
Gbp4 3.405248926 0.000181786
R3hdm4 2.1863913 0.000251891
Slc39a1 3.199473697 0.000708528
Gm10800 0.641967923 0.00083472
Cxcl10 3.425848442 0.001808979
Alkbh5 3.19927987 0.001977138
Cxcl9 2.422667011 0.002384972
Dtx3l 1.744309287 0.004686724
Wtap 2.846340387 0.004866485
AC131780.3 1.105647313 0.005073109
Gbp3 1.396086788 0.005888858
Wac 2.867605317 0.008312287
Pml 2.963358709 0.013544203
Arf4 1.885252908 0.015554393
Irf1 1.437877607 0.022724835
Gbp2 2.124613484 0.045504232
96
97
98
Figure 4.15 Expression of immune-related molecules by myeloid cells. Heatmaps showing
normalised mRNA expression of select (A) chemokines, (B) costimulatory molecules and (C)
cytokines and respective receptors (rows) by single splenic cDCs and Ly6Chi monocytes (columns)
from naïve or 3-day PcAS-infected mice.
99
4.3.8 Ly6Chi monocytes support Th1 fate, but not Tfh fate, commitment
Ly6Chi inflammatory monocytes have been shown to migrate from the bone marrow to the
spleen during blood-stage Plasmodium infection, and furthermore, up-regulate MHCII expression
(Sponaas, Freitas do Rosario et al. 2009). Therefore, it was hypothesised that they also played a role
in mediating Th cell responses. Firstly, PCA of all monocyte scRNAseq data allowed for unbiased
separation of naïve and day 3 p.i. cells along PC2 (Figure 4.16 and 4.17A). Differential gene
expression analysis of naïve versus day 3 p.i. cells identified approximately 100 genes, which
unlike cDCs, were both up- and down-regulated during infection (Figure 4.17B and 4.18). This
highlights a significant difference in the directionality of gene expression during infection between
cDCs and monocytes. Among the top upregulated genes were chemokines including Cxcl2, Ccl2
and Ccl3. Of particular interest, ~40% of up-regulated genes by monocytes were in common with
those up-regulated in cDCs (Figures 4.13C and 4.17C), including Stat1, Irf1 and Cxcl10. This
suggested possible similarities in the functions of monocytes and cDCs during infection.
Furthermore, monocytes up-regulated an array of immune-interaction related genes including Tnf,
Cd40, Pdl1, Ccl4, Ccl5, Cxcl16, Cxcl9, and Cxcl11, providing evidence of complex interactions and
multiple roles for these cells during infection (Figure 4.15). Assessment of the kinetics of one of
these chemokines, Cxcl9, a ligand for CXCR3 that was highly expressed by non-bifurcated PbTII
cells (Figure 4.6), showed similar expression in both cDCs and Ly6Chi monocytes (Figure 4.19).
Expression of CXCL9 in both myeloid populations was evident by day 4 p.i., which corresponded
to the start of PbTII bifurcation (Figure 4.3C and 4.19). Thus, these results indicated that, like
cDCs, Ly6Chi monocytes possessed the ability to signal to CXCR3+ uncommitted PbTII cells.
100
Figure 4.16 Principal Component Analysis of Ly6Chi monocytes from naïve and infected mice. Results of Principal Component Analysis, using scRNAseq mRNA reads (filtered by minimum
expression of 100 TPM in at least 2 cells), from 154 single splenic Ly6Chi monocytes from naïve
and infected mice. PC1-PC6 shown. Axis labels show proportional contribution of respective PC.
Arrows demonstrate the correlation between number of expressed genes and PCs.
101
Figure 4.17 Ly6Chi monocytes display similar functional capacity as cDCs. (A) Principal
Component Analysis of mRNA reads, filtered by minimum expression of 100 TPM in at least 2 cells,
of 154 single Ly6Chi monocytes from naïve and infected mice, showing PC combinations best
separating populations of Ly6Chi monocytes from naïve and infected mice. (B) Volcano plots
showing fold-change and confidence for differentially expressed genes between Ly6Chi monocytes in
infected versus naïve mice - genes filtered on expression in >10 cells; genes satisfying qval<0.05
are represented in colours according to functional classification displayed. (C) Expression
heatmaps for significantly (qval<0.05) differentially expressed genes in Ly6Chi monocytes, between
naive and infected mice: cells and genes are ordered according to PC2 as in (A).
102
Gene names Log2 (Fold Change) qval
Gbp2 5.343418344 2.14E-33
Egr1 5.025006039 1.11E-25
Ifi47 3.25317286 6.85E-20
Cxcl10 9.85360446 8.78E-20
Irf1 3.970316816 3.93E-17
Tgtp1 12.50667977 9.12E-17
Tgtp2 3.857804903 7.32E-15
Stat1 2.746907486 2.36E-10
Gbp4 5.769038177 1.34E-09
Igtp 2.698204505 1.46E-09
Fam26f 4.706888987 1.56E-08
Ifi205 2.558201091 6.71E-08
Gbp7 2.716164761 9.43E-07
U2 3.961441106 9.47E-07
U2 3.961231475 9.48E-07
U2 3.961976492 9.48E-07
U2 3.961489939 9.48E-07
Gbp6 7.596693594 1.30E-06
Irgm1 2.554582038 2.23E-06
Gbp3 3.654656366 3.14E-06
Serpina3g 10.47471346 4.62E-06
Nfkbiz 3.217801159 7.52E-06
Gm17334 3.707732087 8.59E-06
Gbp5 5.768713305 9.75E-06
D4Wsu53e -1.288040437 1.86E-05
Ceacam1 -1.486635161 1.94E-05
Gpcpd1 -3.576733856 1.98E-05
Hpgd -2.92213678 2.11E-05
Pim1 2.213701378 2.51E-05
Cd244 -2.007720552 3.26E-05
Cd40 1.698069689 7.05E-05
Cd274 5.404622826 8.55E-05
Cd300lb -1.80189338 0.000103172
Kdm6b 2.709769407 0.000130236
CT572998.1 4.259284122 0.000138539
Nfkbia 2.509585516 0.000147245
Cxcl2 5.033164709 0.000187925
Ccl3 5.803174704 0.00021635
Pira2 -2.108050548 0.000224494
Susd3 -1.732317859 0.000287997
Nfic -4.21991054 0.000325979
Ogt -1.844048384 0.000337242
Mll3 -2.637985297 0.000371892
Mast3 -9.017849562 0.000378042
Ptpre -1.633894765 0.000403653
Ccrl2 4.814048545 0.000416755
Lilra6 -2.054712791 0.000437711
Atp2b1 -1.48633724 0.000471865
Ptplad2 -1.122982025 0.00083638
Dnm1l -2.684877387 0.000891606
Stk4 -1.035914887 0.001069216
Hmgb2 -0.207565085 0.001163912
Mar-01 -1.991700596 0.001322837
Ifit2 3.957433264 0.00143919
Klf4 -2.630782711 0.001586378
Calm2 -0.875337793 0.001609773
Itfg3 -1.448044803 0.002167052
Dnase1l3 3.164154469 0.002213986
Nrp2 3.684929824 0.002518771
Zbp1 1.922148464 0.003888078
Gbp9 1.57174886 0.003914237
Tsc22d3 -1.148850425 0.00396859
Rell1 -2.692054659 0.004025406
Srsf2 -1.228632903 0.004077318
Jun 2.221736196 0.005316553
Hnrnph1 -2.226101504 0.005488455
Itgb2 -1.023709661 0.005808116
Ifit3 2.666797336 0.005902332
Eif4a2 -1.392997137 0.006046446
Rps6ka1 -1.7229663 0.006594323
Rtp4 2.192950173 0.006616606
Sfr1 -0.700341246 0.006695782
Fam107b -1.630418866 0.007788727
Tmem164 -1.105130173 0.007980954
Mnda 1.139858542 0.009659075
Glg1 -0.769603966 0.010631512
Irgm2 3.514642515 0.011006151
Emilin2 -1.779653439 0.011571272
Tlk1 -2.156357298 0.011857332
Tmem126b -6.422066301 0.014667174
Lrp1 -1.509844249 0.01681349
Zzef1 -4.023332903 0.017752319
Pik3cg -1.615162871 0.01892715
Camk1d -0.381536785 0.019708425
Cd84 -1.748595178 0.019823417
Vps13c -1.655458694 0.020838227
Cd300ld -4.309443608 0.021491441
Atf3 2.585532022 0.021661981
Emr4 -1.483345739 0.022678297
Cx3cr1 -2.061113213 0.02338043
Nedd8 -0.453894943 0.024468547
Tubb6 -1.63027126 0.025148487
Ndrg1 -1.902455843 0.028273704
Mknk2 -1.739508433 0.0286694
Pqlc3 -1.400220797 0.029203455
Nfam1 -1.189024309 0.030856908
Fam89b -1.853036401 0.031955789
U2 8.954028155 0.032731379
U2 8.953370271 0.032731379
Foxj2 -4.788634353 0.033617561
H2-Q10 2.322965089 0.036776651
Ccl2 5.211788278 0.038421772
Idh1 -1.68740312 0.040729371
Gm12250 2.676296613 0.043565984
Fam46a -0.638461732 0.043914316
Ankrd44 -0.778489063 0.045666952
Pdcd4 -0.894788719 0.047438862
Figure 4.18 Differentially-expressed genes between single Ly6Chi monocytes from naïve and day
3 PcAS-infected mice. List of differentially-expressed genes, expressed in >10 cells (qval<0.05)
between Ly6Chi monocytes from naïve and day 3-infected mice. Mean TPM fold-change in gene
expression relative to naïve levels.
103
Figure 4.19 Kinetics of CXCL9 expression by myeloid cell populations. Representative FACS
histograms and proportions of splenic CD8α+ cDCs, CD8α- cDCs and Ly6Chi monocytes expressing
CXCL9 in naive and infected mice between 2-7 days p.i. with PcAS- individual mouse data plotted
with line at mean; data representative of two independent experiments (n=4 mice/time
point/experiment).
To test the requirement for cDCs and Ly6Chi monocytes in supporting Th1 differentiation,
CD11c-DOG and LysMCre x iDTR systems were employed. In these respective systems CD11c-
expressing cDCs and Ly6Chi monocytes were depleted upon administration of DT at day 3 p.i., a
time when adoptively-transferred PbTII cells had been primed, but were yet to differentiate (Figure
4.3C and 4.20A). Of note, other CD11c-expressing cells including B cells are also depleted from
DT-treated CD11c-DOG mice (Hochweller, Striegler et al. 2008). In addition to robust monocyte
depletion from the LysMCre x iDTR mice, in an experiment performed by Ismail Sebina, ~30% of
CD68+ macrophages, but not marginal zone macrophages, were also depleted in these mice (data
not shown). No effect was observed for cDCs, T cells or B cells in DT-treated LysMCre x iDTR mice
during infection (data not shown).
At day 7 p.i., PbTII cells recovered from DT-treated LysMCre x iDTR mice had significantly
lower proportions and a trend towards reduced absolute numbers of Th1 PbTII cells compared to
saline-treated controls (Figure 4.20). Tfh proportions were comparably improved (Figure 4.20).
Similarly, depletion of cDCs resulted in a slight, but not significant decrease in Th1 proportions and
total numbers, and an increased proportion of Tfh PbTII cells (Figure 4.20). Together, these data
supported a model in which progression of activated, uncommitted PbTII cells towards a Tfh fate
N 2 3 4 5 6 7
0
2 0
4 0
6 0
8 0
1 0 0
N 2 3 4 5 6 7
0
2 0
4 0
6 0
8 0
1 0 0
% C
XC
L9
+
N 2 3 4 5 6 7
0
2 0
4 0
6 0
CD8α+ DC CD8α- DC Ly6chi Monocytes
Days post-infection
0
2
3
4
5
6
7
FMOCXCL9
% o
f M
ax
104
was dependent upon B cells, and a Th1 fate was enforced by DCs and more substantially by
chemokine-expressing Ly6Chi inflammatory monocytes (Figure 4.21).
Figure 4.20 Ly6Chi monocytes support Th1 responses. (A) Scheme depicting experimental design:
PbTII cells were transferred into WT, CD11c-DOGmice, LysMCre x iDTR mice 1 day prior to
infection. At 3 days p.i., mice were treated with diphtheria toxin (DT) or control saline, with PbTII
Th responses assessed at 7 days p.i.. (B) Representative FACS plots (gated on splenic PbTII
cells)showing proportions, and (C) absolute numbers of Th1 (T-bethi IFNγ+) and Tfh (CXCR5+)
PbTII cells in DT or saline-treated LysMCre x iDTR mice and DT treated WT and CD11c-DOG
mice. LyMCre-iDTR data are representative of three independent experiments, and CD11c-DOG
data represents a single experiment. Numbers depict proportions within respective gates. Statistics:
Mann-Whitney U Test. ****p<0.0001. NS, not significant.
PcAS infection
Day 0 Day -1 Day 3 Day 7
Monocyte or cDC depletion
(Diphtheria toxin
(DT))
Transfer of PbTII cells
into LysMCre x iDTR or
CD11cCre x iDTR mice
Analysis of PbTII response
Time
4.8
Naive LysMCre x iDTR :
Saline LysMCre x iDTR :
DT
T-bet
IFNγ
CX
CR
5
PD1
0.6
20.8 16.2 19.2 11.6
18.2 25.2 20.3 15.3
WT: DT CD11c-DOG:
DT 0
10
20
30
% T
-bet+
IF
Ng+
NS*
0
20
40
60
80
100
T-b
et+
IF
Ng+
cells
(x 1
04)
NS
NS
WT:DT
CD11
cCre x
iDTR
:DT
LysM
Cre x
iDTR
:Sal
ine
LysM
Cre x
iDTR
:DT
0
10
20
30
40
% C
XC
R5
+
**
WT:
DT
CD11
c-DOG:D
T
LysM
Cre x
iDTR
:Saline
LysM
Cre x
iDTR
:DT
0
20
40
60
80
100
CX
CR
5+ cells
(x 1
04)
NS
NS
105
Figure 4.21 PbTII differentiation is influenced by chemokine-producing cells. Summary model
proposing chemokine interactions between non-bifurcated PbTII cells and myeloid cells support a
Th1 fate, while the Tfh fate is sustained by B cells.
106
4.4 Discussion
Th cells control immune responses during infection, cancer and auto-immunity. Therefore,
understanding the process of Th differentiation is of paramount importance. Previous techniques
have struggled to study this process at a genomic level in vivo due to the extent of heterogeneity
within the responding T cell pool. Here, scRNAseq was applied to PbTII cells during in vivo blood-
stage PcAS infection. Using a newly developed computational approach, the process of
differentiation was modelled from this data, revealing two alternate trajectories corresponding to
Th1 and Tfh differentiation.
Significant findings of this study are novel genes corresponding to either Th differentiation
trajectory. Top hits included previously established genes such as Ifng, Id2, Tcf1 and Cxcr5,
supporting the biological accuracy of this model. In addition, novel genes, such as Mxd1 and Asap1,
associating with Th1 and Tfh differentiation were identified and could represent possible targets for
tailoring Th differentiation. A possible direction for future work is the exploration of the roles
played by these genes in Th differentiation by PbTII cells.
Several studies have followed the cell fate decision to determine contributing factors.
Limiting dilution studies conducted in the laboratory of Marc Jenkins showed that single transferred
T cells gave rise to both Th1 and Tfh effector cells, as seen from PbTII cells. In addition, their study
showed that clonal cells tended to generate a similar pattern of effector cells, consistent with the
idea the unique TCRs predispose T cells toward a particular fate (Tubo, Pagan et al. 2013).
Marchingo et al. employed in vitro culture of CD8+ T cells with different combinations of stimuli
and in vivo validation to further explore the role of the TCR in cell fate (Marchingo, Kan et al.
2014). They showed that early TCR signalling and costimulatory signals imprinted the T cell with a
defined division fate. In vitro work by Pham et al. further showed that interactions with stromal
cells and chemokine receptor signalling resulted in the assymetric cell division of T cell and
differential inheritance of fate determinants by daughter cells (Pham, Shimoni et al. 2015). In this
way, the microenvironment influenced fate decision of developing cells. The current study has
added to this body of work by showing that PbTII cells express many genes prior to fate
commitment, including chemokine receptors that can facilitate either Th1 or Tfh differentiation.
This suggests that uncommitted CD4+ T cells require external signals, such as those provided
through chemokine receptors, to skew gene expression towards one of the effector fates. Without
knowing the true identity of the cells tested here, it is difficult to know exactly when this
commitment occurs. However, the modelling of the expression data suggests that bifurcation occurs
several days after priming and at approximately the same time as peak gene expression, suggesting
that as the cell fate solidifies, gene expression becomes more specific.
107
Among the chemokine receptors that peaked in expression around bifurcation, only Cxcr5
associated with Tfh trend assignment. Since CXCR5 permits T cells to enter the B cell follicle, this
association supports the requirement of B cells in Tfh responses (Kerfoot, Yaari et al. 2011).
Indeed, Tfh responses, but not Th1 responses, were significantly impaired upon B cells depletion.
The initial differentiation of Tfh cells has been reported to occur independently of B cells (Kerfoot,
Yaari et al. 2011). In a separatestudy, differentiation of Tfh cells was demonstrated to rely on
CD8α- cDCs within the interfollicular zone via enhanced ICOSL and OX40L expression in
response to targeted Yersinia pestia and OVA antigens (Shin, Han et al. 2015). Here, scRNAseq of
cDCs at the time of PbTII bifurcation revealed expression of ligands for CXCR3, but not CXCR5,
suggesting they preferentially support Th1 differentiation (Groom, Richmond et al. 2012).
Furthermore, timed depletion of CD11c-expressing DCs resulted in a trend towards decreased Th1
responses, but no change in Tfh responses. T, this suggests that B cells in the follicle are the
primary support for Tfh responses during Plasmodium infection, however other cells may be
involved at different stages of Tfh differentiation.
For the first time, inflammatory monocytes were shown to adopt a similar transcriptional
profile to cDCs, suggesting similar roles during in vivo Plasmodium infection. Previous ex vivo
studies dismissed the role of inflammatory monocytes in priming CD4+ T cell responses during
malaria (Sponaas, Cadman et al. 2006), but did not determine whether they provided support for Th
differentiation. By using a timed-depletion system in vivo, inflammatory monocytes were
demonstrated to provide support to activated PbTII cells. While Th1 responses were impaired in
these monocyte-depleted mice, the absolute number of Tfh PbTII cells was unchanged, suggesting
that monocytes have a role in enforcing rather than driving Th1 commitment at the expense of Tfh
differentiation. An important caveat was the partial depletion of splenic CD68+ macrophages in the
LysMCre x iDTR transgenic system. Therefore, a role for these macrophages in supporting Th1 fate
cannot be discounted. Nevertheless, inflammatory monocyte-mediated support for Th1 responses is
consistent with viral and fungal infection studies (Hohl, Rivera et al. 2009, Nakano, Lin et al. 2009,
Wuthrich, Ersland et al. 2012).
Together, these data support a model in which cDCs prime naïve antigen-specific T cells,
driving them to proliferate and reach a state of high cell-cycling and stochastic gene expression.
PbTII cells then become receptive to chemoattractant signals from multiple cell types in different
zones of the spleen. For example, B cells support Tfh commitment, while cDCs and inflammatory
monocytes enforce Th1 fate commitment. These signals are not necessarily competing. While this
study has focused on intercellular singling as a central mediator of Th fate commitment, upstream
intracellular balances of gene expression likely also contribute. Follow up studies into the spatial
108
positioning of activated T cells within secondary lymphoid tissue and their direct interaction with
chemokine-expressing cells may further solidify this model.
109
Chapter Five:
Interferon Regulatory Factor 3 balances Th1 and Tfh-dependent
immunity during blood-stage Plasmodium infection
5.1 Abstract
Innate immune signalling pathways are activated during blood-stage Plasmodium infection
and serve to elicit an inflammatory response. Given that innate immune cells can modulate parasite-
specific CD4+ T helper cell differentiation, as described in Chapter 4, it was hypothesized that
molecules associated with innate immunity were also involved. To date, however, this has been
largely unstudied during Plasmodium infection. Using non-lethal, resolving models of blood-stage
malaria, endosomal and cytosolic signalling pathways were compared for their role in mediating
PbTII cell responses. While no major roles were identified for individual pathways, IRF3, which
sits at the convergence point for multiple pathways, was shown to influence PbTII responses. In
particular, IRF3 promoted proliferation and differentiation of Th1 cells, which was associated with
MHCII expression by Ly6Chi inflammatory monocytes and early parasite control. Conversely, IRF3
also acted within B cells to suppress anti-parasitic humoral immune responses, such as the
development of germinal centre B cells, Ig-class switching and Tfh cell responses. Importantly,
IRF3-mediated suppression of humoral immunity was associated with impaired resolution of
infection. Thus, a novel role for an innate immune transcription factor, IRF3, was delineated in
governing the balance between Th1 and Tfh-dependent immunity during experimental blood-stage
malaria
110
5.2 Introduction
Pattern Recognition Receptor (PRR) pathways have been implicated in innate immune
recognition of pRBC-derived molecules such as haemozoin and Plasmodium DNA, via TLRs,
NOD-like receptors (NLRs), and cytosolic DNA detection via STING (encoded by
Tmem173)(Krishnegowda, Hajjar et al. 2005, Parroche, Lauw et al. 2007, Kalantari, DeOliveira et
al. 2014). In these studies, the biological importance of PRR-related molecules was inferred in vivo
based on systemic inflammatory cytokine production. However, few studies have explored in vivo
roles for PRR-related molecules in driving adaptive immune responses during Plasmodium
infection (Franklin, Rodrigues et al. 2007).
IRFs were originally discovered, and are best known for roles in driving production of Type
I IFN, and expression of Interferon-stimulated genes (ISGs) (Tamura, Yanai et al. 2008). However,
it is becoming increasingly clear that IRFs perform many distinct roles in vivo. For instance, while
IRF7 is a master controller of Type I IFN responses (Honda, Yanai et al. 2005), IRF1, 2, 4 and 8
play crucial roles in the development and immunological responses of haematopoietically-derived
immune cells. IRF3 has been reported to perform several functions, including the production of
IFNβ and the suppression of tumour growth via apoptosis in response to DNA-damage.
Furthermore, an in vitro report described a role for IRF3 in B cells responding to CpG (Oganesyan,
Saha et al. 2008), while TBK1, a primary activator of IRF3, was reported to restrain B cells from
immunoglobulin class-switching and IgA-mediated pathology in mice (Jin, Xiao et al. 2012).
Finally, IRF3 is positioned at a convergence point for multiple PRR-signalling pathways, including
those mediated by TRIF-dependent TLRs, MAVS, and STING (Servant, Grandvaux et al. 2002),
which highlights its capacity to integrate and convey innate immune signals to the adaptive immune
system. In support of this, IRF3 has been reported to play context-dependent roles in controlling Th
responses. During viral and bacterial co-infection, IRF3 suppressed Th1 responses by competing for
binding to the IL12β promoter in macrophages (Negishi, Yanai et al. 2012). Conversely, IRF3
drove Th1 and Th17 responses in the central nervous system during experimental autoimmune
encephalomyelitis (Fitzgerald, O'Brien et al. 2014). Therefore, IRF3 displays significant potential to
influence Th and B cell responses, and indeed is likely activated in response to pRBCs (Sharma,
DeOliveira et al. 2011); yet the consequences of this for adaptive immunity to malaria remain
unexplored.
Here, the role of PRR pathways in modulating PbTII responses to in vivo infection is first
tested. Minor roles for the TLR adaptor molecules, MyD88 and Trif are identified. However, most
strikingly, a critical role for IRF3 for the expansion of Plasmodium-specific CD4+ T cells and for
111
promoting their differentiation towards the Th1 fate is observed. Additionally, IRF3 suppresses Tfh-
mediated humoral responses, in a likely secondary mechanism, leading to poorer Plasmodium-
specific antibody production and ultimately, poorer resolution of infection.
112
5.3 Results
5.3.1 Individual PRRs play only modest roles in controlling Plasmodium-specific CD4+ T cell
responses during blood-stage infection
Numerous PRRs have been reported to participate in early innate immune responses to
blood-stage Plasmodium parasites in vivo. Nevertheless, their role in generating antigen-specific
CD4+ T cell responses remains unclear. Therefore, PbTII cells were employed to explore roles for
TLRs, cytosolic DNA/RNA detection, and inflammasomes in mediating CD4+ T cell responses.
PbTII cells were transferred into WT control mice, or those deficient in TLR-signalling (Trif-/-, Tlr3-
/-, and Myd88-/-), or cytosolic DNA/RNA detection (Mavs-/- and Tmem173-/-). After infection with
PcAS, it was noted that PbTII cells expanded equivalently in mice lacking either MAVS or STING
compared to WT controls (Figure 5.1A), suggesting that cytosolic nucleic acid detection was not
essential for the activation of Plasmodium-specific CD4+ T cell responses. Similarly, PbTII
expansion occurred at wild-type levels in mice deficient in Caspase1/11, suggesting that
inflammasome function is dispensable for this response (Figure 5.1A). No requirements were
observed for TLR3, a detector of endosomally located nucleic acids, nor its signalling adaptor,
TRIF, in mediating PbTII proliferative responses (Figure 5.1A). Instead, TRIF suppressed PbTII
responses, while MyD88 played a modest supportive role (Figure 5.1A). Thus, while this approach
revealed modest opposing roles for the TLR adaptors, TRIF and MyD88, it did not identify a
specific PRR-pathway that was critical for driving parasite-specific CD4+ T cell responses. Instead,
IRF3, a convergence point for multiple PRRs, was identified as an important mediator of this
process (Figure 5.1A). To excluded the possibility of non-specific expansion of PbTII cells upon
transfer, physiologically-relevant numbers were transferred into naive C57Bl6/J, Irf3-/-, Myd88-/-,
Mavs-/-, Trif-/-andTmem173-/-, and PcAS-infected WT or Irf3-/-mice. PbTII numbers remained at
approximately one-tenth of the transferred number in all of the naive mice compared to significantly
increased numbers in infected mice by day 8 post-transfer (Figure 5.1B), thus confirming the
Plasmodium-specific expansion of PbTII cells even in immunologically perturbed environments.
113
Figure 5.1 PbTII responses are partially modulated by MyD88- and TRIF-mediated signalling,
but further dependent on IRF3. (A) Enumeration of PbTII cells transferred into naïve mice (106)
or WT, Mavs-/-, Tmem173-/-, Casp-1/11-/-, Tlr3-/-, Trif-/-, Myd88-/-and Irf3-/- mice (104) at 7 days p.i.
with PcAS. (B) Enumeration of PbTII cells (104, indicated by the horizontal dotted line) transferred
into male or female naive C57Bl/6, Irf3-/-,Myd88-/-, Mavs-/-, Trif-/-and Tmem173-/- mice at day 8 post-
transfer, or WT and Irf3-/- at day 7 p.i. with PcAS. (A) Data are pooled from two independent
experiments. (B) Data are from a single experiment of male and female mice. Mann-Whitney
test.*p<0.05, **p<0.01, ****p<0.0001.
5.3.2 Haematopoietic cells employ IRF3 to drive Plasmodium-specific Th responses
Next, the effect of IRF3 on Plasmodium-specific Th differentiation was explored. PbTII
cells were transferred into Irf3-/-or WT mice, and T-bet/IFNγ co-expression (Th1) or Bcl6/CXCR5
0
5
1 0
Pb
TII
(x
10
5)
N a iv e (n = 3 )
W T (n = 1 0 )
C a s p 1 /1 1- /-
( n = 9 )
Pb
TII
(x
10
5)
0
2 0
4 0
** N a iv e (n = 2 )
W T (n = 6 )
T r i f- /-
( n = 7 )
T lr 3- /-
( n = 6 )
Pb
TII
(x
10
5)
0
5
1 0
M a v s- /-
( n = 7 )
N a iv e (n = 3 )
W T (n = 5 )
T m e m 1 7 3- /-
( n = 9 )
0
5
1 0
1 5
Pb
TII
(x
10
5)
********
N a iv e (n = 8 )
W T (n = 1 6 )
M y d 8 8- /-
( n = 2 4 )
I r f3- /-
( n = 1 7 )**
A
B
WT
I rf3- /
-
Myd88- /
-
Mavs- /
-
Tr if
- /-
Tm
em
173- /
-
WT
I rf3- /
-
1 0 1
1 0 2
1 0 3
1 0 4
1 0 5
1 0 6
1 0 7
Pb
TII
ce
lls
/sp
lee
n
*
P c A S
114
co-expression (Tfh) by splenic PbTII cells was assessed at peak PcAS infection. In addition to
reduced numbers of splenic PbTII cells observed in Irf3-/- mice compared to WT controls (Figure
5.1A), there was a substantial qualitative defect in the proportion of PbTII cells developing into Th1
cells (Figure 5.2A). Conversely, Irf3-/- mice had greater proportions of Tfh cells amongst the PbTII
populations (Figure 5.2A). Importantly, IRF3 also supported polyclonal Th1 responses and
dampened Tfh responses during PcAS infection (Figure 5.2B).
To explore which host cells might employ IRF3 to drive PbTII responses, bone marrow
(BM) chimeric mice were generated, in which haematopoietically-derived cells lacked IRF3 (via
reconstitution of lethally irradiated WT mice with Irf3-/-or control WT BM cells; Irf3-/->WT, or
WT>WT controls). In generating these chimeras, flow cytometric assessment of pooled bone
marrow cells was first performed. There were no major differences in the presence of long-term or
short-term haematopoietic stem cells (HSC), or multipotent progenitor cells within the Kit+Sca-1+
HSC compartment between WT and Irf3-/- BM, suggesting no major HSC defect caused by IRF3-
deficiency (Figure 5.3A). After generating the chimeras, no differences were observed in bulk
splenic B-cells, or in modest plasmablast responses between un-infected Irf3-/->WT chimeras and
WT>WT controls (Figure 5.3B). Slight increased numbers of GC B cells were noted in the Irf3-/-
>WT chimeric mice. However, there were no significant differences in absolute numbers of splenic
neutrophils, monocytes, cDCs or T cells in Irf3-/->WT chimeras compared to WT>WT controls
(Figure 5.3C). These data suggested that lethally-irradiated WT mice given Irf3-/- HSC reconstituted
the spleen as effectively as with WT HSC, with only minor perturbations in the B-cell
compartment. Assessment of PbTII responses in PcAS-infected Irf3-/->WT mice and WT>WT
controls revealed that haematopoietic cells required IRF3 to fully support PbTII expansion and Th1
differentiation, while promoting Tfh differentiation (Figure 5.2C). Therefore, our data indicated that
haematopoietic cells, but not CD4+ T cells themselves, employed IRF3 to drive Plasmodium-
specificTh1 responses and suppress Tfh responses. To confirm a requirement for IRF3 within
haematopoietic cells in supporting polyclonal Th1 responses, as shown earlier for PbTII cells
(Figure 5.2C), Irf3-/->WT BM chimeric mice, and WT>WT controls were similarly employed. We
observed that PcAS-infected Irf3-/->WT BM chimeric mice displayed a 50% reduction in splenic
Th1 responses (Figure 5.2D), but a 60% increase in Tfh responses (Figure 5.2D), and increased
parasitemias (Figure 5.2E) compared to WT>WT BM chimeric controls. Together, our results and
previous data demonstrate that while IRF7 and Type I IFN-signalling suppress Th1-immunity
(Haque, Best et al. 2011, Haque, Best et al. 2014, Edwards, Best et al. 2015), haematopoietically-
derived, non-CD4+ T cells require IRF3 to fully support early Th1 responses and anti-parasitic
immunity during non-lethal blood-stage Plasmodium infection.
115
Figure 5.2 IRF3 promotes early protective Th1 responses during blood-stage Plasmodium
infection. (A) Representative FACS plots (gated on CD45.1+ CD4+ TCRβ+ live singlets),
proportions and absolute numbers of splenic PbTII cells exhibiting Th1 (T-bet+ IFNγ+) and Tfh
(CXCR5+ Bcl6+) phenotypes in WT and Irf3-/- mice at 7 days p.i. with PcAS compared to un-
infected WT mice. (B) Representative FACS plots (gated on CD4+ TCRβ+ live singlets), proportions
and absolute numbers of splenic polyclonal CD4+ T cells exhibiting Th1 and Tfh phenotypes in WT
and Irf3-/- mice at 7 days p.i. with PcAS. (C) Numbers of splenic PbTII cells in Irf3-/->WT BM
chimeric mice or WT>WT chimeric controls (receiving 104 PbTII cells) 7 days p.i. with PcAS, as
well as proportions and absolute numbers exhibiting Th1 and Tfh phenotypes. (D) Proportions of
splenic polyclonal CD4+ T cells exhibiting Th1 and Tfh phenotypes at 7 days p.i. with PcAS. Data
are representative of two independent experiments. (E) Parasitemia in Irf3-/->WT BM chimeric
mice or WT>WT chimeric controls at 7 days p.i. with PcAS (data pooled from two independent
experiments). Statistics: Mann-Whitney U test; *p<0.05, **p<0.01, ****p<0.0001.
Irf3-/-WTNaive
Tbet
IFNγ
A0.5 14.223.5
CX
CR
5
Bcl6
10.3 41.9 57.9
FMO (Bcl6)
0
1.1
% T
be
t+IF
N
+
0
1 0
2 0
3 0 **Isotype (Tbet)
FMO (IFNγ)
Bc
l6+ C
XC
R5
+ (
x1
04)
Naiv
e
WT
I rf3- /
-
0
1 0
2 0
3 0 *
Tb
et+
IFN
+ (
x1
04)
0
1 0
2 0
**
% B
cl6
+ C
XC
R5
+
Naiv
e
WT
I rf3- /
-
0
2 0
4 0
6 0
*
Irf3-/-WTNaive
Tbet
IFNγ
0.1 6.6 3.6
B
2.9 22.0 27.2
CX
CR
5
Bcl6 Bc
l6+ C
XC
R5
+(x
10
5)
Naiv
e
WT
I rf3- /
-
0
2 0
4 0
6 0
8 0
1 0 0 *
0
0.4
Tb
et+
IF
N
+(x
10
5)
0
1 0
2 0
3 0
4 0
5 0
****
% T
be
t+ I
FN
+
0
2
4
6
8 ****Isotype (Tbet)
FMO (IFNγ)
FMO (Bcl6)
% B
cl6
+C
XC
R5
+
Naiv
e
WT
I rf3- /
-
0
1 0
2 0
3 0
4 0**
WT
>W
T
I rf3- /
- >W
T
0
5
1 0
1 5
2 0
Pb
TII
(x
10
5)
**
% T
be
t+ I
FN
+
WT
>W
T
I rf3- /
- >W
T
0
2
4
6
8
1 0 ****
E
WT
>W
T
I rf3- /
- >W
T
0
2
4
6
8
Tb
et+
IFN
+ (
x1
05) **
WT
>W
T
I rf3- /
- >W
T
0
2
4
6
Bc
l6+ C
XC
R5
+ (
x1
05)
C
0
1 0
2 0
3 0
4 0
5 0
% T
be
t+ I
FN
+
**
0
2 0
4 0
6 0
% B
cl6
+ C
XC
R5
+
**
% B
cl6
+ C
XC
R5
+
WT
>W
T
I rf3- /
- >W
T
0
1 0
2 0
3 0
**
D
Pa
ras
ite
mia
(%
pR
BC
)
WT
>W
T
I rf3- /
- >W
T
0
2 0
4 0
6 0
*
116
Figure 5.3 Phenotypic characterisation of Irf3-/->WT bone marrow chimeric mice. (A) FACS
gating strategy for long-term haematopoietic stem cells (LT-HSC; Lin- Kit+ Sca1+ CD150+ CD48-),
short-term HSCs (ST-HSC; Lin- Kit+ Sca1+ CD150+ CD48+) and multipotent progenitors (MPP;
Lin-Kit+ Sca1+ CD150- CD48+) in BM cells from WT and Irf3-/- mice (pooled from n=6/group). (BD)
WT or Irf3-/- BM cells were transferred into lethally-irradiated WT mice, and after 8 weeks, splenic
WT Irf3-/-
6.6 9.0
71.1
6.6 7.2
74.3FS
CH
SS
CA
FSCA FSCA
Lin
Kit
FSCA Sca1 CD
15
0
CD48LT-HSC ST-HSC
MPP
A
0.22 0.22
0.27 0.40
GL
7
Fas
IgD
CD
13
8
60.2 63.3
B2
20
CD19
WT>WT Irf3-/->WT
0
2 0
4 0
6 0
% B
22
0+C
D1
9+
0 .0
0 .1
0 .2
0 .3
0 .4
0 .5%
CD
13
8+Ig
D+
0 .0
0 .2
0 .4
0 .6
0 .8
%F
as
+G
L-7
+
B
0
1
2
3
4
5
B2
20
+C
D1
9+
(x1
07)
0
5
1 0
1 5
CD
13
8+Ig
D+
(x1
04)
0
1 0
2 0
3 0
Fa
s+G
L-7
+
(x1
04)
*
8.11 7.4722.4 20.1
TCRβ
CD4
0.65 0.50
Ly6
C
Ly6G
0.46 0.51
CD
11
b
CD11b
0.89 0.52
CD
11
c
MHCII
0
1 0
2 0
%C
D4
+T
CR
+
0
2
4
6
8
%C
D4
-T
CR
+
0 .0
0 .5
1 .0
1 .5
%L
y6
G+C
D1
1b
+
0 .0
0 .2
0 .4
0 .6
0 .8
%L
y6
Ch
i CD
11
b+ *
0 .0
0 .5
1 .0
1 .5
CD
11
ch
i MH
CII
hi
**
0
1
2
3
4
5
CD
4-T
CR
+
(x1
06)
0
5
1 0
1 5
CD
4+T
CR
+
(x1
06)
0
2
4
6
Ly
6G
+C
D1
1b
+
(x1
05)
0
1
2
3
4
Ly
6C
hi C
D1
1b
+
(x1
05)
0
1
2
3
4
5
CD
11
ch
i MH
CII
hi
(x1
05)
WT>WT Irf3-/->WTC
117
immune populations were assessed (n=6). (B) Representative plots (gated on live singlets) showing
proportions and absolute numbers of splenic B cells, plasmablasts (B220+ CD19+ IgDlo CD138+)
and GC B cells (B220+ CD19+ Fas+ GL-7+). (C) Representative FACS plots of various myeloid cell
populations, including proportions and absolute numbers in the spleens of un-infected Irf3-/->WT
and WT>WT chimeric mice; Ly6G+ CD11b+ neutrophils (Ly6Ghi Ly6Clo B220- TCRβ- live singlets),
inflammatory monocytes (Ly6Chi Ly6Glo B220- TCRβ- live singlets), cDCs (CD11chi MHCIIhi B220-
TCRβ- live singlets) and CD4+ or CD8+ T cells (CD4+ TCRβ+ or CD4- TCRβ+ live singlets).
Experiment performed once. Statistics: Mann-Whitney U test, *p<0.05.
5.3.3 IRF3-mediated Th1 support correlates with MHCII-expression by inflammatory
monocytes
The observation of poorer accumulation of PbTII cells in the absence of IRF3 (Fig 5.1A) led
to the consideration of a defect in early activation. However, flow cytometric assessment of
expression of the early activation marker CD69 showed that CTV-labelled PbTII cells were
comparably activated at day 2 p.i. in WT or IRF3 deficient mice (Figure 5.4A). In further
experiments in which 106 PbTII cells were transferred for ease of detection, it was noted that a
greater proportion of PbTII cells in WT mice had divided at least once by day 4 p.i. as evident by
the loss of CTV compared to PbTII cells transferred into Irf3-/- mice (Figure 5.4B). When more
physiologically relevant numbers were transferred and the possibility for intraclonal competition
minimised, a trend towards reduced Th1 responses was observed by day 4 p.i., which reached
statistical significance by day 5 p.i. (Figure 5.4C). IRF3 did not support accumulation of PbTII cells
by preventing apoptosis, since no differences in PbTII cells from infected WT and Irf3-/-recipients
was evident, either in expression of the anti-apoptotic protein Bcl-2 (Figure 5.4D), or cell-surface
display of phosphatidylserine (Figure 5.4E). Therefore, this data suggested that IRF3 supports
splenic PbTII responses by sustaining their proliferation, rather than mediating early T cell
activation or preventing T cell apoptosis.
118
Figure 5.4 Requirements for IRF3 in early activation of PbTII cells. (A) CTV labelled PbTII cells
(106) were transferred into WT and Irf3-/- mice one day prior to infection with PcAS. (B)
Representative FACS plots (gated on CD45.1+ CD4+ TCRβ+ live singlets) of CTV positivity and
CD69 expression, and proportion of unproliferated PbTII cells (CTVhi) that are CD69+ at 1, 2 and
3 days p.i. with PcAS. (C) Absolute numbers and proportions exhibiting a Th1 (IFNγ+ T-bet+) or
Tfh (CXCR5+ Bcl6+) phenotype. (D) Representative histograms (gated on CD45.1+ CD4+ TCRβ+
live singlets), and expression of Bcl2 expression by PbTII cells in WT or Ir3-/- mice at 2, 3 and 4
days p.i. with PcAS relative to naive PbTII cells (n=4). (E) Representative plots (gated on CD45.1+
CD4+ TCRβ+ live singlets) of 7AAD and Annexin V-positivity by PbTII cells in WT or Irf3-/- mice at
7 days p.i. with PcAS and plot showing staining of FSCAlo dead/dying cells for comparison. (A)
Data are representative of replicate experiments. (B-E) Data from experiments performed once
(n=4). Geom Mean: Geometric mean. Statistics: Mann-Whitney test. *p<0.05, **p<0.01. NS, not
significant.
0 1 2 3 4 5
-2 0 0 0
0
2 0 0 0
4 0 0 0
D a y s p o s t - in fe c t io n
BC
L-2
le
ve
ls r
ela
tiv
e t
o u
nin
fec
ted
Annexin V
7A
AD
WT
Irf3-/-
WT
I rf3- /
-
1 5
2 0
2 5
3 0%
An
ne
xin
+ 7
AA
D-
ED
FSCAlo
control
0 1.2
27.6
0.81 31.4
39.4
0 1.90
19.3
Naive
WT
Irf3-/-
FMO
Bcl2
A
CTV
CD
69
48.6
65.7Irf3-/-
WT
Naive 7.9
Irf3-/-
WT
Naive
Day 3 Day 4
CTV
B
C
4 5
0 .1
1
1 0
Pb
TII
ce
lls
(x
10
5)
**
N S
4 5
0
1 0
2 0
3 0
4 0
% I
FN
+ T
be
t+
4 5
0
1 0
2 0
3 0
4 0
5 0
% C
XC
R5
+ B
cl6
+
*
3 4
0
2 0
4 0
6 0
8 0
% P
roli
fera
ted
ce
lls
*
Naiv
e
WT
I rf3- /
-
0
1
2
3
4
CD
69
+ (
x 1
04)
Naiv
e
WT
I rf3- /
-
0
2 0
4 0
6 0
8 0
%C
D6
9+
*
Days post-infection
Days post-infection
119
5.3.4 Conventional dendritic cell activation during Plasmodium infection is independent of
IRF3 expression
Next, it was hypothesized that haematopoietic myeloid cells employed IRF3 to support
proliferation and Th1-differentiation of activated CD4+ T cells. CD4+ T cells require continual
antigen presentation for each new round of division (Obst, van Santen et al. 2005). Moreover,
prolonged MHCII-mediated signals have been demonstrated to encourage Th1-differentiation in
vivo (Celli, Lemaitre et al. 2007). Thus, the activation and signalling capacity of conventional
dendritic cells, which are essential for CD4+ T cells response (Fig 3.2B), was assessed during the
course of PcAS infection (Haque, Best et al. 2014). In WT mice, cDCs experienced peak expression
of cell surface MHCII, or co-stimulatory molecules, CD86 or CD40 followed by a sharp decrease in
expression (Figure 5.5A and Figure 5.5B). Splenic cDCs in Irf3-/- mice also demonstrated
comparable expression of these markers suggesting an equivalent capacity to support CD4+ T cell
responses (Figure 5.5B). These results did not support a role for IRF3 in cDC-mediated PbTII
activation during PcAS infection.
120
Figure 5.5 Activation kinetics of conventional dendritic cells during PcAS infection. (A) Gating
strategy for CD11c+ MHCII+ dendritic cells and Ly6Chi CD11b+ inflammatory monocytes. (B)
Expression of MHCII, CD86 and CD40 by CD8α+ and Sirpα+ CD11c+ MHCII+ dendritic cells from
WT or Irf3-/-mice at 1-4 and 7 days p.i. with PcAS. Data are representative of two independent
experiments. Geom Mean: geometric Mean fluorescence intensity.
FS
CH
Liv
e/D
ea
d
SS
CA
FSCA
FSCA
FSCA
B2
20
TC
Rβ
CD
11
c
FSCA
FSCA
MHCII
Ly6
C
CD11b
Ly6
G
Ly6C
CD8α
Sirpα
A
0
2 0 0 0
4 0 0 0
6 0 0 0
1 2 3 4 7
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
0
2 0 0
4 0 0
6 0 0
8 0 0
W T
I r f 3- /-
1 2 3 4 7
0
2 0 0
4 0 0
6 0 0
CD
8α
-cD
CC
D8α
+ c
DC
Ge
o m
ea
n F
L
CD86 CD40
Ge
om
me
an
FL
Days post-infection
B
121
5.3.5 IRF3 drives MHCII signalling by inflammatory monocytes to support accumulation of
PbTII cells
Inflammatory monocytes migrate from the bone marrow to the spleen during blood-stage
infection and are reported to be involved in the clearance of pRBC (Sponaas, Freitas do Rosario et
al. 2009). In other in vivo infection systems, inflammatory monocytes are also reported to support
Th1 responses (Leon, Lopez-Bravo et al. 2007, Flores-Langarica, Marshall et al. 2011).
Furthermore, CD4+ T cell proliferation after experimental vaccination depended on both
inflammatory monocytes in association with IRF3 (Marichal, Ohata et al. 2011). Therefore, Ly6Chi
monocytic responses were assessed first in WT mice infected with PcAS (Figure 5.5A). Strikingly,
splenic Ly6Chi CD11b+ inflammatory monocytes dramatically up-regulated cell surface MHCII
expression up until peak PcAS infection, to a level close to that seen on cDCs from naive mice
(Figure 5.6A and 5.6B). Ly6Chi inflammatory monocytes in Irf3-/-mice, however, displayed a
profound defect in MHCII upregulation compared to WT controls (Figure 5.6B). This defect in
MHCII expression and total numbers of MHCII expression cells in Irf3-/- mice was evident at the
same time PbTII cells displayed reduced expansion (Figure 5.4C and 5.6C). Finally, Irf3-/->WT BM
chimeras confirmed the haematopoetic requirement for IRF3 in driving MHCII expression by
inflammatory monocytes (Figure 5.6D). Taken together, these data suggested that IRF3 did not
influence initial priming of CD4+ T cells, but instead promoted inflammatory monocytic responses
that might sustain Th1 responses during infection.
122
Figure 5.6 Inflammatory monocytes express MHCII in an IRF3-dependent manner. (A)
Expression kinetics and numbers of MHCII+ by inflammatory monocytes during PcAS infection in
WT mice. (B) Representative histograms, proportion of MHCII+ and mean expression of MHCII by
Ly6Chi CD11b+ Ly6G- inflammatory monocytes from naïve or WT and Irf3-/- monocytes at 7 days p.i.
with PcAS. Histogram also shows MHCII expression by cDCs from naïve WT mice as a
comparison. (C) Proportions, geometric mean fluorescence and absolute numbers of MHCII+
splenic Ly6Chi monocytes at days 5 and 7 p.i. with PcAS. (D) MHCII expression and proportions of
MHCII+ Ly6Chi CD11b+ Ly6G- monocytes from lethally irradiated WT BM chimeric mice
reconstituted with WT or Irf3-/- bone marrow. Data are representative of two independent
experiments. Geom Mean: geometric mean fluorescence intensity. Mann-Whitney test. *p<0.05,
**p<0.01. NS, not significant.
Na
ive
WT
Irf3
-/-
cD
C
MHCII
5 7
0
2 0
4 0
6 0
% M
HC
II+
**
**
A
0 2 4 6 8
0
1 0
2 0
3 0
4 0
5 0
6 0
D a y s p o s t - in fe c t io n
% M
HC
II+
0 2 4 6 8
0
1
2
3
4
5
6
7
D a y s p o s t - in fe c t io n
MH
CII
+
CD
11
bh
i Ly
6C
hi
(x
10
5)
5 7
0
1 0 0 0
2 0 0 0
3 0 0 0
4 0 0 0
5 0 0 0
MH
CII
Ge
o M
ea
n F
L
**
**
5 7
0
2 0
4 0
6 0
% M
HC
II+
**
**
5 7
0
5
1 0
MH
CII
+(x
10
5)
**
**
Days post-infection
C
Naiv
e
WT
>W
T
I rf3- /
- >W
T
0
5
1 0
1 5
2 0
MH
CII
+ (
x1
05)
N S
Naiv
e
WT
>W
T
I rf3- /
- >W
T
0
2 0
4 0
6 0
% M
HC
II+
**D
Naiv
e
WT
>W
T
I rf3- /
- >W
T
6 0 0
8 0 0
1 0 0 0
1 2 0 0
1 4 0 0
MH
CII
Ge
o M
ea
n F
L **
B
123
5.3.6 IRF3 suppresses humoral immunity during blood-stage Plasmodium infection
Although IRF3 supported splenic PbTII numbers (Figures 5.3A), of those recovered from
Irf3-/- mice, a greater proportion had become Tfh cells compared with WT controls (Figure 5.2A).
This data indicated that IRF3 was not required for Tfh differentiation, and in fact regulated humoral
responses. Since Tfh responses are known to support affinity maturation of B cells and the
production of antibodies (Arnold, Campbell et al. 2007), it was next hypothesized that IRF3 played
another role during the later stages of infection in suppressing humoral immunity. In support of this,
Irf3-/-mice exhibited improved resolution of PcAS infection compared to their WT counterparts (Fig
5.7A). Since Plasmodium-specific antibodies have been shown to contribute to the clearance of
Plasmodium infection, antibody titres were assessed in WT and Irf3-/- mice throughout the course of
PcAS infection. Higher levels of total IgG, IgM, IgG1, IgG2a, IgG2b and IgG3 were seen in Irf3-/-
mice throughout infection (Fig 5.7B). Furthermore, increased GC B cell responses were observed in
Irf3-/- mice compared to WT controls at 7 and 14 days p.i. with PcAS (Fig 5.8A and 5.8B). Using
Irf3-/->WT BM chimeric mice, the observed suppression of GC B cells was shown to be due to a
hematopoietic role for IRF3 (Figure 5.8C). Finally, memory B cell responses were significantly
stronger at day 40 p.i. in Irf3-/- mice, determined by the co-expression of CD38 and CD80 (Figure
5.8D) (Tomayko, Steinel et al. 2010). Together, these results support a role for IRF3 in suppressing
Tfh-mediated GC B cell, antibody and memory responses during non-lethal blood-stage
Plasmodium infection.
124
Figure 5.7 IRF3 limits Plasmodium-specific antibody responses. (A-B) Time-course analysis of
(A) parasitemia and (B) parasite-specific IgM, total IgG, IgG1, IgG2b, IgG2c and IgG3 in sera
(diluted 1 in 400) in WT and Irf3-/- mice (n=6/group) infected with PcAS. Data are pooled from
two independent experiments. Mann-Whitney test. *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001.
A Total IgGIgM IgG1
IgG2b IgG2c IgG3
B
Days post-infection
0 1 0 2 0 3 0 4 0
0
1
2
3
*
* * * *
* * * *
0 1 0 2 0 3 0 4 0
0 .0
0 .5
1 .0
1 .5
2 .0
OD
(4
92
nm
)
* * * **
* ** * * *
0 1 0 2 0 3 0 4 0
0 .0
0 .5
1 .0
1 .5
2 .0
* * *
* * *
*
0 1 0 2 0 3 0 4 0
0 .0
0 .5
1 .0
1 .5
* * *
* * *
* * * *
* * *
0 1 0 2 0 3 0 4 0
0 .0
0 .5
1 .0
1 .5
2 .0
* * *
* * * *
* *
0 1 0 2 0 3 0 4 0
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
* * *
* * * *
0 1 0 2 0 3 0 4 0 5 0
0 .1
1
1 0
D a y s p o s t - in fe c t io n
Pa
ras
ite
mia
(%
pR
BC
s)
W T
I r f3- /-
* *
* ** *
* *
* ** *
* *
* ** *
* *
* *
**
* *
*
* * *
125
Figure 5.8 IRF3 limits Plasmodium-specific antibodies GC B cells and Tfh cell differentiation.
(A) FACS gating strategy for splenic B-cells. (B) Representative FACS plots (gated on B220+
CD19+ live singlets) showing proportions and absolute numbers of splenic GC B cells (Fas+ GL7+)
in WT and Irf3-/- mice, at indicated days p.i. with PcAS. (C) Absolute numbers of splenic GC B cells
(Fas+ GL7+) in Irf3-/->WT BM chimeric mice and WT>WT chimeric controls at 7 days p.i. with
PcAS. (D) Representative FACS plots (gated on IgDlo B-cells) showing proportions and absolute
numbers of splenic B cells exhibiting a CD38hi CD80hi memory phenotype in WT and Irf3-/- mice at
73 days p.i. with PcAS, compared with naïve WT mice. Data (B) & (C) are representative and (D)
pooled from two independent experiments. Statistics: Mann-Whitney U test; *p<0.05, **p<0.01,
***p<0.001.
Fa
s+ G
l7+ (
x1
06)
WT
I rf3- /
-
WT
I rf3- /
-
WT
I rf3- /
-
0
1 0
2 0
3 0
**
**
*
% F
as
+ G
L7
+
0
1 0
2 0
3 0
****
Day 15
Irf3-/-
WT 1.7
3.9
19.5
24.0
Day 7
Fas
GL
7
Day 0A
FS
CH
Liv
e/D
ea
d
SS
CA
B2
20
FSCA FSCA
FSCA CD19
Day 7 Day 15Day 0
0.5
0.2
C
9.39 18.2 28.1
Irf3-/-Naive
CD38
CD
80
WTD
Naiv
e
WT
I rf3- /
-
0
1 0
2 0
3 0
4 0%
CD
80
+C
D3
8+
***
Naiv
eW
T
I rf3- /
-
0
2
4
6
8
1 0
CD
80
+ C
D3
8+ (
x1
06)
IgD
CD
13
8
IgDlo gating
WT
>W
T
I rf3- /
- >W
T
0
2
4
6
8
1 0
Fa
s+
GL
7+ (
x1
06) **
B
126
5.3.7 IRF3 expression by B cells impairs development of humoral immune responses
Given that IRF3 and its upstream kinase TBK1 were previously reported to operate within B
cells (Oganesyan, Saha et al. 2008, Jin, Xiao et al. 2012); a possible B cell-intrinsic function for
IRF3 during blood-stage Plasmodium infection was next explored. To this end, mixed BM chimeric
mice were generated in which only B cells were IRF3-deficient. This was achieved by
reconstituting lethally-irradiated WT mice with a mixture of BM cells (80% from B-cell deficient,
μMT, mice and 20%either from Irf3-/-or WT control mice) (Figure 5.9A). B cell-specific IRF3-
deficient chimeras displayed no defect in the production of Plasmodium-specific serum IgG, by 15
days p.i with PcAS, compared to WT control mixed BM chimeras, suggesting that B cells did not
depend on IRF3 to suppress high-affinity IgG production (Figure 5.9B). However, it was observed
that when B cells lacked IRF3, polyclonal Tfh responses were modestly increased by 15 days p.i.
(Figure 5.9C). Together, these data pointed towards a subtle role for IRF3 in B cells, not in
suppressing bulk GC B cell responses, but in modulating interactions between B cells and Tfh cells.
To expose subtle roles for IRF3 in B cells, a competitive chimeric approach was adopted, in
which mixtures of WT and Irf3-/- BM were used to reconstitute lethally-irradiated WT mice (Figure
5.9D). In preliminary experiments, 50:50 ratios of BM cells yielded expected ratios within T cell
and myeloid cell compartments (data not shown), but the B cell compartment was skewed heavily
towards Irf3-/- B cells (data not shown). In subsequent experiments we employed 70:30 mixtures of
WT and Irf3-/-BM, and again yielded marked skewing only of B cells (not T cells or myeloid cells)
towards an Irf3-/-genotype (Figure 5.9E and data not shown). These data suggested that in the
context of BM transplantation, IRF3 specifically suppressed B cell development from
haematopoietic stem cells (HSC). Nevertheless, WT and Irf3-/-B cells in mixed BM chimeric mice
displayed similar capacities to populate follicular, extra-follicular and marginal zone compartments
in the spleen, as assessed by expression of CD23 and CD21 (Figure 5.9F). Next, mixed BM
chimeric mice were infected with PcAS, and early GC B cell formation was examined (Figure
5.9G). Firstly, it was noted that uninfected controls exhibited background GC B cell responses,
although this had not generated Plasmodium-specific IgG (Figure 5.9B), and was likely the result of
total body irradiation and BM engraftment. More importantly, in this competitive environment, Irf3-
/-B cells possessed an advantage in generating early GC B cell responses compared to WT B cells in
the same animals (Figure 5.9G). Taken together, this approach revealed that IRF3 acted in B cells,
not only to restrain B cell development from HSC, but also to suppress GC B cell responses during
blood-stage Plasmodium infection.
127
Figure 5.9 IRF3 within B cells dampens maturation and GC B cell responses during infection.
(A) Schematic of lethally-irradiated WT mice reconstituted with 80% μMT and 20% WT or Irf3-/-
bone marrow. (B) PcAS-specific total IgG and (C) proportion of CXCR5+ ICOS+ CD4+ TCRβ+ cells
in chimeras described in (A) at 15 days p.i. (pooled from two independent experiments). (D)
Schematic of lethally-irradiated WT mice administered 70% WT (CD45.1) and 30% Irf3-/- (CD45.2)
bone marrow-derived cells. (E) Representative plots (gated on B220+ CD19+ live singlets) and
pooled proportions of WT and Irf3-/- B220+CD19+ cells, and (F) their localisation to the extra-
follicular, follicular and marginal zone within the spleens of naïve chimeric mice described in (D)
at 12 weeks post-transplant. (G) Representative plots (gated on CD45.1+/CD45.1- B220+ CD19+
live singlets) and enumeration of Gl7 and Fas co-expression by B splenocytes in chimeric mice
described in (D) at 15 days p.i. with PcAS. (F-G) Data are representative data of two independent
experiments. Statistical analyses are Mann-Whitney test except (D), which is a one-way ANOVA
corrected with Tukey’s multiple comparison test. *p<0.05, ****p<0.0001. NS, not significant.
D E
A
WT
I rf3- /
-
0
5
1 0
1 5
2 0
% C
D2
3-C
D2
1-
N S
E x tra F o l l ic u la r
30% Irf3-/-
(CD45.2+) WT
(CD45.1+)
70% WT
(CD45.1+)
GWTIrf3-/-
Gl7
Fas
Naive PcAS
C
F
4.75 14.31.3 2.80
B
Irf3-/- (CD45.2+)
WT
(C
D4
5.1
+)
8.1
83.3
WT
80% µMT
20% Irf3-/-
or WT
or
WT B cells
Irf3-/- B cells
WT
Irf3
-/-
WT
Irf3
-/-
0
1 0
2 0
3 0
4 0
% C
XC
R5
+ I
CO
S+
N a ive P c A S
*
N S
WT
Irf3
-/-
WT
Irf3
-/-
0
5
1 0
1 5
% F
as
+ G
L7
+
****
N a ive P c A S
N S
8-12 weeks
reconstitution
8-10 weeks
reconstitution
WT
I rf3- /
-
0
2 0
4 0
6 0
8 0
% C
D2
3+ C
D2
1- *
F o ll ic u la r
Irf3-/-WT
1:4
00
1:8
00
1:1
600
1:3
200
0 .0
0 .5
1 .0
1 .5
2 .0
OD
(4
92
nm
)
N a iv e W T
N a ive I r f 3- /-
P c A S W T
P c A S I r f 3- /-
WT
I rf3- /
-
1
1 0
1 0 0
% o
f s
ple
nic
B-c
ell
s
WT
I rf3- /
-
0
5
1 0
1 5
% C
D2
3-C
D2
1+
N S
M a rg in a l Z o n e
128
To further explore the role of IRF3 in suppressing humoral immunity during experimental
malaria, a second model of resolving infection, Py17XNL, was employed. While WT mice
recovered from Py17XNL infection after 30 days, as expected, mice deficient of T and B cells
(Rag1-/-) succumbed to hyperparasitemia, highlighting the importance of adaptive immune
responses in controlling this infection. Irf7-/- mice experienced significantly lower burdens of
infection and faster resolution compared to WT mice, consistent with recent reports in other murine
malaria models (Haque, Best et al. 2014, Edwards, Best et al. 2015). IRF3 deficient mice, however,
showed reduced control of the initial ascent in parasite burden, but improved resolution of infection
compared to WT mice (Figure 5.10A). As in the PcAS system, improved resolution of Py17XNL
infection by Irf3-/- mice was associated with higher titres of Plasmodium-specific total IgG, IgM,
IgG1, IgG2b, IgG2c and IgG3 levels, which were maintained up to day 81 p.i. compared to WT
levels (Figure 5.10B). Furthermore, GC B cell proportions and total numbers were significantly
improved in the absence of IRF3 (Figure 5.10C). Lastly, memory B cell responses as determined by
proportions and total numbers of CD80+ and CD38+memory B cells were markedly improved in
Irf3-/- mice compared to their WT counterparts at day 81 p.i. (Figure 5.10D). Thus, IRF3 dampened
GC B cell responses, antibody titres and resolution of infection in a second model of slow resolving
Plasmodium infection.
129
Figure 5.10 IRF3 limits humoral immune responses during Py17XNL infection. (A) Time-course
analysis of parasitemia in Irf3-/-, Irf7-/, Rag1-/- and C57Bl/6 mice (n=5-6) infected with Py17XNL;
cross indicates ethically-motivated euthanasia of heavily infected mice. (B) Time-course analysis of
parasite-specific IgM, total IgG, IgG1, IgG2b, IgG2c and IgG3 in sera (1/400 dilution) in Irf3-/- and
WT mice (n=6/group) infected with Py17XNL. (C) Representative FACS plots (gated on B220+
CD19+ live singlets) and graphs showing proportions and absolute numbers of splenic B cells
exhibiting a GC B cell phenotype (Fas+ GL7+) in infected Irf3-/- and WT mice, at 7 and 14 dpi with
Py17XNL, compared to un-infected WT controls. (D) Representative FACS plots (gated on IgDlo
B220+ CD19+ live singlets) and graphs showing proportions and absolute numbers of splenic B
cells exhibiting a CD38hi CD80+ memory phenotype in naïve WT or infected WT and Irf3-/- mice at
81 dpi with Py17XNL. Data representative of (A, C & D) or pooled (B) from two independent
experiments. Statistics: Mann-Whitney U test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
A
IgG2c IgG3
B
0 2 0 4 0 6 0 8 0
0
1
2
3
****
****
****** ********
0 2 0 4 0 6 0 8 0
0 .0
0 .5
1 .0
1 .5
OD
(4
92
nm
)
****
0 2 0 4 0 6 0 8 0
0 .0
0 .5
1 .0
1 .5
2 .0
****
****
****
****
********
0 2 0 4 0 6 0 8 0
0 .0
0 .5
1 .0
1 .5
2 .0
*
****
****
******
**
0 2 0 4 0 6 0 8 0
0
1
2
3
*
****
****
********
********
0 2 0 4 0 6 0 8 0
0
1
2
3
OD
(4
92
nm
)
***
****
****
****
********
IgG1
IgG2b
Total IgGIgM
Days post-infection
D14D7
D14
Naive WT Irf3-/-
Fas
Gl7
C0.9 1.80.2
16.7 37.6
D7 D14D7
0.2
Naive WT Irf3-/-
CD38
CD
80
9.51 19.4 30.6
D
D a y s p o s t - in fe c t io n
Pa
ras
ite
mia
(%
pR
BC
)
0 1 0 2 0 3 0
0
2 0
4 0
6 0
8 0 W T
I r f 3- /-
R a g 1- /-
I r f 7- /-
* *
* *
* ** *
* ** *
*
* *
* ** ** * * * * *
* *
†
IgD
CD
13
8
Naiv
e
WT
I rf3- /
-
Naiv
e
WT
I rf3- /
-
0 .0
0 .5
2
4
6
8
1 0
1 2
Fa
s+
Gl7
+ (
x1
06
)
**
**
Naiv
e
WT
I rf3- /
-
Naiv
e
WT
I rf3- /
-
0
2
1 0
2 0
3 0
4 0
5 0
%F
as
+ G
L7
+
*
*
IgDlo gating
Naiv
e
WT
I rf3- /
-
0
1 0
2 0
3 0
4 0
% C
D8
0+ C
D3
8+
**
Naiv
e
WT
I rf3- /
-
0
2
4
6
8
1 0
CD
80
+ C
D3
8+ (
x1
06) **
130
5.3.8 IRF3 contributes to disease severity during lethal experimental malaria
Since IRF3 suppressed Tfh-mediated humoral responses during non-lethal Plasmodium
infections, whether IRF3 could also modulate the outcome of lethal infection was explored. To this
end, PbA, a model of severe and cerebral malaria was employed. WT mice infected with PbA
succumbed to cerebral symptoms between 7 and 10 days p.i. (Figure 5.11). Mice deficient of
granzyme B experienced no cerebral symptoms as expected (Haque, Best et al. 2011), confirming
the role of cytotoxic cytokines in these ECM, but succumbed to the infection at approximately day
15 p.i. (Figure 5.11). As expected, Rag1-/- mice were also immune to cerebral malaria (Amante,
Haque et al. 2010), but were unable to resolve the infection. Strikingly, in the absence of IRF3,
mice experienced no cerebral symptoms and furthermore, were able to completely clear infection
after approximately 30 days (Figure 5.11). These results further support a role for IRF3, in
suppressing the antibody-mediated resolution of blood-stage infection.
Figure 5.11 IRF3 impairs resolution of PbA infection in mice. Time-course analysis of PbA
parasitemia in C57Bl/6, Irf3-/-, Rag1-/- and Gzmb-/- mice (n=6). Grey box denotes time-frame of
cerebral symptoms experienced by WT mice.
D a y s p o s t - in fe c t io n
Pa
ras
ite
mia
(%
iR
BC
)
0 5 1 0 1 5 2 0 2 5 3 0 3 5
0 .1
1
1 0
1 0 0W T
I r f 3- /-
R a g 1- /-
G z m B- /-
A
131
5.4 Discussion
In this study, whether PRR-signalling pathways direct Plasmodium-specific CD4+ T cell
responses during non-lethal, experimental malaria have been assessed. Modest opposing roles for
MyD88 and TRIF-dependent signalling were identified, but more importantly, a complex, biphasic
role for the innate immune transcription factor, IRF3, which is ubiquitously expressed by immune
cells and sits at the convergence point of multiple PRRs, was discovered. Over the course of
infection, IRF3 was initially critical for driving Th1 responses, activating monocytes, and
controlling pRBC, but later suppressed B cell responses, limited Plasmodium-specific antibody
production, and delayed resolution of infection.
Naturally-acquired immunity to malaria requires multiple infections over many months to
years to fully develop. Nonetheless, protective immunity against blood-stage Plasmodium parasites
can be generated in humans, and thus efforts to accelerate its onset will likely be beneficial. The
innate immune system plays a crucial role in sculpting adaptive immune responses. However, few if
any molecular mechanisms have been reported via which innate immune responses drive adaptive
immunity to malaria. Several endosomal and cell-surface PRRs, and their associated signalling
adaptors, have been implicated in Plasmodium sensing in vivo. Parasite RNA activated the
cytoplasmic receptor, MDA5, during the liver stage of infection (Liehl, Zuzarte-Luis et al. 2014).
TLR2 and TLR4 signalled in response to Plasmodium glycosylphosphatidylinositol (GPI) moieties
(Krishnegowda, Hajjar et al. 2005). TLR9 detected malaria haemozoin, possibly in complex with
parasite DNA (Coban, Ishii et al. 2005). Finally, the STING/TBK1/IRF3 axis was activated,
predominantly in vitro, by AT-rich Plasmodium DNA motifs (Sharma, DeOliveira et al. 2011).
Despite these reports, only a single study has suggested that a PRR-signalling adaptor, in this case
MyD88, could elicit Th cell responses during Plasmodium infection (Franklin, Rodrigues et al.
2007). For the first time, PbTII cells have allowed for the delineation of a modest contributory role
for MyD88, and a similarly modest suppressive role for TRIF-signalling. However, these data did
not support roles for caspase 1/11-dependent inflammasomes or the STING pathway in driving
CD4+ T cell responses. Given reports that these pathways are activated in vivo, it is speculated that
myeloid cells other than those involved in T cell responses, for example certain macrophage
subsets, employ STING and inflammasome pathways to trigger inflammatory cytokine production
during infection.
Another possibility is that functional redundancy exists between these PRR pathways, such
that in any given innate immune cell, the absence of one pathway is readily compensated for by the
activation of another. Such functional redundancy could ensure robust innate immune defense
132
against a spectrum of microbial challenges in a genetically diverse population. The concept of
functional redundancy of PRR signalling pathways in response to pRBCs is indirectly supported by
the fact that IRF3, which can integrate multiple PRR signals, was crucial for monocyte activation
and Th1 responses. Thus, IRF3 constitutes one of the first described innate immune targets for
driving CD4+ T cell responses during malaria, and as such could be investigated as a molecular
target for novel adjuvants in candidate malaria vaccines.
The finding that IRF3 drives Th1 responses contrasts with previous reports that Type I IFN
signalling via IFNAR1 and the transcription factor IRF7 suppressed Th1-immunity to malaria.
Indeed, while IFNAR1-signalling suppressed monocytic responses in this previous work (Haque,
Best et al. 2014, Edwards, Best et al. 2015), IRF3 was essential here for driving activation of
inflammatory monocytes. Therefore, the findings here adds to an increasing body of work showing
that IRF3 acts very differently to its related IRF family member, IRF7, and re-enforces the view that
IRF3 does not simply induce Type I IFN responses, but plays a number of other roles in multiple
immune cells.
In order for CD4+ T cells to differentiate into Th1 cells, they are reported to require
sustained MHCII signalling, after an initial period of cDC-activation (Celli, Lemaitre et al. 2007).
Therefore, one possible mechanism by which IRF3 supports Th1 responses is by driving
inflammatory monocytes to provide MHCII-mediated signals to activated CD4+ T cells. Indeed,
data reported in Chapter 4 indicate that monocyte/macrophages are specifically required to support
Th1 responses during Plasmodium infection. Moreover, a link between IRF3 and inflammatory
monocyte-mediated Th support was previously demonstrated in the observation by Marichal et al
that the adjuvanticity of alum during experimental vaccination was strongly dependent on IRF3 and
inflammatory monocytes (Marichal, Ohata et al. 2011). Therefore, it is proposed that IRF3 allows
inflammatory monocytes in the spleen to support Th1 differentiation in activated Plasmodium-
specificCD4+ T cells.
The involvement of IRFs in eliciting Type I IFN responses to pathogens and controlling
development of haematopoietically-derived immune cells is well documented (reviewed by
(Battistini 2009) and (Tamura, Yanai et al. 2008)). While IRF4 and IRF8 are well established to
control many aspects of B lymphocyte biology, whether IRF3 acts in B cells is less clear. IRF3
activation occurs in CpG-treated B cells in vitro (Oganesyan, Saha et al. 2008). Furthermore, the
IRF3-related kinase, TBK1 acts within B cells to suppress pathogenic IgA production in mice (Jin,
Xiao et al. 2012). Results discussed here demonstrated a B cell-intrinsic role for IRF3, which
suppresses B cell development from HSC after lethal irradiation and bone marrow transplantation.
133
Furthermore, IRF3 acted in B cells to suppress GC B cell responses and Tfh cells during infection.
Thus, this work provides the first direct in vivo evidence that IRF3 can act within B cells to
suppress their function. One caveat of the BM chimeric approach was the significant amount of
non-Plasmodium-specific GC B cell activity, likely generated in response to irradiation and bone
marrow transplantation. Thus, in the future, transgenic tools such as inducible B cell-specific IRF3-
deficient mice will enable more stringent testing of how IRF3 controls B cell function in vivo.
Nevertheless, in this study, improved Plasmodium-specific IgG production, GC B cell and Tfh
responses were seen when IRF3-mediated suppression of humoral immunity was lifted. Thus, we
propose IRF3 as a B cell-intrinsic regulator of humoral responses during Plasmodium infection,
which acts to limit production of parasite-specific antibodies.
Here, for the first time, PbA-infected Irf3-/- mice were shown to be resistant to ECM, but
more importantly, completely resolved infection. PbA infection in C57Bl/6J mice is characterised
by the sequestration of pRBCs into soft tissues leading to the fatal cerebral pathology. The Th1
cytokine, IFNγ, contributes to sequestration by increasing the expression of leukocyte adhesion
molecules on the cerebral microvascular endothelium (Hunt and Grau 2003). Additionally, previous
studies have shown CXCR3-mediated Th1 traffic to the brain correlated with the onset of cerebral
symptoms (Hansen, Bernard et al. 2007). A role for IRF3 in promoting Th1 responses during PbA
infection, as evident in non-lethal infections, could explain the absence of ECM in Irf3-/-mice.
However, this mechanism was not tested, and the possibility of IRF3 having a T cell-independent
role in mediating ECM cannot be ruled out. In addition to resistance to ECM, Irf3-/- mice may be
the first knock-out line to clear PbA infection. Given the observed role of IRF3 in suppressing
Plasmodium-specific antibodies during PcAS and Py17XNL infections and the reported importance
of antibodies in resolving infection, it is speculated that IRF3 also plays a role in suppressing the
development of Plasmodium-specific antibodies during PbA infection. It will be important in
future experiments to determine the precise molecular and cellular mechanisms by which IRF3
limits humoral immunity. Such information may reveal a novel immune-target to boost humoral
immunity to malaria.
In summary, a biphasic role for IRF3 was revealed during non-lethal experimental malaria.
Firstly, IRF3 acted to drive Th1 responses, likely via up-regulation of MHCII on inflammatory
monocytes, which resulted in better control of pRBC numbers during the early phase of infection.
During later stages of infection, IRF3 performed a separate function within B cells to suppress GC
B cell and Tfh responses, which was associated with limited production of Plasmodium-specific
antibodies and delayed resolution of infection. Given its unique position downstream of several
134
PRR pathways, and its potential role in B cells, IRF3 represents a unique molecular target for
modulating cellular and humoral immunity to malaria.
135
Chapter Six:
Final discussion
Malaria remains a leading cause of global deaths due to infection. While extensive research
efforts support roles for CD4+ T cells and antibodies in providing immunity to human and
experimental malaria, how these responses can be induced in vivo is poorly understood. To address
this gap in knowledge, this thesis aimed to determine novel cellular and molecular determinants
mediating adaptive immune responses during malaria, with particular focus on Th responses. The
three objectives of this thesis were to:
1. Determine whether a newly developed Plasmodium-specific CD4+ T cell can be effectively
used to track T helper responses.
2. Resolve the process of Th1 and Tfh cell differentiation to gain molecular insight into
mechanisms controlling Th fate decision-making.
3. Investigate whether innate immune signalling pathways can influence Th1- and Tfh-
dependent immune responses during infection.
6.1 PbTII cells represent an effective tool for studying in vivo CD4+ T cell
responses
CD4+ T cell responses during Plasmodium infection have been difficult to study partly due
to the absence of appropriate antigen-specific tools (Stephens, Albano et al. 2005). In Chapter 3 of
this thesis, a malaria-specific TCR transgenic mouse, which contains CD4+ T (PbTII) cells specific
for Plasmodium, was tested in vivo for its responsiveness. PbTII cells proliferated and differentiated
into Th1 and Tfh cells, which resembled the endogenous polyclonal response.
In addition to Th1 and Tfh effector subsets, PbTII cells were also observed to differentiate
into IL-10 and IFNγ co-producing cells, referred to as Tr1 cells. Tr1 may be important for
controlling immunopathology caused by potent inflammatory responses during both experimental
and human infections(Couper, Blount et al. 2008, Walther, Jeffries et al. 2009, Freitas do Rosario,
Lamb et al. 2012, Jagannathan, Eccles-James et al. 2014, Portugal, Moebius et al. 2014, Montes de
Oca, Kumar et al. 2016). Modelling of PbTII scRNAseq data revealed that Tr1 cells emerged from
the end of the Th1 differentiation branch, supporting the idea that Tr1 cells are direct descendants of
136
Th1 cells (Cardone, Le Friec et al. 2010). Further scRNAseq and computational analysis of PbTII
cells could elucidate the relationship betweenTh1 and Tr1 cells, with the objective of identifying
novel approaches for balancing parasite control and immunopathology during infection.
Immunological memory relies on long-term memory cells that are induced by previous
infections. Memory responses during Plasmodium infection are difficult to induce and,
unfortunately, difficult to maintain, as evidenced by the difficulty in developing naturally-acquired
immunity and in the modest results from leading vaccine strategies(Stanisic, Mueller et al. 2010,
Olotu, Fegan et al. 2013). Here, PbTII cells developed into both effector and central memory (TCM
and TEM) phenotypes late in infection. Further studies determining the longevity of these responses
in vivo will demonstrate the utility of PbTII cells for examining memory responses. In addition, the
transition between effector cells and memory cells during in vivo infection could be studied through
modelling scRNAseq data of PbTII cells. Possible findings could include identification of unique
subsets of effector cells that are inclined to become memory cells,or novel molecular mechanisms
associating with this transition. Such information will be imperative to improving strategies to boost
immunological memory in individuals at risk of infection.
6.2 Modelling of scRNAseq analysis of PbTII cells reveals the emergence of Th
fates in vivo
Studying the emergence of Th responses in vivo has previously been confounded by
extensive heterogeneity within cell populations at any given time, and different response kinetics. In
Chapter 4, computational modelling of PbTII scRNAseq data was used to resolve the co-emergence
of Th responses during PcAS infection. This allowed for the identification of gene expression
profiles corresponding with either Th1 or Tfh differentiation, including expression of a range of
transcription factors, receptors and genes with unclassified function. A critical next step in this
research is to confirm with functional studies the relationship between these genes and
differentiation. As a proof of concept, preliminary studies have focussed on CXCR3, which
associated with Th1 differentiation.Blockade of CXCR3 during infection resulted in skewed
differentiation of PbTII cells towards a Tfh state. Ongoing work has applied CRISPR-Cas9
technology to delete Cxcr3 from PbTII cells to further demonstrate the requirement of CXCR3
signalling for Th1 differentiation.
An initial hypothesis of this thesis was that innate immune cells shape Th responses during
Plasmodium infection. The first evidence to support this hypothesis was the identification of two
waves of Th-associate chemokine receptor expression - one that peaked late in differentiation and
137
an earlier wave that peaked around bifurcation. This suggests that while receptors expressed after
bifurcation might mediate migration and effector function of PbTII cells, those peaking at
bifurcation could allow T cells to sense chemokine-expressing cells. Of thechemokines expressed
early, only Cxcr5 associated with commitment to Tfh fate decision. CXCR5 promotes the migration
of Tfh cells to the B- and T-cell bordered where they provide ‘help’ to B cells for production of
high-affinity antibodies(Crotty 2011). As demonstrated here and previously, B cells are also
necessary to sustain the Tfh phenotype(Kerfoot, Yaari et al. 2011). On the other hand, Th1 fate
commitment was associated with expression of several chemokine receptors that peaked at
bifurcation. Among these wasCxcr3, which has previously been demonstrated facilitate cDC - T
cell interactions and promote Th1 responses(Groom, Richmond et al. 2012).
Ly6Chiinflammatory monocytes are known to migrate to the spleen during Plasmodium
infection(Sponaas, Cadman et al. 2006). They were inferior primers of naive CD4+ T cells
compared to cDCs (Sponaas, Cadman et al. 2006), however their interaction with activated T cells
had not been explored. Here, scRNAseq analysis supported a novel role for Ly6Chi monocytes in
sustaining Th1 responses throughCXCR3:CXCL9/10 chemokine axis. Using the LysMCre x iDTR
system to deplete monocytes/macrophages after PbTII cells had been primed but were yet to
differentiate, strong evidence has been provided for their involvement. Comparison of scRNAseq
analysis of monocytes with cDCs revealed an overlap of approximately 40% of genes differentially
unregulated during infection. This suggests that monocytes have a similar function to cDCs during
PcAS infection. To explore whether monocytes can act as APCs, preliminary studies have
investigated PbTII responses in LysMcre x IAbf/fmice, in which monocytes do not express MHCII.
While early activation of PbTII cells to infection was not perturbed in these mice, total number of
Th1 cells at peak infection was significantly reduced. These data supports a model in which naive
CD4+ T cells are primed by cDCs, and require additional antigen stimulation thereafter to sustain
their response(Obst, van Santen et al. 2005). Since Th1 cells provide 'help' to another immune cells,
including macrophages and NK cells (Taylor-Robinson and Phillips 1998), it seems reasonable that
their responses would be tightly regulated by a requirement for continued antigen presentation, such
that other response are indirectly limited.
Activated PbTII cells expressed an assortment of chemokine receptors prior to Th
differentiation. This indicates that they are receptive to competing chemokine signals, which
increase the likelihood of interacting with different cells in a heterogeneous tissue environment. In
this way, PbTII differentiation could result from chance events, rather than preprogramming during
priming. To explore the relationship between PbTII differentiation and spatial intercellular
interactions, intravital imaging of PbTII cells, myeloid cells and B cells within the spleen could be
138
performed during PcAS infection. Furthermore, sorting PbTII cells from microdissected T cell
zones, marginal zones and follicles could allow for more in-depth analysis of their phenotype by
scRNAseq. Results from this research would provide clues for accurate delivery of antigen to the
right APCs and in the right location to induce appropriate T cell responses to infections or vaccine
challenges.
As demonstrated here and in other studies, scRNAseq can be applied to explore
heterogeneity between cells and to model biological processes(Jaitin, Kenigsberg et al. 2014,
Gaublomme, Yosef et al. 2015). Another feature of scRNAseq is that it allows for extensive
information to be gained from as few as a handful of cells. This is particularly attractive for human
immunological studies, which are often complicated by ethical constraints limiting the number of
cells or range of tissues attainable for assessment. Although many studies use peripheral blood
mononuclear cells (PBMCs) as a surrogate for immune response in peripheral tissues, comparison
of cellular responses from both sites has revealed striking differences(Strauss, Bergmann et al.
2007, Czarnowicki, Gonzalez et al. 2015). ScRNAseq has already proven useful in the area of
human cancer research(Patel, Tirosh et al. 2014, Navin 2015, Kim, Lee et al. 2016) and in studying
human embryogenesis (Yan, Yang et al. 2013). Future human disease studies could apply
scRNAseq on cells from biopsies taken during diagnosis and disease management assessments,
such as for Crohn's disease, to model how cells contribute to changes in disease state.
An important caveat of scRNAseq is that transcriptional activity does not necessarily
correspond to translation into protein, or indeed cellular function. Extensive research into the
relationship between RNA translation and protein levels has shown only a 50% overlap in the loci
controlling the expression of these elements, suggesting distinct regulator mechanisms(Wu,
Candille et al. 2013). Additionally, factors such as microRNAs that regulate translation, as well as
mRNA synthesis and decay rates modulate the level of protein expressed(Baek, Villen et al. 2008,
Schwanhausser, Busse et al. 2011).Therefore, the field is moving towards a multi-omics approach,
in which genomics is combined with proteomics to gain a more holistic picture of the cellular
activity. To demonstrate how this might be achieved, in a hypothetical study of T cell
differentiation, phosphoproteomics could be used to monitor phosphorylation signalling of
transcription factor localisation of such regulatory factors. Transcriptomics would elucidate the
cohort of genes up or downregulated by activated transcription factors. Finally, proteomics would
determine which transcripts become proteins at which time.
139
6.3 IRF3 balances Th1 and Tfh-mediated immune responses
Following from the observation that monocytes support Th1 differentiation, in Chapter 6
innate immune signaling pathways were compared for their contribution to Th responses. Although
STING, TLRs and NLRs have all been implicated in the detection of Plasmodium products
(Krishnegowda, Hajjar et al. 2005, Parroche, Lauw et al. 2007, Sharma, DeOliveira et al. 2011,
Kalantari, DeOliveira et al. 2014), no role for isolated PRRs was observed in eliciting an immune
response. This highlights a caveat of a reductionist approach to immunological studies, since the
removal of one element from a system does not take into account possible compensation by other
elements. Thus, it is possible that functional redundancy exists between PRRs in driving Th
responses, as suggested by the literature for ensuring robustness in innate responses towards
continually evolving pathogens (Nish and Medzhitov 2011). To circumvent this issue, PbTII
responses to infection could be followed in mice deficient in two or even three key molecules in
different signaling pathways.
Here, a critical role for IRF3, a regulator of TI IFNs that sits downstream of a number of
PRR signaling pathways, was identified. IRF3 promoted expansion of antigen-specific CD4+ T cell
responses and their differentiation into Th1 cells. This contrasts with a recently reported role for TI
IFN and the master transcription factor IRF7 in impairing Th1 responses during Plasmodium
infection (Haque, Best et al. 2014, Edwards, Best et al. 2015). Therefore, this data suggests that
IRF3 displays a diverse array of functions in immune cells. The role for IRF3 in supporting Th1
responses after their initial activation was associated with MHCII expression by Ly6Chi
inflammatory monocytes. Together with scRNAseq data reported in Chapter 4, this suggests a
model in which monocytes upregulate MHCII expression under direction of IRF3 and facilitate
encounters with CXCR3+ T cells through production of CXCL9/10. Monocytes support Th1
responses, which assist in clearance of pRBCs(Amante and Good 1997). An obvious question
arising from this data is whether IRF3 is activated within monocytes. Future work in this area could
implement phosphoproteomics, to assess the phosphorylation of IRF3 within sorted Ly6Chi
monocytes as a measure of its activation. Furthermore, chromatin immunoprecipitation followed by
sequencing (ChIP-seq) analysis could be used to determine where IRF3 is binding to the genome to
provide mechanistic insight into its function. Advancements in this technology could include single-
cell ChIP-seq (Rotem, Ram et al. 2015) in a single-cell multi-omics analysis as suggested above.
B cell-intrinsic IRF3 was shown to suppress the development of GC B cell responses and
subsequent Plasmodium-specific antibody titres during blood-stage infection. This is consistent
with previous reports and suggestions of IRF3 activation with B cells (Oganesyan, Saha et al. 2008,
140
Jin, Xiao et al. 2012). Tfh differentiation was also dampened, likely as a direct consequence of
suppressed GC B cell responses. This suggests that IRF3 acts as a negative regulator of B cells to
prevent excessive humoral responses. Indeed, IRF3, independently of interferons, has been shown
to be induced by DNA-damaging agents, and was involved in cell cycle checkpoint control in
response to these signals (Kim, Kim et al. 1999, Kim, Kim et al. 2000, Weaver, Ando et al. 2001).
Ectopic expression of IRF3 significantly attenuated cell growth, while expression of mutated IRF3
facilitated oncogenic transformation of human cell lines (Kim, Lee et al. 2003). Importantly, the
data presented here showed that in the absence of IRF3 mice were able to clear the infection sooner
and exhibited greater numbers of memory B cells. Intriguingly, mice deficient in IRF3 cleared a
lethal infection of PbA, possibly due to improved humoral responses. The mechanism behind how
IRF3-deficient mice survive cerebral symptoms of PbA infection would be an interesting avenue to
pursue.
6.4 Concluding remarks
Using a new antigen-specific TCR transgenic tool and cutting-edge scRNAseq technology
with computational modelling, this thesis has demonstrated novel cellular and molecular
mechanisms for modulating protective immunity during malaria. These findings have profound
significance in identifying novel strategies to boost immunity to malaria, for example by using
suitable adjuvants to induce monocytic responses or carefully alleviating the effects of IRF3 in B
cells to improve humoral immunity. Future studies utilising the PbTII system and scRNAseq will
continue to provide a more in-depth picture of the complex immune mechanisms that currently
hinder the eradication of malaria.
141
Chapter Seven:
References
Abbas, A. K., C. Benoist, J. A. Bluestone, D. J. Campbell, S. Ghosh, S. Hori, S. Jiang, V. K.
Kuchroo, D. Mathis, M. G. Roncarolo, A. Rudensky, S. Sakaguchi, E. M. Shevach, D. A. Vignali
and S. F. Ziegler (2013). "Regulatory T cells: recommendations to simplify the nomenclature." Nat
Immunol14(4): 307-308.
Achtman, A. H., R. Stephens, E. T. Cadman, V. Harrison and J. Langhorne (2007). "Malaria-
specific antibody responses and parasite persistence after infection of mice with Plasmodium
chabaudi chabaudi." Parasite Immunol29(9): 435-444.
Adachi, O., T. Kawai, K. Takeda, M. Matsumoto, H. Tsutsui, M. Sakagami, K. Nakanishi and S.
Akira (1998). "Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated
function." Immunity9(1): 143-150.
Aguzzi, A., J. Kranich and N. J. Krautler (2014). "Follicular dendritic cells: origin, phenotype, and
function in health and disease." Trends Immunol35(3): 105-113.
Ahlfors, H., P. J. Morrison, J. H. Duarte, Y. Li, J. Biro, M. Tolaini, P. Di Meglio, A. J. Potocnik and
B. Stockinger (2014). "IL-22 fate reporter reveals origin and control of IL-22 production in
homeostasis and infection." J Immunol193(9): 4602-4613.
Akpogheneta, O. J., N. O. Duah, K. K. Tetteh, S. Dunyo, D. E. Lanar, M. Pinder and D. J. Conway
(2008). "Duration of naturally acquired antibody responses to blood-stage Plasmodium falciparum
is age dependent and antigen specific." Infect Immun76(4): 1748-1755.
Alexopoulou, L., A. C. Holt, R. Medzhitov and R. A. Flavell (2001). "Recognition of double-
stranded RNA and activation of NF-kappaB by Toll-like receptor 3." Nature413(6857): 732-738.
Allan, R. S., C. M. Smith, G. T. Belz, A. L. van Lint, L. M. Wakim, W. R. Heath and F. R. Carbone
(2003). "Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans
cells." Science301(5641): 1925-1928.
Altman, J. D., P. A. Moss, P. J. Goulder, D. H. Barouch, M. G. McHeyzer-Williams, J. I. Bell, A. J.
McMichael and M. M. Davis (1996). "Phenotypic analysis of antigen-specific T lymphocytes."
Science274(5284): 94-96.
142
Amani, V., A. M. Vigario, E. Belnoue, M. Marussig, L. Fonseca, D. Mazier and L. Renia (2000).
"Involvement of IFN-gamma receptor-medicated signaling in pathology and anti-malarial immunity
induced by Plasmodium berghei infection." Eur J Immunol30(6): 1646-1655.
Amanna, I. J., N. E. Carlson and M. K. Slifka (2007). "Duration of humoral immunity to common
viral and vaccine antigens." N Engl J Med357(19): 1903-1915.
Amante, F. H. and M. F. Good (1997). "Prolonged Th1-like response generated by a Plasmodium
yoelii-specific T cell clone allows complete clearance of infection in reconstituted mice." Parasite
Immunol19(3): 111-126.
Amante, F. H., A. Haque, A. C. Stanley, L. Rivera Fde, L. M. Randall, Y. A. Wilson, G. Yeo, C.
Pieper, B. S. Crabb, T. F. de Koning-Ward, R. J. Lundie, M. F. Good, A. Pinzon-Charry, M. S.
Pearson, M. G. Duke, D. P. McManus, A. Loukas, G. R. Hill and C. R. Engwerda (2010).
"Immune-mediated mechanisms of parasite tissue sequestration during experimental cerebral
malaria." J Immunol185(6): 3632-3642.
Amante, F. H., A. C. Stanley, L. M. Randall, Y. Zhou, A. Haque, K. McSweeney, A. P. Waters, C.
J. Janse, M. F. Good, G. R. Hill and C. R. Engwerda (2007). "A role for natural regulatory T cells in
the pathogenesis of experimental cerebral malaria." Am J Pathol171(2): 548-559.
Armah, H. B., N. O. Wilson, B. Y. Sarfo, M. D. Powell, V. C. Bond, W. Anderson, A. A. Adjei, R.
K. Gyasi, Y. Tettey, E. K. Wiredu, J. E. Tongren, V. Udhayakumar and J. K. Stiles (2007).
"Cerebrospinal fluid and serum biomarkers of cerebral malaria mortality in Ghanaian children."
Malar J6: 147.
Arnold, C. N., D. J. Campbell, M. Lipp and E. C. Butcher (2007). "The germinal center response is
impaired in the absence of T cell-expressed CXCR5." Eur J Immunol37(1): 100-109.
Aubert, R. D., A. O. Kamphorst, S. Sarkar, V. Vezys, S. J. Ha, D. L. Barber, L. Ye, A. H. Sharpe,
G. J. Freeman and R. Ahmed (2011). "Antigen-specific CD4 T-cell help rescues exhausted CD8 T
cells during chronic viral infection." Proc Natl Acad Sci U S A108(52): 21182-21187.
Badovinac, V. P., J. S. Haring and J. T. Harty (2007). "Initial T cell receptor transgenic cell
precursor frequency dictates critical aspects of the CD8(+) T cell response to infection."
Immunity26(6): 827-841.
Baek, D., J. Villen, C. Shin, F. D. Camargo, S. P. Gygi and D. P. Bartel (2008). "The impact of
microRNAs on protein output." Nature455(7209): 64-71.
143
Barnden, M. J., J. Allison, W. R. Heath and F. R. Carbone (1998). "Defective TCR expression in
transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of
heterologous regulatory elements." Immunol Cell Biol76(1): 34-40.
Barry, A. E., A. Trieu, F. J. Fowkes, J. Pablo, M. Kalantari-Dehaghi, A. Jasinskas, X. Tan, M. A.
Kayala, L. Tavul, P. M. Siba, K. P. Day, P. Baldi, P. L. Felgner and D. L. Doolan (2011). "The
stability and complexity of antibody responses to the major surface antigen of Plasmodium
falciparum are associated with age in a malaria endemic area." Mol Cell Proteomics10(11): M111
008326.
Batista, F. D. and N. E. Harwood (2009). "The who, how and where of antigen presentation to B
cells." Nat Rev Immunol9(1): 15-27.
Battistini, A. (2009). "Interferon regulatory factors in hematopoietic cell differentiation and immune
regulation." J Interferon Cytokine Res29(12): 765-780.
Bautista, J. L., C. W. Lio, S. K. Lathrop, K. Forbush, Y. Liang, J. Luo, A. Y. Rudensky and C. S.
Hsieh (2009). "Intraclonal competition limits the fate determination of regulatory T cells in the
thymus." Nat Immunol10(6): 610-617.
Becher, B., A. Schlitzer, J. Chen, F. Mair, H. R. Sumatoh, K. W. Teng, D. Low, C. Ruedl, P.
Riccardi-Castagnoli, M. Poidinger, M. Greter, F. Ginhoux and E. W. Newell (2014). "High-
dimensional analysis of the murine myeloid cell system." Nat Immunol15(12): 1181-1189.
Bedoui, S., P. G. Whitney, J. Waithman, L. Eidsmo, L. Wakim, I. Caminschi, R. S. Allan, M.
Wojtasiak, K. Shortman, F. R. Carbone, A. G. Brooks and W. R. Heath (2009). "Cross-presentation
of viral and self antigens by skin-derived CD103+ dendritic cells." Nat Immunol10(5): 488-495.
Berretta, F., J. St-Pierre, C. A. Piccirillo and M. M. Stevenson (2011). "IL-2 contributes to
maintaining a balance between CD4+Foxp3+ regulatory T cells and effector CD4+ T cells required
for immune control of blood-stage malaria infection." J Immunol186(8): 4862-4871.
Blackman, M. J., H. G. Heidrich, S. Donachie, J. S. McBride and A. A. Holder (1990). "A single
fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and
is the target of invasion-inhibiting antibodies." J Exp Med172(1): 379-382.
Blythe, J. E., X. Y. Yam, C. Kuss, Z. Bozdech, A. A. Holder, K. Marsh, J. Langhorne and P. R.
Preiser (2008). "Plasmodium falciparum STEVOR proteins are highly expressed in patient isolates
144
and located in the surface membranes of infected red blood cells and the apical tips of merozoites."
Infect Immun76(7): 3329-3336.
Borgulya, P., H. Kishi, Y. Uematsu and H. von Boehmer (1992). "Exclusion and inclusion of alpha
and beta T cell receptor alleles." Cell69(3): 529-537.
Breitfeld, D., L. Ohl, E. Kremmer, J. Ellwart, F. Sallusto, M. Lipp and R. Forster (2000). "Follicular
B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support
immunoglobulin production." J Exp Med192(11): 1545-1552.
Brunkow, M. E., E. W. Jeffery, K. A. Hjerrild, B. Paeper, L. B. Clark, S. A. Yasayko, J. E.
Wilkinson, D. Galas, S. F. Ziegler and F. Ramsdell (2001). "Disruption of a new forkhead/winged-
helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse." Nat
Genet27(1): 68-73.
Buchholz, V. R., T. N. Schumacher and D. H. Busch (2016). "T Cell Fate at the Single-Cell Level."
Annu Rev Immunol34: 65-92.
Bull, P. C., B. S. Lowe, M. Kortok, C. S. Molyneux, C. I. Newbold and K. Marsh (1998). "Parasite
antigens on the infected red cell surface are targets for naturally acquired immunity to malaria." Nat
Med4(3): 358-360.
Burnet, F. M. (1957). "A modification of Jerne's theory of antibody production using the concept of
clonal selection." The Australian Journal of Science(20): 67-69.
Butler, N. S., J. Moebius, L. L. Pewe, B. Traore, O. K. Doumbo, L. T. Tygrett, T. J. Waldschmidt,
P. D. Crompton and J. T. Harty (2012). "Therapeutic blockade of PD-L1 and LAG-3 rapidly clears
established blood-stage Plasmodium infection." Nat Immunol13(2): 188-195.
Butler, N. S., N. W. Schmidt and J. T. Harty (2010). "Differential effector pathways regulate
memory CD8 T cell immunity against Plasmodium berghei versus P. yoelii sporozoites." J
Immunol184(5): 2528-2538.
Cardone, J., G. Le Friec, P. Vantourout, A. Roberts, A. Fuchs, I. Jackson, T. Suddason, G. Lord, J.
P. Atkinson, A. Cope, A. Hayday and C. Kemper (2010). "Complement regulator CD46 temporally
regulates cytokine production by conventional and unconventional T cells." Nat Immunol11(9):
862-871.
145
Carter, R. and K. N. Mendis (2002). "Evolutionary and historical aspects of the burden of malaria."
Clin Microbiol Rev15(4): 564-594.
Casanova, J. L., P. Romero, C. Widmann, P. Kourilsky and J. L. Maryanski (1991). "T cell receptor
genes in a series of class I major histocompatibility complex-restricted cytotoxic T lymphocyte
clones specific for a Plasmodium berghei nonapeptide: implications for T cell allelic exclusion and
antigen-specific repertoire." J Exp Med174(6): 1371-1383.
Cavlar, T., A. Ablasser and V. Hornung (2012). "Induction of type I IFNs by intracellular DNA-
sensing pathways." Immunol Cell Biol90(5): 474-482.
Celli, S., F. Lemaitre and P. Bousso (2007). "Real-time manipulation of T cell-dendritic cell
interactions in vivo reveals the importance of prolonged contacts for CD4+ T cell activation."
Immunity27(4): 625-634.
Cesta, M. F. (2006). "Normal structure, function, and histology of the spleen." Toxicol Pathol34(5):
455-465.
Chakravarty, S., I. A. Cockburn, S. Kuk, M. G. Overstreet, J. B. Sacci and F. Zavala (2007). "CD8+
T lymphocytes protective against malaria liver stages are primed in skin-draining lymph nodes."
Nat Med13(9): 1035-1041.
Chen, F., Z. Liu, W. Wu, C. Rozo, S. Bowdridge, A. Millman, N. Van Rooijen, J. F. Urban, Jr., T.
A. Wynn and W. C. Gause (2012). "An essential role for TH2-type responses in limiting acute
tissue damage during experimental helminth infection." Nat Med18(2): 260-266.
Cheng, Q., N. Cloonan, K. Fischer, J. Thompson, G. Waine, M. Lanzer and A. Saul (1998). "stevor
and rif are Plasmodium falciparum multicopy gene families which potentially encode variant
antigens." Mol Biochem Parasitol97(1-2): 161-176.
Choi, Y. S., J. A. Gullicksrud, S. Xing, Z. Zeng, Q. Shan, F. Li, P. E. Love, W. Peng, H. H. Xue
and S. Crotty (2015). "LEF-1 and TCF-1 orchestrate T(FH) differentiation by regulating
differentiation circuits upstream of the transcriptional repressor Bcl6." Nat Immunol16(9): 980-990.
Choi, Y. S., R. Kageyama, D. Eto, T. C. Escobar, R. J. Johnston, L. Monticelli, C. Lao and S.
Crotty (2011). "ICOS receptor instructs T follicular helper cell versus effector cell differentiation
via induction of the transcriptional repressor Bcl6." Immunity34(6): 932-946.
146
Chotivanich, K., R. Udomsangpetch, R. McGready, S. Proux, P. Newton, S. Pukrittayakamee, S.
Looareesuwan and N. J. White (2002). "Central role of the spleen in malaria parasite clearance." J
Infect Dis185(10): 1538-1541.
Christen, U. and M. G. von Herrath (2004). "Manipulating the type 1 vs type 2 balance in type 1
diabetes." Immunol Res30(3): 309-325.
Chtanova, T., S. G. Tangye, R. Newton, N. Frank, M. R. Hodge, M. S. Rolph and C. R. Mackay
(2004). "T follicular helper cells express a distinctive transcriptional profile, reflecting their role as
non-Th1/Th2 effector cells that provide help for B cells." J Immunol173(1): 68-78.
Clark, I. A., N. H. Hunt, G. A. Butcher and W. B. Cowden (1987). "Inhibition of murine malaria
(Plasmodium chabaudi) in vivo by recombinant interferon-gamma or tumor necrosis factor, and its
enhancement by butylated hydroxyanisole." J Immunol139(10): 3493-3496.
Clyde, D. F. (1975). "Immunization of man against falciparum and vivax malaria by use of
attenuated sporozoites." Am J Trop Med Hyg24(3): 397-401.
Coban, C., K. J. Ishii, T. Kawai, H. Hemmi, S. Sato, S. Uematsu, M. Yamamoto, O. Takeuchi, S.
Itagaki, N. Kumar, T. Horii and S. Akira (2005). "Toll-like receptor 9 mediates innate immune
activation by the malaria pigment hemozoin." J Exp Med201(1): 19-25.
Cockburn, I. A., R. Amino, R. K. Kelemen, S. C. Kuo, S. W. Tse, A. Radtke, L. Mac-Daniel, V. V.
Ganusov, F. Zavala and R. Menard (2013). "In vivo imaging of CD8+ T cell-mediated elimination
of malaria liver stages." Proc Natl Acad Sci U S A110(22): 9090-9095.
Cockburn, I. A., S. W. Tse and F. Zavala (2014). "CD8+ T cells eliminate liver-stage Plasmodium
berghei parasites without detectable bystander effect." Infect Immun82(4): 1460-1464.
Cohen, S., I. McGregor and S. Carrington (1961). "Gamma-globulin and acquired immunity to
human malaria." Nature192: 733-737.
Coquet, J. M., L. Rausch and J. Borst (2015). "The importance of co-stimulation in the
orchestration of T helper cell differentiation." Immunol Cell Biol93(9): 780-788.
Couper, K. N., D. G. Blount, M. S. Wilson, J. C. Hafalla, Y. Belkaid, M. Kamanaka, R. A. Flavell,
J. B. de Souza and E. M. Riley (2008). "IL-10 from CD4CD25Foxp3CD127 adaptive regulatory T
cells modulates parasite clearance and pathology during malaria infection." PLoS Pathog4(2):
e1000004.
147
Crompton, P. D., M. A. Kayala, B. Traore, K. Kayentao, A. Ongoiba, G. E. Weiss, D. M. Molina,
C. R. Burk, M. Waisberg, A. Jasinskas, X. Tan, S. Doumbo, D. Doumtabe, Y. Kone, D. L. Narum,
X. Liang, O. K. Doumbo, L. H. Miller, D. L. Doolan, P. Baldi, P. L. Felgner and S. K. Pierce
(2010). "A prospective analysis of the Ab response to Plasmodium falciparum before and after a
malaria season by protein microarray." Proc Natl Acad Sci U S A107(15): 6958-6963.
Crotty, S. (2011). "Follicular helper CD4 T cells (TFH)." Annu Rev Immunol29: 621-663.
Crotty, S. (2014). "T follicular helper cell differentiation, function, and roles in disease."
Immunity41(4): 529-542.
Curtis, M. M. and S. S. Way (2009). "Interleukin-17 in host defence against bacterial,
mycobacterial and fungal pathogens." Immunology126(2): 177-185.
Czarnowicki, T., J. Gonzalez, A. Shemer, D. Malajian, H. Xu, X. Zheng, S. Khattri, P. Gilleaudeau,
M. Sullivan-Whalen, M. Suarez-Farinas, J. G. Krueger and E. Guttman-Yassky (2015). "Severe
atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22,
but not TH17/TC17, cells within the skin-homing T-cell population." J Allergy Clin
Immunol136(1): 104-115 e107.
Dame, J. B., J. L. Williams, T. F. McCutchan, J. L. Weber, R. A. Wirtz, W. T. Hockmeyer, W. L.
Maloy, J. D. Haynes, I. Schneider, D. Roberts and et al. (1984). "Structure of the gene encoding the
immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium
falciparum." Science225(4662): 593-599.
Danke, N. A., D. M. Koelle, C. Yee, S. Beheray and W. W. Kwok (2004). "Autoreactive T cells in
healthy individuals." J Immunol172(10): 5967-5972.
Danke, N. A., J. Yang, C. Greenbaum and W. W. Kwok (2005). "Comparative study of GAD65-
specific CD4+ T cells in healthy and type 1 diabetic subjects." J Autoimmun25(4): 303-311.
Davis, M. M. and P. J. Bjorkman (1988). "T-cell antigen receptor genes and T-cell recognition."
Nature334(6181): 395-402.
Deloron, P., C. Chougnet, J. P. Lepers, S. Tallet and P. Coulanges (1991). "Protective value of
elevated levels of gamma interferon in serum against exoerythrocytic stages of Plasmodium
falciparum." J Clin Microbiol29(9): 1757-1760.
148
den Haan, J. M. and M. J. Bevan (2002). "Constitutive versus activation-dependent cross-
presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo." J Exp
Med196(6): 817-827.
deWalick, S., F. H. Amante, K. A. McSweeney, L. M. Randall, A. C. Stanley, A. Haque, R. D.
Kuns, K. P. MacDonald, G. R. Hill and C. R. Engwerda (2007). "Cutting edge: conventional
dendritic cells are the critical APC required for the induction of experimental cerebral malaria." J
Immunol178(10): 6033-6037.
Dominguez-Sola, D., G. D. Victora, C. Y. Ying, R. T. Phan, M. Saito, M. C. Nussenzweig and R.
Dalla-Favera (2012). "The proto-oncogene MYC is required for selection in the germinal center and
cyclic reentry." Nat Immunol13(11): 1083-1091.
Dondorp, A. M., V. Desakorn, W. Pongtavornpinyo, D. Sahassananda, K. Silamut, K. Chotivanich,
P. N. Newton, P. Pitisuttithum, A. M. Smithyman, N. J. White and N. P. Day (2005). "Estimation of
the total parasite biomass in acute falciparum malaria from plasma PfHRP2." PLoS Med2(8): 23.
Doolan, D. L., C. Dobano and J. K. Baird (2009). "Acquired immunity to malaria." Clin Microbiol
Rev22(1): 13-36, Table of Contents.
Dorfman, J. R., P. Bejon, F. M. Ndungu, J. Langhorne, M. M. Kortok, B. S. Lowe, T. W. Mwangi,
T. N. Williams and K. Marsh (2005). "B cell memory to 3 Plasmodium falciparum blood-stage
antigens in a malaria-endemic area." J Infect Dis191(10): 1623-1630.
Dorovini-Zis, K., K. Schmidt, H. Huynh, W. Fu, R. O. Whitten, D. Milner, S. Kamiza, M.
Molyneux and T. E. Taylor (2011). "The neuropathology of fatal cerebral malaria in malawian
children." Am J Pathol178(5): 2146-2158.
Dudziak, D., A. O. Kamphorst, G. F. Heidkamp, V. R. Buchholz, C. Trumpfheller, S. Yamazaki, C.
Cheong, K. Liu, H. W. Lee, C. G. Park, R. M. Steinman and M. C. Nussenzweig (2007).
"Differential antigen processing by dendritic cell subsets in vivo." Science315(5808): 107-111.
Duhen, T., R. Geiger, D. Jarrossay, A. Lanzavecchia and F. Sallusto (2009). "Production of
interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells." Nat
Immunol10(8): 857-863.
Edwards, C. L., S. E. Best, S. Y. Gun, C. Claser, K. R. James, M. M. de Oca, I. Sebina, L. Rivera
Fde, F. H. Amante, P. J. Hertzog, C. R. Engwerda, L. Renia and A. Haque (2015). "Spatiotemporal
149
requirements for IRF7 in mediating type I IFN-dependent susceptibility to blood-stage Plasmodium
infection." Eur J Immunol45(1): 130-141.
Enea, V., J. Ellis, F. Zavala, D. E. Arnot, A. Asavanich, A. Masuda, I. Quakyi and R. S.
Nussenzweig (1984). "DNA cloning of Plasmodium falciparum circumsporozoite gene: amino acid
sequence of repetitive epitope." Science225(4662): 628-630.
Eto, D., C. Lao, D. DiToro, B. Barnett, T. C. Escobar, R. Kageyama, I. Yusuf and S. Crotty (2011).
"IL-21 and IL-6 are critical for different aspects of B cell immunity and redundantly induce optimal
follicular helper CD4 T cell (Tfh) differentiation." PLoS One6(3): e17739.
Eyerich, S., K. Eyerich, D. Pennino, T. Carbone, F. Nasorri, S. Pallotta, F. Cianfarani, T. Odorisio,
C. Traidl-Hoffmann, H. Behrendt, S. R. Durham, C. B. Schmidt-Weber and A. Cavani (2009).
"Th22 cells represent a distinct human T cell subset involved in epidermal immunity and
remodeling." J Clin Invest119(12): 3573-3585.
Favre, N., B. Ryffel, G. Bordmann and W. Rudin (1997). "The course of Plasmodium chabaudi
chabaudi infections in interferon-gamma receptor deficient mice." Parasite Immunol19(8): 375-383.
Fernandez, V., M. Hommel, Q. Chen, P. Hagblom and M. Wahlgren (1999). "Small, clonally
variant antigens expressed on the surface of the Plasmodium falciparum-infected erythrocyte are
encoded by the rif gene family and are the target of human immune responses." J Exp Med190(10):
1393-1404.
Fernandez-Ruiz DL, L. S., N. Ghazanfari, C. M. Jones, W. Y. Ng, G. N. Davey, D. Berthold, L.
Holz, K. R. James, A. Cozijnsen, V. Mollard, T. de Koning-Ward, P. Gilson, T. Kaisho, K. M.
Murphy, A. Haque, B. S. Crabb, F. R. Carbone, G. I. McFadden and W. R. Heath (2016). "A Novel
CD4+ TCR Transgenic Line Reveals CTL Immunity to Blood Stage Malaria Requires XCR1 DC
and Help Mediated by CD40 signaling."
Finney, O. C., D. Nwakanma, D. J. Conway, M. Walther and E. M. Riley (2009). "Homeostatic
regulation of T effector to Treg ratios in an area of seasonal malaria transmission." Eur J
Immunol39(5): 1288-1300.
Fitzgerald, D. C., K. O'Brien, A. Young, Z. Fonseca-Kelly, A. Rostami and B. Gran (2014).
"Interferon regulatory factor (IRF) 3 is critical for the development of experimental autoimmune
encephalomyelitis." J Neuroinflammation11: 130.
150
Fitzgerald, K. A., D. C. Rowe, B. J. Barnes, D. R. Caffrey, A. Visintin, E. Latz, B. Monks, P. M.
Pitha and D. T. Golenbock (2003). "LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the
toll adapters TRAM and TRIF." J Exp Med198(7): 1043-1055.
Flores-Langarica, A., J. L. Marshall, S. Bobat, E. Mohr, J. Hitchcock, E. A. Ross, R. E. Coughlan,
M. Khan, N. Van Rooijen, I. R. Henderson, I. C. Maclennan and A. F. Cunningham (2011). "T-
zone localized monocyte-derived dendritic cells promote Th1 priming to Salmonella." Eur J
Immunol41(9): 2654-2665.
Foulds, K. E., M. J. Rotte and R. A. Seder (2006). "IL-10 is required for optimal CD8 T cell
memory following Listeria monocytogenes infection." J Immunol177(4): 2565-2574.
Fowkes, F. J., J. S. Richards, J. A. Simpson and J. G. Beeson (2010). "The relationship between
anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review
and meta-analysis." PLoS Med7(1): e1000218.
Franke-Fayard, B., C. J. Janse, M. Cunha-Rodrigues, J. Ramesar, P. Buscher, I. Que, C. Lowik, P.
J. Voshol, M. A. den Boer, S. G. van Duinen, M. Febbraio, M. M. Mota and A. P. Waters (2005).
"Murine malaria parasite sequestration: CD36 is the major receptor, but cerebral pathology is
unlinked to sequestration." Proc Natl Acad Sci U S A102(32): 11468-11473.
Franklin, B. S., S. O. Rodrigues, L. R. Antonelli, R. V. Oliveira, A. M. Goncalves, P. A. Sales-
Junior, E. P. Valente, J. I. Alvarez-Leite, C. Ropert, D. T. Golenbock and R. T. Gazzinelli (2007).
"MyD88-dependent activation of dendritic cells and CD4(+) T lymphocytes mediates symptoms,
but is not required for the immunological control of parasites during rodent malaria." Microbes
Infect9(7): 881-890.
Freitas do Rosario, A. P., T. Lamb, P. Spence, R. Stephens, A. Lang, A. Roers, W. Muller, A.
O'Garra and J. Langhorne (2012). "IL-27 promotes IL-10 production by effector Th1 CD4+ T cells:
a critical mechanism for protection from severe immunopathology during malaria infection." J
Immunol188(3): 1178-1190.
Freund, J., H. E. Sommer and A. W. Walter (1945). "Immunization against Malaria: Vaccination of
Ducks with Killed Parasites Incorporated with Adjuvants." Science102(2643): 200-202.
Fujii, T., T. Kumazaki, T. Nagasawa, M. Kobayashi, T. Abe and Y. Mitsui (1996). "Modulation of
hemopoietic factor production in relation to endothelial cell aging by interleukin-1 induction." Exp
Cell Res226(2): 356-362.
151
Fullwood, M. J., C. L. Wei, E. T. Liu and Y. Ruan (2009). "Next-generation DNA sequencing of
paired-end tags (PET) for transcriptome and genome analyses." Genome Res19(4): 521-532.
Gaublomme, J. T., N. Yosef, Y. Lee, R. S. Gertner, L. V. Yang, C. Wu, P. P. Pandolfi, T. Mak, R.
Satija, A. K. Shalek, V. K. Kuchroo, H. Park and A. Regev (2015). "Single-Cell Genomics Unveils
Critical Regulators of Th17 Cell Pathogenicity." Cell163(6): 1400-1412.
Gebhardt, T., L. M. Wakim, L. Eidsmo, P. C. Reading, W. R. Heath and F. R. Carbone (2009).
"Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with
herpes simplex virus." Nat Immunol10(5): 524-530.
Glennie, N. D., V. A. Yeramilli, D. P. Beiting, S. W. Volk, C. T. Weaver and P. Scott (2015).
"Skin-resident memory CD4+ T cells enhance protection against Leishmania major infection." J
Exp Med212(9): 1405-1414.
Grewal, I. S., H. G. Foellmer, K. D. Grewal, J. Xu, F. Hardardottir, J. L. Baron, C. A. Janeway, Jr.
and R. A. Flavell (1996). "Requirement for CD40 ligand in costimulation induction, T cell
activation, and experimental allergic encephalomyelitis." Science273(5283): 1864-1867.
Griffith, J. W., T. Sun, M. T. McIntosh and R. Bucala (2009). "Pure Hemozoin is inflammatory in
vivo and activates the NALP3 inflammasome via release of uric acid." J Immunol183(8): 5208-
5220.
Groettrup, M., K. Ungewiss, O. Azogui, R. Palacios, M. J. Owen, A. C. Hayday and H. von
Boehmer (1993). "A novel disulfide-linked heterodimer on pre-T cells consists of the T cell
receptor beta chain and a 33 kd glycoprotein." Cell75(2): 283-294.
Groom, J. R., J. Richmond, T. T. Murooka, E. W. Sorensen, J. H. Sung, K. Bankert, U. H. von
Andrian, J. J. Moon, T. R. Mempel and A. D. Luster (2012). "CXCR3 chemokine receptor-ligand
interactions in the lymph node optimize CD4+ T helper 1 cell differentiation." Immunity37(6):
1091-1103.
Groux, H., A. O'Garra, M. Bigler, M. Rouleau, S. Antonenko, J. E. de Vries and M. G. Roncarolo
(1997). "A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis."
Nature389(6652): 737-742.
Grun, J. L., C. A. Long and W. P. Weidanz (1985). "Effects of splenectomy on antibody-
independent immunity to Plasmodium chabaudi adami malaria." Infect Immun48(3): 853-858.
152
Grun, J. L. and W. P. Weidanz (1981). "Immunity to Plasmodium chabaudi adami in the B-cell-
deficient mouse." Nature290(5802): 143-145.
Hafalla, J. C., C. Claser, K. N. Couper, G. E. Grau, L. Renia, J. B. de Souza and E. M. Riley (2012).
"The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to
Plasmodium-induced acute immune pathology." PLoS Pathog8(2): e1002504.
Hale, J. S., B. Youngblood, D. R. Latner, A. U. Mohammed, L. Ye, R. S. Akondy, T. Wu, S. S. Iyer
and R. Ahmed (2013). "Distinct memory CD4+ T cells with commitment to T follicular helper- and
T helper 1-cell lineages are generated after acute viral infection." Immunity38(4): 805-817.
Hansen, D. S., N. J. Bernard, C. Q. Nie and L. Schofield (2007). "NK cells stimulate recruitment of
CXCR3+ T cells to the brain during Plasmodium berghei-mediated cerebral malaria." J
Immunol178(9): 5779-5788.
Haque, A., S. E. Best, A. Ammerdorffer, L. Desbarrieres, M. M. de Oca, F. H. Amante, F. de
Labastida Rivera, P. Hertzog, G. M. Boyle, G. R. Hill and C. R. Engwerda (2011). "Type I
interferons suppress CD4(+) T-cell-dependent parasite control during blood-stage Plasmodium
infection." Eur J Immunol41(9): 2688-2698.
Haque, A., S. E. Best, M. Montes de Oca, K. R. James, A. Ammerdorffer, C. L. Edwards, F. de
Labastida Rivera, F. H. Amante, P. T. Bunn, M. Sheel, I. Sebina, M. Koyama, A. Varelias, P. J.
Hertzog, U. Kalinke, S. Y. Gun, L. Renia, C. Ruedl, K. P. MacDonald, G. R. Hill and C. R.
Engwerda (2014). "Type I IFN signaling in CD8- DCs impairs Th1-dependent malaria immunity." J
Clin Invest124(6): 2483-2496.
Haque, A., S. E. Best, K. Unosson, F. H. Amante, F. de Labastida, N. M. Anstey, G. Karupiah, M.
J. Smyth, W. R. Heath and C. R. Engwerda (2011). "Granzyme B expression by CD8+ T cells is
required for the development of experimental cerebral malaria." J Immunol186(11): 6148-6156.
Hirunpetcharat, C. and M. F. Good (1998). "Deletion of Plasmodium berghei-specific CD4+ T cells
adoptively transferred into recipient mice after challenge with homologous parasite." Proc Natl
Acad Sci U S A95(4): 1715-1720.
Hisaeda, H., Y. Maekawa, D. Iwakawa, H. Okada, K. Himeno, K. Kishihara, S. Tsukumo and K.
Yasutomo (2004). "Escape of malaria parasites from host immunity requires CD4+ CD25+
regulatory T cells." Nat Med10(1): 29-30.
153
Hochweller, K., J. Striegler, G. J. Hammerling and N. Garbi (2008). "A novel CD11c.DTR
transgenic mouse for depletion of dendritic cells reveals their requirement for homeostatic
proliferation of natural killer cells." Eur J Immunol38(10): 2776-2783.
Hofmann, M., A. Oschowitzer, S. R. Kurzhals, C. C. Kruger and H. Pircher (2013). "Thymus-
resident memory CD8+ T cells mediate local immunity." Eur J Immunol43(9): 2295-2304.
Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan and F. R. Carbone (1994).
"T cell receptor antagonist peptides induce positive selection." Cell76(1): 17-27.
Hohl, T. M., A. Rivera, L. Lipuma, A. Gallegos, C. Shi, M. Mack and E. G. Pamer (2009).
"Inflammatory monocytes facilitate adaptive CD4 T cell responses during respiratory fungal
infection." Cell Host Microbe6(5): 470-481.
Honda, K., H. Yanai, H. Negishi, M. Asagiri, M. Sato, T. Mizutani, N. Shimada, Y. Ohba, A.
Takaoka, N. Yoshida and T. Taniguchi (2005). "IRF-7 is the master regulator of type-I interferon-
dependent immune responses." Nature434(7034): 772-777.
Horne-Debets, J. M., R. Faleiro, D. S. Karunarathne, X. Q. Liu, K. E. Lineburg, C. M. Poh, G. M.
Grotenbreg, G. R. Hill, K. P. MacDonald, M. F. Good, L. Renia, R. Ahmed, A. H. Sharpe and M.
N. Wykes (2013). "PD-1 dependent exhaustion of CD8+ T cells drives chronic malaria." Cell
Rep5(5): 1204-1213.
Hunt, N. H., J. Golenser, T. Chan-Ling, S. Parekh, C. Rae, S. Potter, I. M. Medana, J. Miu and H. J.
Ball (2006). "Immunopathogenesis of cerebral malaria." Int J Parasitol36(5): 569-582.
Hunt, N. H. and G. E. Grau (2003). "Cytokines: accelerators and brakes in the pathogenesis of
cerebral malaria." Trends Immunol24(9): 491-499.
Iijima, N. and A. Iwasaki (2014). "T cell memory. A local macrophage chemokine network sustains
protective tissue-resident memory CD4 T cells." Science346(6205): 93-98.
Illingworth, J., N. S. Butler, S. Roetynck, J. Mwacharo, S. K. Pierce, P. Bejon, P. D. Crompton, K.
Marsh and F. M. Ndungu (2013). "Chronic exposure to Plasmodium falciparum is associated with
phenotypic evidence of B and T cell exhaustion." J Immunol190(3): 1038-1047.
Imwong, M., G. Snounou, S. Pukrittayakamee, N. Tanomsing, J. R. Kim, A. Nandy, J. P.
Guthmann, F. Nosten, J. Carlton, S. Looareesuwan, S. Nair, D. Sudimack, N. P. Day, T. J.
154
Anderson and N. J. White (2007). "Relapses of Plasmodium vivax infection usually result from
activation of heterologous hypnozoites." J Infect Dis195(7): 927-933.
Ishizuka, A. S., K. E. Lyke, A. DeZure, A. A. Berry, T. L. Richie, F. H. Mendoza, M. E. Enama, I.
J. Gordon, L. J. Chang, U. N. Sarwar, K. L. Zephir, L. A. Holman, E. R. James, P. F. Billingsley, A.
Gunasekera, S. Chakravarty, A. Manoj, M. Li, A. J. Ruben, T. Li, A. G. Eappen, R. E. Stafford, C.
N. K, T. Murshedkar, H. DeCederfelt, S. H. Plummer, C. S. Hendel, L. Novik, P. J. Costner, J. G.
Saunders, M. B. Laurens, C. V. Plowe, B. Flynn, W. R. Whalen, J. P. Todd, J. Noor, S. Rao, K.
Sierra-Davidson, G. M. Lynn, J. E. Epstein, M. A. Kemp, G. A. Fahle, S. A. Mikolajczak, M.
Fishbaugher, B. K. Sack, S. H. Kappe, S. A. Davidson, L. S. Garver, N. K. Bjorkstrom, M. C.
Nason, B. S. Graham, M. Roederer, B. K. Sim, S. L. Hoffman, J. E. Ledgerwood and R. A. Seder
(2016). "Protection against malaria at 1 year and immune correlates following PfSPZ vaccination."
Nat Med22(6): 614-623.
Islam, S., U. Kjallquist, A. Moliner, P. Zajac, J. B. Fan, P. Lonnerberg and S. Linnarsson (2011).
"Characterization of the single-cell transcriptional landscape by highly multiplex RNA-seq."
Genome Res21(7): 1160-1167.
Iyoda, T., S. Shimoyama, K. Liu, Y. Omatsu, Y. Akiyama, Y. Maeda, K. Takahara, R. M. Steinman
and K. Inaba (2002). "The CD8+ dendritic cell subset selectively endocytoses dying cells in culture
and in vivo." J Exp Med195(10): 1289-1302.
Jacob, J., G. Kelsoe, K. Rajewsky and U. Weiss (1991). "Intraclonal generation of antibody mutants
in germinal centres." Nature354(6352): 389-392.
Jagannathan, P., I. Eccles-James, K. Bowen, F. Nankya, A. Auma, S. Wamala, C. Ebusu, M. K.
Muhindo, E. Arinaitwe, J. Briggs, B. Greenhouse, J. W. Tappero, M. R. Kamya, G. Dorsey and M.
E. Feeney (2014). "IFNgamma/IL-10 co-producing cells dominate the CD4 response to malaria in
highly exposed children." PLoS Pathog10(1): e1003864.
Jaitin, D. A., E. Kenigsberg, H. Keren-Shaul, N. Elefant, F. Paul, I. Zaretsky, A. Mildner, N.
Cohen, S. Jung, A. Tanay and I. Amit (2014). "Massively parallel single-cell RNA-seq for marker-
free decomposition of tissues into cell types." Science343(6172): 776-779.
Jenkins, M. K., H. H. Chu, J. B. McLachlan and J. J. Moon (2010). "On the composition of the
preimmune repertoire of T cells specific for Peptide-major histocompatibility complex ligands."
Annu Rev Immunol28: 275-294.
155
Jin, J., Y. Xiao, J. H. Chang, J. Yu, H. Hu, R. Starr, G. C. Brittain, M. Chang, X. Cheng and S. C.
Sun (2012). "The kinase TBK1 controls IgA class switching by negatively regulating noncanonical
NF-kappaB signaling." Nat Immunol13(11): 1101-1109.
Jin, L., K. K. Hill, H. Filak, J. Mogan, H. Knowles, B. Zhang, A. L. Perraud, J. C. Cambier and L.
L. Lenz (2011). "MPYS is required for IFN response factor 3 activation and type I IFN production
in the response of cultured phagocytes to bacterial second messengers cyclic-di-AMP and cyclic-di-
GMP." J Immunol187(5): 2595-2601.
Joffre, O. P., E. Segura, A. Savina and S. Amigorena (2012). "Cross-presentation by dendritic
cells." Nat Rev Immunol12(8): 557-569.
Jung, S., D. Unutmaz, P. Wong, G. Sano, K. De los Santos, T. Sparwasser, S. Wu, S. Vuthoori, K.
Ko, F. Zavala, E. G. Pamer, D. R. Littman and R. A. Lang (2002). "In vivo depletion of CD11c+
dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens."
Immunity17(2): 211-220.
Kaech, S. M. and R. Ahmed (2001). "Memory CD8+ T cell differentiation: initial antigen encounter
triggers a developmental program in naive cells." Nat Immunol2(5): 415-422.
Kalantari, P., R. B. DeOliveira, J. Chan, Y. Corbett, V. Rathinam, A. Stutz, E. Latz, R. T.
Gazzinelli, D. T. Golenbock and K. A. Fitzgerald (2014). "Dual engagement of the NLRP3 and
AIM2 inflammasomes by plasmodium-derived hemozoin and DNA during malaria." Cell Rep6(1):
196-210.
Kang, Z., C. Wang, J. Zepp, L. Wu, K. Sun, J. Zhao, U. Chandrasekharan, P. E. DiCorleto, B. D.
Trapp, R. M. Ransohoff and X. Li (2013). "Act1 mediates IL-17-induced EAE pathogenesis
selectively in NG2+ glial cells." Nat Neurosci16(10): 1401-1408.
Kaplan, M. H., M. M. Hufford and M. R. Olson (2015). "The development and in vivo function of
T helper 9 cells." Nat Rev Immunol15(5): 295-307.
Kaslow, D. C. and S. Biernaux (2015). "RTS,S: Toward a first landmark on the Malaria Vaccine
Technology Roadmap." Vaccine33(52): 7425-7432.
Kaviratne, M., S. M. Khan, W. Jarra and P. R. Preiser (2002). "Small variant STEVOR antigen is
uniquely located within Maurer's clefts in Plasmodium falciparum-infected red blood cells."
Eukaryot Cell1(6): 926-935.
156
Kayagaki, N., S. Warming, M. Lamkanfi, L. Vande Walle, S. Louie, J. Dong, K. Newton, Y. Qu, J.
Liu, S. Heldens, J. Zhang, W. P. Lee, M. Roose-Girma and V. M. Dixit (2011). "Non-canonical
inflammasome activation targets caspase-11." Nature479(7371): 117-121.
Kerfoot, S. M., G. Yaari, J. R. Patel, K. L. Johnson, D. G. Gonzalez, S. H. Kleinstein and A. M.
Haberman (2011). "Germinal center B cell and T follicular helper cell development initiates in the
interfollicular zone." Immunity34(6): 947-960.
Kester, K. E., J. F. Cummings, O. Ofori-Anyinam, C. F. Ockenhouse, U. Krzych, P. Moris, R.
Schwenk, R. A. Nielsen, Z. Debebe, E. Pinelis, L. Juompan, J. Williams, M. Dowler, V. A. Stewart,
R. A. Wirtz, M. C. Dubois, M. Lievens, J. Cohen, W. R. Ballou, D. G. Heppner, Jr. and S. V. E. G.
Rts (2009). "Randomized, double-blind, phase 2a trial of falciparum malaria vaccines
RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic
associates of protection." J Infect Dis200(3): 337-346.
Keswani, T. and A. Bhattacharyya (2014). "Differential role of T regulatory and Th17 in Swiss
mice infected with Plasmodium berghei ANKA and Plasmodium yoelii." Exp Parasitol141: 82-92.
Kim, C. H., L. S. Rott, I. Clark-Lewis, D. J. Campbell, L. Wu and E. C. Butcher (2001).
"Subspecialization of CXCR5+ T cells: B helper activity is focused in a germinal center-localized
subset of CXCR5+ T cells." J Exp Med193(12): 1373-1381.
Kim, K. T., H. W. Lee, H. O. Lee, H. J. Song, E. Jeong da, S. Shin, H. Kim, Y. Shin, D. H. Nam, B.
C. Jeong, D. G. Kirsch, K. M. Joo and W. Y. Park (2016). "Application of single-cell RNA
sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma."
Genome Biol17: 80.
Kim, S. K., D. S. Reed, W. R. Heath, F. Carbone and L. Lefrancois (1997). "Activation and
migration of CD8 T cells in the intestinal mucosa." J Immunol159(9): 4295-4306.
Kim, T., T. Y. Kim, W. G. Lee, J. Yim and T. K. Kim (2000). "Signaling pathways to the assembly
of an interferon-beta enhanceosome. Chemical genetic studies with a small molecule." J Biol
Chem275(22): 16910-16917.
Kim, T., T. Y. Kim, Y. H. Song, I. M. Min, J. Yim and T. K. Kim (1999). "Activation of interferon
regulatory factor 3 in response to DNA-damaging agents." J Biol Chem274(43): 30686-30689.
157
Kim, T. Y., K. H. Lee, S. Chang, C. Chung, H. W. Lee, J. Yim and T. K. Kim (2003). "Oncogenic
potential of a dominant negative mutant of interferon regulatory factor 3." J Biol Chem278(17):
15272-15278.
Kisielow, P., H. Bluthmann, U. D. Staerz, M. Steinmetz and H. von Boehmer (1988). "Tolerance in
T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes."
Nature333(6175): 742-746.
Kitamura, D., J. Roes, R. Kuhn and K. Rajewsky (1991). "A B cell-deficient mouse by targeted
disruption of the membrane exon of the immunoglobulin mu chain gene." Nature350(6317): 423-
426.
Klein, L., B. Kyewski, P. M. Allen and K. A. Hogquist (2014). "Positive and negative selection of
the T cell repertoire: what thymocytes see (and don't see)." Nat Rev Immunol14(6): 377-391.
Krishnegowda, G., A. M. Hajjar, J. Zhu, E. J. Douglass, S. Uematsu, S. Akira, A. S. Woods and D.
C. Gowda (2005). "Induction of proinflammatory responses in macrophages by the
glycosylphosphatidylinositols of Plasmodium falciparum: cell signaling receptors,
glycosylphosphatidylinositol (GPI) structural requirement, and regulation of GPI activity." J Biol
Chem280(9): 8606-8616.
Kumar, H., T. Kawai, H. Kato, S. Sato, K. Takahashi, C. Coban, M. Yamamoto, S. Uematsu, K. J.
Ishii, O. Takeuchi and S. Akira (2006). "Essential role of IPS-1 in innate immune responses against
RNA viruses." J Exp Med203(7): 1795-1803.
Kumararatne, D. S., H. Bazin and I. C. MacLennan (1981). "Marginal zones: the major B cell
compartment of rat spleens." Eur J Immunol11(11): 858-864.
Langhorne, J. (1989). "The role of CD4+ T-cells in the immune response to Plasmodium chabaudi."
Parasitol Today5(11): 362-364.
Langhorne, J. (1994). "The immune response to the blood stages of Plasmodium in animal models."
Immunol Lett41(2-3): 99-102.
Langhorne, J., P. Buffet, M. Galinski, M. Good, J. Harty, D. Leroy, M. M. Mota, E. Pasini, L.
Renia, E. Riley, M. Stins and P. Duffy (2011). "The relevance of non-human primate and rodent
malaria models for humans." Malar J10: 23.
158
Langhorne, J., S. Gillard, B. Simon, S. Slade and K. Eichmann (1989). "Frequencies of CD4+ T
cells reactive with Plasmodium chabaudi chabaudi: distinct response kinetics for cells with Th1 and
Th2 characteristics during infection." Int Immunol1(4): 416-424.
Langhorne, J., S. J. Meding, K. Eichmann and S. S. Gillard (1989). "The response of CD4+ T cells
to Plasmodium chabaudi chabaudi." Immunol Rev112: 71-94.
Langhorne, J., F. M. Ndungu, A. M. Sponaas and K. Marsh (2008). "Immunity to malaria: more
questions than answers." Nat Immunol9(7): 725-732.
Langhorne, J. and B. Simon (1989). "Limiting dilution analysis of the T cell response to
Plasmodium chabaudi chabaudi in mice." Parasite Immunol11(5): 545-559.
Lao, K. Q., F. Tang, C. Barbacioru, Y. Wang, E. Nordman, C. Lee, N. Xu, X. Wang, B. Tuch, J.
Bodeau, A. Siddiqui and M. A. Surani (2009). "mRNA-sequencing whole transcriptome analysis of
a single cell on the SOLiD system." J Biomol Tech20(5): 266-271.
Lau, L. S., D. Fernandez-Ruiz, V. Mollard, A. Sturm, M. A. Neller, A. Cozijnsen, J. L. Gregory, G.
M. Davey, C. M. Jones, Y. H. Lin, A. Haque, C. R. Engwerda, C. Q. Nie, D. S. Hansen, K. M.
Murphy, A. T. Papenfuss, J. J. Miles, S. R. Burrows, T. de Koning-Ward, G. I. McFadden, F. R.
Carbone, B. S. Crabb and W. R. Heath (2014). "CD8+ T cells from a novel T cell receptor
transgenic mouse induce liver-stage immunity that can be boosted by blood-stage infection in
rodent malaria." PLoS Pathog10(5): e1004135.
Lavazec, C., S. Sanyal and T. J. Templeton (2006). "Hypervariability within the Rifin, Stevor and
Pfmc-2TM superfamilies in Plasmodium falciparum." Nucleic Acids Res34(22): 6696-6707.
Lawrence, N. D. T., M. K. (2010). "Bayesian gaussian process latent variable model." Proceedings
of the 13th international conference on artificial intelligence and statistics844.
Leech, J. H., J. W. Barnwell, L. H. Miller and R. J. Howard (1984). "Identification of a strain-
specific malarial antigen exposed on the surface of Plasmodium falciparum-infected erythrocytes."
J Exp Med159(6): 1567-1575.
Leon, B., M. Lopez-Bravo and C. Ardavin (2007). "Monocyte-derived dendritic cells formed at the
infection site control the induction of protective T helper 1 responses against Leishmania."
Immunity26(4): 519-531.
159
Liehl, P., V. Zuzarte-Luis, J. Chan, T. Zillinger, F. Baptista, D. Carapau, M. Konert, K. K. Hanson,
C. Carret, C. Lassnig, M. Muller, U. Kalinke, M. Saeed, A. F. Chora, D. T. Golenbock, B. Strobl,
M. Prudencio, L. P. Coelho, S. H. Kappe, G. Superti-Furga, A. Pichlmair, A. M. Vigario, C. M.
Rice, K. A. Fitzgerald, W. Barchet and M. M. Mota (2014). "Host-cell sensors for Plasmodium
activate innate immunity against liver-stage infection." Nat Med20(1): 47-53.
Liu, X. and R. Bosselut (2004). "Duration of TCR signaling controls CD4-CD8 lineage
differentiation in vivo." Nat Immunol5(3): 280-288.
Liu, X., X. Yan, B. Zhong, R. I. Nurieva, A. Wang, X. Wang, N. Martin-Orozco, Y. Wang, S. H.
Chang, E. Esplugues, R. A. Flavell, Q. Tian and C. Dong (2012). "Bcl6 expression specifies the T
follicular helper cell program in vivo." J Exp Med209(10): 1841-1852, S1841-1824.
Liu, Y. J., D. E. Joshua, G. T. Williams, C. A. Smith, J. Gordon and I. C. MacLennan (1989).
"Mechanism of antigen-driven selection in germinal centres." Nature342(6252): 929-931.
Lohoff, M., H. W. Mittrucker, S. Prechtl, S. Bischof, F. Sommer, S. Kock, D. A. Ferrick, G. S.
Duncan, A. Gessner and T. W. Mak (2002). "Dysregulated T helper cell differentiation in the
absence of interferon regulatory factor 4." Proc Natl Acad Sci U S A99(18): 11808-11812.
Long, C. A. and F. Zavala (2016). "Malaria vaccines and human immune responses." Curr Opin
Microbiol32: 96-102.
Lu, R., K. L. Medina, D. W. Lancki and H. Singh (2003). "IRF-4,8 orchestrate the pre-B-to-B
transition in lymphocyte development." Genes Dev17(14): 1703-1708.
Luckheeram, R. V., R. Zhou, A. D. Verma and B. Xia (2012). "CD4(+)T cells: differentiation and
functions." Clin Dev Immunol2012: 925135.
Lundie, R. J., T. F. de Koning-Ward, G. M. Davey, C. Q. Nie, D. S. Hansen, L. S. Lau, J. D.
Mintern, G. T. Belz, L. Schofield, F. R. Carbone, J. A. Villadangos, B. S. Crabb and W. R. Heath
(2008). "Blood-stage Plasmodium infection induces CD8+ T lymphocytes to parasite-expressed
antigens, largely regulated by CD8alpha+ dendritic cells." Proc Natl Acad Sci U S A105(38):
14509-14514.
Luscher, B. (2012). "MAD1 and its life as a MYC antagonist: an update." Eur J Cell Biol91(6-7):
506-514.
160
Mackay, L. K., A. Rahimpour, J. Z. Ma, N. Collins, A. T. Stock, M. L. Hafon, J. Vega-Ramos, P.
Lauzurica, S. N. Mueller, T. Stefanovic, D. C. Tscharke, W. R. Heath, M. Inouye, F. R. Carbone
and T. Gebhardt (2013). "The developmental pathway for CD103(+)CD8+ tissue-resident memory
T cells of skin." Nat Immunol14(12): 1294-1301.
Mahata, B., X. Zhang, A. A. Kolodziejczyk, V. Proserpio, L. Haim-Vilmovsky, A. E. Taylor, D.
Hebenstreit, F. A. Dingler, V. Moignard, B. Gottgens, W. Arlt, A. N. McKenzie and S. A.
Teichmann (2014). "Single-cell RNA sequencing reveals T helper cells synthesizing steroids de
novo to contribute to immune homeostasis." Cell Rep7(4): 1130-1142.
Mallone, R., S. A. Kochik, H. Reijonen, B. Carson, S. F. Ziegler, W. W. Kwok and G. T. Nepom
(2005). "Functional avidity directs T-cell fate in autoreactive CD4+ T cells." Blood106(8): 2798-
2805.
Mandl, J. N., J. P. Monteiro, N. Vrisekoop and R. N. Germain (2013). "T cell-positive selection
uses self-ligand binding strength to optimize repertoire recognition of foreign antigens."
Immunity38(2): 263-274.
Marchingo, J. M., A. Kan, R. M. Sutherland, K. R. Duffy, C. J. Wellard, G. T. Belz, A. M. Lew, M.
R. Dowling, S. Heinzel and P. D. Hodgkin (2014). "T cell signaling. Antigen affinity,
costimulation, and cytokine inputs sum linearly to amplify T cell expansion." Science346(6213):
1123-1127.
Marichal, T., K. Ohata, D. Bedoret, C. Mesnil, C. Sabatel, K. Kobiyama, P. Lekeux, C. Coban, S.
Akira, K. J. Ishii, F. Bureau and C. J. Desmet (2011). "DNA released from dying host cells
mediates aluminum adjuvant activity." Nat Med17(8): 996-1002.
Marshall, H. D., A. Chandele, Y. W. Jung, H. Meng, A. C. Poholek, I. A. Parish, R. Rutishauser,
W. Cui, S. H. Kleinstein, J. Craft and S. M. Kaech (2011). "Differential expression of Ly6C and T-
bet distinguish effector and memory Th1 CD4(+) cell properties during viral infection."
Immunity35(4): 633-646.
Martin, F. and J. F. Kearney (2002). "Marginal-zone B cells." Nat Rev Immunol2(5): 323-335.
Mastelic, B., A. P. do Rosario, M. Veldhoen, J. C. Renauld, W. Jarra, A. M. Sponaas, S. Roetynck,
B. Stockinger and J. Langhorne (2012). "IL-22 Protects Against Liver Pathology and Lethality of an
Experimental Blood-Stage Malaria Infection." Front Immunol3: 85.
161
Matsuyama, T., T. Kimura, M. Kitagawa, K. Pfeffer, T. Kawakami, N. Watanabe, T. M. Kundig, R.
Amakawa, K. Kishihara, A. Wakeham and et al. (1993). "Targeted disruption of IRF-1 or IRF-2
results in abnormal type I IFN gene induction and aberrant lymphocyte development." Cell75(1):
83-97.
Mbogo, C. N., R. W. Snow, E. W. Kabiru, J. H. Ouma, J. I. Githure, K. Marsh and J. C. Beier
(1993). "Low-level Plasmodium falciparum transmission and the incidence of severe malaria
infections on the Kenyan coast." Am J Trop Med Hyg49(2): 245-253.
McElroy, P. D., J. C. Beier, C. N. Oster, C. Beadle, J. A. Sherwood, A. J. Oloo and S. L. Hoffman
(1994). "Predicting outcome in malaria: correlation between rate of exposure to infected mosquitoes
and level of Plasmodium falciparum parasitemia." Am J Trop Med Hyg51(5): 523-532.
Meding, S. J. and J. Langhorne (1991). "CD4+ T cells and B cells are necessary for the transfer of
protective immunity to Plasmodium chabaudi chabaudi." Eur J Immunol21(6): 1433-1438.
Mewono, L., S. T. Agnandji, D. W. Matondo Maya, A. M. Mouima, B. A. Iroungou, S. Issifou and
P. G. Kremsner (2009). "Malaria antigen-mediated enhancement of interleukin-21 responses of
peripheral blood mononuclear cells in African adults." Exp Parasitol122(1): 37-40.
Mewono, L., D. W. Matondo Maya, P. B. Matsiegui, S. T. Agnandji, E. Kendjo, F. Barondi, S.
Issifou, P. G. Kremsner and E. Mavoungou (2008). "Interleukin-21 is associated with IgG1 and
IgG3 antibodies to erythrocyte-binding antigen-175 peptide 4 of Plasmodium falciparum in
Gabonese children with acute falciparum malaria." Eur Cytokine Netw19(1): 30-36.
Meyer-Hermann, M., E. Mohr, N. Pelletier, Y. Zhang, G. D. Victora and K. M. Toellner (2012). "A
theory of germinal center B cell selection, division, and exit." Cell Rep2(1): 162-174.
Migot, F., C. Chougnet, D. Henzel, B. Dubois, R. Jambou, N. Fievet and P. Deloron (1995). "Anti-
malaria antibody-producing B cell frequencies in adults after a Plasmodium falciparum outbreak in
Madagascar." Clin Exp Immunol102(3): 529-534.
Migot, F., C. Chougnet, L. Raharimalala, P. Astagneau, J. P. Lepers and P. Deloron (1993).
"Human immune responses to the Plasmodium falciparum ring-infected erythrocyte surface antigen
(Pf155/RESA) after a decrease in malaria transmission in Madagascar." Am J Trop Med Hyg48(3):
432-439.
Miller, J. L., B. K. Sack, M. Baldwin, A. M. Vaughan and S. H. Kappe (2014). "Interferon-
mediated innate immune responses against malaria parasite liver stages." Cell Rep7(2): 436-447.
162
Mombaerts, P., J. Iacomini, R. S. Johnson, K. Herrup, S. Tonegawa and V. E. Papaioannou (1992).
"RAG-1-deficient mice have no mature B and T lymphocytes." Cell68(5): 869-877.
Montes de Oca, M., R. Kumar, F. de Labastida Rivera, F. H. Amante, M. Sheel, R. J. Faleiro, P. T.
Bunn, S. E. Best, L. Beattie, S. S. Ng, C. L. Edwards, W. Muller, E. Cretney, S. L. Nutt, M. J.
Smyth, A. Haque, G. R. Hill, S. Sundar, A. Kallies and C. R. Engwerda (2016). "Correction: Blimp-
1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-Mediated Tissue Pathology." PLoS
Pathog12(2): e1005460.
Moon, J. J., H. H. Chu, M. Pepper, S. J. McSorley, S. C. Jameson, R. M. Kedl and M. K. Jenkins
(2007). "Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire
diversity and response magnitude." Immunity27(2): 203-213.
Moorthy, V. S., M. F. Good and A. V. Hill (2004). "Malaria vaccine developments."
Lancet363(9403): 150-156.
Moskophidis, D., F. Lechner, H. Pircher and R. M. Zinkernagel (1993). "Virus persistence in
acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells."
Nature362(6422): 758-761.
Mosmann, T. R., H. Cherwinski, M. W. Bond, M. A. Giedlin and R. L. Coffman (1986). "Two
types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and
secreted proteins." J Immunol136(7): 2348-2357.
Mueller, S. N., W. Heath, J. D. McLain, F. R. Carbone and C. M. Jones (2002). "Characterization of
two TCR transgenic mouse lines specific for herpes simplex virus." Immunol Cell Biol80(2): 156-
163.
Naito, Y., H. Takematsu, S. Koyama, S. Miyake, H. Yamamoto, R. Fujinawa, M. Sugai, Y. Okuno,
G. Tsujimoto, T. Yamaji, Y. Hashimoto, S. Itohara, T. Kawasaki, A. Suzuki and Y. Kozutsumi
(2007). "Germinal center marker GL7 probes activation-dependent repression of N-
glycolylneuraminic acid, a sialic acid species involved in the negative modulation of B-cell
activation." Mol Cell Biol27(8): 3008-3022.
Nakano, H., K. L. Lin, M. Yanagita, C. Charbonneau, D. N. Cook, T. Kakiuchi and M. D. Gunn
(2009). "Blood-derived inflammatory dendritic cells in lymph nodes stimulate acute T helper type 1
immune responses." Nat Immunol10(4): 394-402.
163
Nakayamada, S., Y. Kanno, H. Takahashi, D. Jankovic, Kristina T. Lu, Thomas A. Johnson, H.-w.
Sun, G. Vahedi, O. Hakim, R. Handon, Pamela L. Schwartzberg, Gordon L. Hager and John J.
O'Shea (2011). "Early Th1 Cell Differentiation Is Marked by a Tfh Cell-like Transition."
Immunity35(6): 919-931.
Nanan, R., D. Heinrich, M. Frosch and H. W. Kreth (2001). "Acute and long-term effects of booster
immunisation on frequencies of antigen-specific memory B-lymphocytes." Vaccine20(3-4): 498-
504.
Navin, N. E. (2015). "The first five years of single-cell cancer genomics and beyond." Genome
Res25(10): 1499-1507.
Negishi, H., Y. Fujita, H. Yanai, S. Sakaguchi, X. Ouyang, M. Shinohara, H. Takayanagi, Y. Ohba,
T. Taniguchi and K. Honda (2006). "Evidence for licensing of IFN-gamma-induced IFN regulatory
factor 1 transcription factor by MyD88 in Toll-like receptor-dependent gene induction program."
Proc Natl Acad Sci U S A103(41): 15136-15141.
Negishi, H., Y. Ohba, H. Yanai, A. Takaoka, K. Honma, K. Yui, T. Matsuyama, T. Taniguchi and
K. Honda (2005). "Negative regulation of Toll-like-receptor signaling by IRF-4." Proc Natl Acad
Sci U S A102(44): 15989-15994.
Negishi, H., H. Yanai, A. Nakajima, R. Koshiba, K. Atarashi, A. Matsuda, K. Matsuki, S. Miki, T.
Doi, A. Aderem, J. Nishio, S. T. Smale, K. Honda and T. Taniguchi (2012). "Cross-interference of
RLR and TLR signaling pathways modulates antibacterial T cell responses." Nat Immunol13(7):
659-666.
Nepom, G. T. (2012). "MHC class II tetramers." J Immunol188(6): 2477-2482.
Newell, E. W. and M. M. Davis (2014). "Beyond model antigens: high-dimensional methods for the
analysis of antigen-specific T cells." Nat Biotechnol32(2): 149-157.
Newell, E. W., N. Sigal, S. C. Bendall, G. P. Nolan and M. M. Davis (2012). "Cytometry by time-
of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum
of CD8+ T cell phenotypes." Immunity36(1): 142-152.
Niang, M., X. Yan Yam and P. R. Preiser (2009). "The Plasmodium falciparum STEVOR
multigene family mediates antigenic variation of the infected erythrocyte." PLoS Pathog5(2):
e1000307.
164
Nish, S. and R. Medzhitov (2011). "Host defense pathways: role of redundancy and compensation
in infectious disease phenotypes." Immunity34(5): 629-636.
Nitcheu, J., O. Bonduelle, C. Combadiere, M. Tefit, D. Seilhean, D. Mazier and B. Combadiere
(2003). "Perforin-dependent brain-infiltrating cytotoxic CD8+ T lymphocytes mediate experimental
cerebral malaria pathogenesis." J Immunol170(4): 2221-2228.
Nogaro, S. I., J. C. Hafalla, B. Walther, E. J. Remarque, K. K. Tetteh, D. J. Conway, E. M. Riley
and M. Walther (2011). "The breadth, but not the magnitude, of circulating memory B cell
responses to P. falciparum increases with age/exposure in an area of low transmission." PLoS
One6(10): e25582.
Nolte, M. A., J. A. Belien, I. Schadee-Eestermans, W. Jansen, W. W. Unger, N. van Rooijen, G.
Kraal and R. E. Mebius (2003). "A conduit system distributes chemokines and small blood-borne
molecules through the splenic white pulp." J Exp Med198(3): 505-512.
Nurieva, R. I., Y. Chung, G. J. Martinez, X. O. Yang, S. Tanaka, T. D. Matskevitch, Y. H. Wang
and C. Dong (2009). "Bcl6 mediates the development of T follicular helper cells."
Science325(5943): 1001-1005.
Nussenzweig, R. S., J. Vanderberg, H. Most and C. Orton (1967). "Protective immunity produced
by the injection of x-irradiated sporozoites of plasmodium berghei." Nature216(5111): 160-162.
Oakley, M. S., B. R. Sahu, L. Lotspeich-Cole, N. R. Solanki, V. Majam, P. T. Pham, R. Banerjee,
Y. Kozakai, S. C. Derrick, S. Kumar and S. L. Morris (2013). "The transcription factor T-bet
regulates parasitemia and promotes pathogenesis during Plasmodium berghei ANKA murine
malaria." J Immunol191(9): 4699-4708.
Obeng-Adjei, N., S. Portugal, T. M. Tran, T. B. Yazew, J. Skinner, S. Li, A. Jain, P. L. Felgner, O.
K. Doumbo, K. Kayentao, A. Ongoiba, B. Traore and P. D. Crompton (2015). "Circulating Th1-
Cell-type Tfh Cells that Exhibit Impaired B Cell Help Are Preferentially Activated during Acute
Malaria in Children." Cell Rep13(2): 425-439.
Obst, R., H. M. van Santen, D. Mathis and C. Benoist (2005). "Antigen persistence is required
throughout the expansion phase of a CD4(+) T cell response." J Exp Med201(10): 1555-1565.
Ochs, H. D., S. F. Ziegler and T. R. Torgerson (2005). "FOXP3 acts as a rheostat of the immune
response." Immunol Rev203: 156-164.
165
Oganesyan, G., S. K. Saha, E. M. Pietras, B. Guo, A. K. Miyahira, B. Zarnegar and G. Cheng
(2008). "IRF3-dependent type I interferon response in B cells regulates CpG-mediated antibody
production." J Biol Chem283(2): 802-808.
Ogasawara, K., S. Hida, N. Azimi, Y. Tagaya, T. Sato, T. Yokochi-Fukuda, T. A. Waldmann, T.
Taniguchi and S. Taki (1998). "Requirement for IRF-1 in the microenvironment supporting
development of natural killer cells." Nature391(6668): 700-703.
Oling, V., J. Marttila, J. Ilonen, W. W. Kwok, G. Nepom, M. Knip, O. Simell and H. Reijonen
(2005). "GAD65- and proinsulin-specific CD4+ T-cells detected by MHC class II tetramers in
peripheral blood of type 1 diabetes patients and at-risk subjects." J Autoimmun25(3): 235-243.
Oliver, A. M., F. Martin and J. F. Kearney (1997). "Mouse CD38 is down-regulated on germinal
center B cells and mature plasma cells." J Immunol158(3): 1108-1115.
Olotu, A., G. Fegan, J. Wambua, G. Nyangweso, K. O. Awuondo, A. Leach, M. Lievens, D.
Leboulleux, P. Njuguna, N. Peshu, K. Marsh and P. Bejon (2013). "Four-year efficacy of
RTS,S/AS01E and its interaction with malaria exposure." N Engl J Med368(12): 1111-1120.
Padovan, E., G. Casorati, P. Dellabona, S. Meyer, M. Brockhaus and A. Lanzavecchia (1993).
"Expression of two T cell receptor alpha chains: dual receptor T cells." Science262(5132): 422-424.
Parkin, J. and B. Cohen (2001). "An overview of the immune system." Lancet357(9270): 1777-
1789.
Parroche, P., F. N. Lauw, N. Goutagny, E. Latz, B. G. Monks, A. Visintin, K. A. Halmen, M.
Lamphier, M. Olivier, D. C. Bartholomeu, R. T. Gazzinelli and D. T. Golenbock (2007). "Malaria
hemozoin is immunologically inert but radically enhances innate responses by presenting malaria
DNA to Toll-like receptor 9." Proc Natl Acad Sci U S A104(6): 1919-1924.
Patel, A. P., I. Tirosh, J. J. Trombetta, A. K. Shalek, S. M. Gillespie, H. Wakimoto, D. P. Cahill, B.
V. Nahed, W. T. Curry, R. L. Martuza, D. N. Louis, O. Rozenblatt-Rosen, M. L. Suva, A. Regev
and B. E. Bernstein (2014). "Single-cell RNA-seq highlights intratumoral heterogeneity in primary
glioblastoma." Science344(6190): 1396-1401.
Patro, R. D., G.; Kingsford, C. (2015). "Salmon: Accurate, Versatile and Ultrafast Quantification
from RNA-seq Data using Lightweight-Alignment." biRxiv.
166
Pereira, J. P., L. M. Kelly and J. G. Cyster (2010). "Finding the right niche: B-cell migration in the
early phases of T-dependent antibody responses." Int Immunol22(6): 413-419.
Perez-Mazliah, D. and J. Langhorne (2014). "CD4 T-cell subsets in malaria: TH1/TH2 revisited."
Front Immunol5: 671.
Perez-Mazliah, D., D. H. Ng, A. P. Freitas do Rosario, S. McLaughlin, B. Mastelic-Gavillet, J.
Sodenkamp, G. Kushinga and J. Langhorne (2015). "Disruption of IL-21 signaling affects T cell-B
cell interactions and abrogates protective humoral immunity to malaria." PLoS Pathog11(3):
e1004715.
Perraut, R., O. Mercereau-Puijalon, D. Mattei, E. Bourreau, O. Garraud, B. Bonnemains, L. Pereia
de Silva and J. C. Michel (1995). "Induction of opsonizing antibodies after injection of recombinant
Plasmodium falciparum vaccine candidate antigens in preimmune Saimiri sciureus monkeys."
Infect Immun63(2): 554-562.
Perry, J. A., A. Rush, R. J. Wilson, C. S. Olver and A. C. Avery (2004). "Dendritic cells from
malaria-infected mice are fully functional APC." J Immunol172(1): 475-482.
Pham, K., R. Shimoni, M. Charnley, M. J. Ludford-Menting, E. D. Hawkins, K. Ramsbottom, J.
Oliaro, D. Izon, S. B. Ting, J. Reynolds, G. Lythe, C. Molina-Paris, H. Melichar, E. Robey, P. O.
Humbert, M. Gu and S. M. Russell (2015). "Asymmetric cell division during T cell development
controls downstream fate." J Cell Biol210(6): 933-950.
Pinzon-Charry, A., V. McPhun, V. Kienzle, C. Hirunpetcharat, C. Engwerda, J. McCarthy and M.
F. Good (2010). "Low doses of killed parasite in CpG elicit vigorous CD4+ T cell responses against
blood-stage malaria in mice." J Clin Invest120(8): 2967-2978.
Pinzon-Charry, A., T. Woodberry, V. Kienzle, V. McPhun, G. Minigo, D. A. Lampah, E.
Kenangalem, C. Engwerda, J. A. Lopez, N. M. Anstey and M. F. Good (2013). "Apoptosis and
dysfunction of blood dendritic cells in patients with falciparum and vivax malaria." J Exp
Med210(8): 1635-1646.
Pombo, D. J., G. Lawrence, C. Hirunpetcharat, C. Rzepczyk, M. Bryden, N. Cloonan, K. Anderson,
Y. Mahakunkijcharoen, L. B. Martin, D. Wilson, S. Elliott, D. P. Eisen, J. B. Weinberg, A. Saul and
M. F. Good (2002). "Immunity to malaria after administration of ultra-low doses of red cells
infected with Plasmodium falciparum." Lancet360(9333): 610-617.
167
Portugal, S., J. Moebius, J. Skinner, S. Doumbo, D. Doumtabe, Y. Kone, S. Dia, K. Kanakabandi,
D. E. Sturdevant, K. Virtaneva, S. F. Porcella, S. Li, O. K. Doumbo, K. Kayentao, A. Ongoiba, B.
Traore and P. D. Crompton (2014). "Exposure-dependent control of malaria-induced inflammation
in children." PLoS Pathog10(4): e1004079.
Prakash, D., C. Fesel, R. Jain, P. A. Cazenave, G. C. Mishra and S. Pied (2006). "Clusters of
cytokines determine malaria severity in Plasmodium falciparum-infected patients from endemic
areas of Central India." J Infect Dis194(2): 198-207.
Radtke, A. J., W. Kastenmuller, D. A. Espinosa, M. Y. Gerner, S. W. Tse, P. Sinnis, R. N. Germain,
F. P. Zavala and I. A. Cockburn (2015). "Lymph-node resident CD8alpha+ dendritic cells capture
antigens from migratory malaria sporozoites and induce CD8+ T cell responses." PLoS
Pathog11(2): e1004637.
Ramskold, D., S. Luo, Y. C. Wang, R. Li, Q. Deng, O. R. Faridani, G. A. Daniels, I. Khrebtukova,
J. F. Loring, L. C. Laurent, G. P. Schroth and R. Sandberg (2012). "Full-length mRNA-Seq from
single-cell levels of RNA and individual circulating tumor cells." Nat Biotechnol30(8): 777-782.
Reddy, K. S., A. K. Pandey, H. Singh, T. Sahar, A. Emmanuel, C. E. Chitnis, V. S. Chauhan and D.
Gaur (2014). "Bacterially expressed full-length recombinant Plasmodium falciparum RH5 protein
binds erythrocytes and elicits potent strain-transcending parasite-neutralizing antibodies." Infect
Immun82(1): 152-164.
Reizis, B., A. Bunin, H. S. Ghosh, K. L. Lewis and V. Sisirak (2011). "Plasmacytoid dendritic cells:
recent progress and open questions." Annu Rev Immunol29: 163-183.
Renia, L., S. W. Howland, C. Claser, A. Charlotte Gruner, R. Suwanarusk, T. Hui Teo, B. Russell
and L. F. Ng (2012). "Cerebral malaria: mysteries at the blood-brain barrier." Virulence3(2): 193-
201.
Riley, E. M. and V. A. Stewart (2013). "Immune mechanisms in malaria: new insights in vaccine
development." Nat Med19(2): 168-178.
Robinson, D. S., Q. Hamid, S. Ying, A. Tsicopoulos, J. Barkans, A. M. Bentley, C. Corrigan, S. R.
Durham and A. B. Kay (1992). "Predominant TH2-like bronchoalveolar T-lymphocyte population
in atopic asthma." N Engl J Med326(5): 298-304.
Rose, M. L., M. S. Birbeck, V. J. Wallis, J. A. Forrester and A. J. Davies (1980). "Peanut lectin
binding properties of germinal centres of mouse lymphoid tissue." Nature284(5754): 364-366.
168
Rotem, A., O. Ram, N. Shoresh, R. A. Sperling, A. Goren, D. A. Weitz and B. E. Bernstein (2015).
"Single-cell ChIP-seq reveals cell subpopulations defined by chromatin state." Nat
Biotechnol33(11): 1165-1172.
Russ, B. E., J. E. Prier, S. Rao and S. J. Turner (2013). "T cell immunity as a tool for studying
epigenetic regulation of cellular differentiation." Front Genet4: 218.
Ryg-Cornejo, V., L. J. Ioannidis, A. Ly, C. Y. Chiu, J. Tellier, D. L. Hill, S. P. Preston, M.
Pellegrini, D. Yu, S. L. Nutt, A. Kallies and D. S. Hansen (2015). "Severe Malaria Infections Impair
Germinal Center Responses by Inhibiting T Follicular Helper Cell Differentiation." Cell Rep.
Sallusto, F., J. Geginat and A. Lanzavecchia (2004). "Central memory and effector memory T cell
subsets: function, generation, and maintenance." Annu Rev Immunol22: 745-763.
Sam-Yellowe, T. Y., L. Florens, J. R. Johnson, T. Wang, J. A. Drazba, K. G. Le Roch, Y. Zhou, S.
Batalov, D. J. Carucci, E. A. Winzeler and J. R. Yates, 3rd (2004). "A Plasmodium gene family
encoding Maurer's cleft membrane proteins: structural properties and expression profiling."
Genome Res14(6): 1052-1059.
Sanz, I., C. Wei, F. E. Lee and J. Anolik (2008). "Phenotypic and functional heterogeneity of
human memory B cells." Semin Immunol20(1): 67-82.
Sato, M., H. Suemori, N. Hata, M. Asagiri, K. Ogasawara, K. Nakao, T. Nakaya, M. Katsuki, S.
Noguchi, N. Tanaka and T. Taniguchi (2000). "Distinct and essential roles of transcription factors
IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction." Immunity13(4): 539-
548.
Schaerli, P., K. Willimann, A. B. Lang, M. Lipp, P. Loetscher and B. Moser (2000). "CXC
chemokine receptor 5 expression defines follicular homing T cells with B cell helper function." J
Exp Med192(11): 1553-1562.
Schlub, T. E., J. C. Sun, S. M. Walton, S. H. Robbins, A. K. Pinto, M. W. Munks, A. B. Hill, L.
Brossay, A. Oxenius and M. P. Davenport (2011). "Comparing the kinetics of NK cells, CD4, and
CD8 T cells in murine cytomegalovirus infection." J Immunol187(3): 1385-1392.
Schwanhausser, B., D. Busse, N. Li, G. Dittmar, J. Schuchhardt, J. Wolf, W. Chen and M. Selbach
(2011). "Global quantification of mammalian gene expression control." Nature473(7347): 337-342.
169
Scialdone, A., K. N. Natarajan, L. R. Saraiva, V. Proserpio, S. A. Teichmann, O. Stegle, J. C.
Marioni and F. Buettner (2015). "Computational assignment of cell-cycle stage from single-cell
transcriptome data." Methods85: 54-61.
Seder, R. A., L. J. Chang, M. E. Enama, K. L. Zephir, U. N. Sarwar, I. J. Gordon, L. A. Holman, E.
R. James, P. F. Billingsley, A. Gunasekera, A. Richman, S. Chakravarty, A. Manoj, S. Velmurugan,
M. Li, A. J. Ruben, T. Li, A. G. Eappen, R. E. Stafford, S. H. Plummer, C. S. Hendel, L. Novik, P.
J. Costner, F. H. Mendoza, J. G. Saunders, M. C. Nason, J. H. Richardson, J. Murphy, S. A.
Davidson, T. L. Richie, M. Sedegah, A. Sutamihardja, G. A. Fahle, K. E. Lyke, M. B. Laurens, M.
Roederer, K. Tewari, J. E. Epstein, B. K. Sim, J. E. Ledgerwood, B. S. Graham, S. L. Hoffman and
V. R. C. S. Team (2013). "Protection against malaria by intravenous immunization with a
nonreplicating sporozoite vaccine." Science341(6152): 1359-1365.
Segura, E. and J. A. Villadangos (2009). "Antigen presentation by dendritic cells in vivo." Curr
Opin Immunol21(1): 105-110.
Servant, M. J., N. Grandvaux and J. Hiscott (2002). "Multiple signaling pathways leading to the
activation of interferon regulatory factor 3." Biochem Pharmacol64(5-6): 985-992.
Shaffer, A. L., K. I. Lin, T. C. Kuo, X. Yu, E. M. Hurt, A. Rosenwald, J. M. Giltnane, L. Yang, H.
Zhao, K. Calame and L. M. Staudt (2002). "Blimp-1 orchestrates plasma cell differentiation by
extinguishing the mature B cell gene expression program." Immunity17(1): 51-62.
Shalek, A. K., R. Satija, X. Adiconis, R. S. Gertner, J. T. Gaublomme, R. Raychowdhury, S.
Schwartz, N. Yosef, C. Malboeuf, D. Lu, J. J. Trombetta, D. Gennert, A. Gnirke, A. Goren, N.
Hacohen, J. Z. Levin, H. Park and A. Regev (2013). "Single-cell transcriptomics reveals bimodality
in expression and splicing in immune cells." Nature498(7453): 236-240.
Shalek, A. K., R. Satija, J. Shuga, J. J. Trombetta, D. Gennert, D. Lu, P. Chen, R. S. Gertner, J. T.
Gaublomme, N. Yosef, S. Schwartz, B. Fowler, S. Weaver, J. Wang, X. Wang, R. Ding, R.
Raychowdhury, N. Friedman, N. Hacohen, H. Park, A. P. May and A. Regev (2014). "Single-cell
RNA-seq reveals dynamic paracrine control of cellular variation." Nature510(7505): 363-369.
Sharma, S., R. B. DeOliveira, P. Kalantari, P. Parroche, N. Goutagny, Z. Jiang, J. Chan, D. C.
Bartholomeu, F. Lauw, J. P. Hall, G. N. Barber, R. T. Gazzinelli, K. A. Fitzgerald and D. T.
Golenbock (2011). "Innate immune recognition of an AT-rich stem-loop DNA motif in the
Plasmodium falciparum genome." Immunity35(2): 194-207.
170
Shaw, L. A., S. Belanger, K. D. Omilusik, S. Cho, J. P. Scott-Browne, J. P. Nance, J. Goulding, A.
Lasorella, L. F. Lu, S. Crotty and A. W. Goldrath (2016). "Id2 reinforces TH1 differentiation and
inhibits E2A to repress TFH differentiation." Nat Immunol17(7): 834-843.
Sherry, B. A., G. Alava, K. J. Tracey, J. Martiney, A. Cerami and A. F. Slater (1995). "Malaria-
specific metabolite hemozoin mediates the release of several potent endogenous pyrogens (TNF,
MIP-1 alpha, and MIP-1 beta) in vitro, and altered thermoregulation in vivo." J Inflamm45(2): 85-
96.
Shin, C., J. A. Han, H. Koh, B. Choi, Y. Cho, H. Jeong, J. S. Ra, P. S. Sung, E. C. Shin, S. Ryu and
Y. Do (2015). "CD8alpha(-) Dendritic Cells Induce Antigen-Specific T Follicular Helper Cells
Generating Efficient Humoral Immune Responses." Cell Rep11(12): 1929-1940.
Shio, M. T., S. C. Eisenbarth, M. Savaria, A. F. Vinet, M. J. Bellemare, K. W. Harder, F. S.
Sutterwala, D. S. Bohle, A. Descoteaux, R. A. Flavell and M. Olivier (2009). "Malarial hemozoin
activates the NLRP3 inflammasome through Lyn and Syk kinases." PLoS Pathog5(8): e1000559.
Smith, J. D., C. E. Chitnis, A. G. Craig, D. J. Roberts, D. E. Hudson-Taylor, D. S. Peterson, R.
Pinches, C. I. Newbold and L. H. Miller (1995). "Switches in expression of Plasmodium falciparum
var genes correlate with changes in antigenic and cytoadherent phenotypes of infected
erythrocytes." Cell82(1): 101-110.
Snow, R. W., J. A. Omumbo, B. Lowe, C. S. Molyneux, J. O. Obiero, A. Palmer, M. W. Weber, M.
Pinder, B. Nahlen, C. Obonyo, C. Newbold, S. Gupta and K. Marsh (1997). "Relation between
severe malaria morbidity in children and level of Plasmodium falciparum transmission in Africa."
Lancet349(9066): 1650-1654.
Sospedra, M. and R. Martin (2005). "Immunology of multiple sclerosis." Annu Rev Immunol23:
683-747.
Sponaas, A. M., E. T. Cadman, C. Voisine, V. Harrison, A. Boonstra, A. O'Garra and J. Langhorne
(2006). "Malaria infection changes the ability of splenic dendritic cell populations to stimulate
antigen-specific T cells." J Exp Med203(6): 1427-1433.
Sponaas, A. M., A. P. Freitas do Rosario, C. Voisine, B. Mastelic, J. Thompson, S. Koernig, W.
Jarra, L. Renia, M. Mauduit, A. J. Potocnik and J. Langhorne (2009). "Migrating monocytes
recruited to the spleen play an important role in control of blood stage malaria." Blood114(27):
5522-5531.
171
Stanisic, D. I., I. Mueller, I. Betuela, P. Siba and L. Schofield (2010). "Robert Koch redux: malaria
immunology in Papua New Guinea." Parasite Immunol32(8): 623-632.
Steketee, R. W. and C. C. Campbell (2010). "Impact of national malaria control scale-up
programmes in Africa: magnitude and attribution of effects." Malaria Journal9.
Stephens, R., F. R. Albano, S. Quin, B. J. Pascal, V. Harrison, B. Stockinger, D. Kioussis, H. U.
Weltzien and J. Langhorne (2005). "Malaria-specific transgenic CD4(+) T cells protect
immunodeficient mice from lethal infection and demonstrate requirement for a protective threshold
of antibody production for parasite clearance." Blood106(5): 1676-1684.
Stephens, R., R. L. Culleton and T. J. Lamb (2012). "The contribution of Plasmodium chabaudi to
our understanding of malaria." Trends in Parasitology28(2): 73-82.
Stephens, R. and J. Langhorne (2010). "Effector memory Th1 CD4 T cells are maintained in a
mouse model of chronic malaria." PLoS Pathog6(11): e1001208.
Stoute, J. A., M. Slaoui, D. G. Heppner, P. Momin, K. E. Kester, P. Desmons, B. T. Wellde, N.
Garcon, U. Krzych and M. Marchand (1997). "A preliminary evaluation of a recombinant
circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine
Evaluation Group." N Engl J Med336(2): 86-91.
Strauss, L., C. Bergmann, M. Szczepanski, W. Gooding, J. T. Johnson and T. L. Whiteside (2007).
"A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming
growth factor-beta1 mediates suppression in the tumor microenvironment." Clin Cancer Res13(15
Pt 1): 4345-4354.
Stubbington MJT, L. T., Proserpio V, Clare S, Speak AO, Dougan G, Teichmann SA (2015).
"Simultaneously inferring T cell fate and clonality from single cell transcriptomes." bioRxiv.
Su, X. Z., V. M. Heatwole, S. P. Wertheimer, F. Guinet, J. A. Herrfeldt, D. S. Peterson, J. A.
Ravetch and T. E. Wellems (1995). "The large diverse gene family var encodes proteins involved in
cytoadherence and antigenic variation of Plasmodium falciparum-infected erythrocytes." Cell82(1):
89-100.
Su, Z. and M. M. Stevenson (2000). "Central role of endogenous gamma interferon in protective
immunity against blood-stage Plasmodium chabaudi AS infection." Infect Immun68(8): 4399-4406.
172
Sun, P., R. Schwenk, K. White, J. A. Stoute, J. Cohen, W. R. Ballou, G. Voss, K. E. Kester, D. G.
Heppner and U. Krzych (2003). "Protective immunity induced with malaria vaccine, RTS,S, is
linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells
producing IFN-gamma." J Immunol171(12): 6961-6967.
Suss, G., K. Eichmann, E. Kury, A. Linke and J. Langhorne (1988). "Roles of CD4- and CD8-
bearing T lymphocytes in the immune response to the erythrocytic stages of Plasmodium chabaudi."
Infect Immun56(12): 3081-3088.
Suzuki, S., K. Honma, T. Matsuyama, K. Suzuki, K. Toriyama, I. Akitoyo, K. Yamamoto, T.
Suematsu, M. Nakamura, K. Yui and A. Kumatori (2004). "Critical roles of interferon regulatory
factor 4 in CD11bhighCD8alpha- dendritic cell development." Proc Natl Acad Sci U S A101(24):
8981-8986.
Szabo, S. J., S. T. Kim, G. L. Costa, X. Zhang, C. G. Fathman and L. H. Glimcher (2000). "A novel
transcription factor, T-bet, directs Th1 lineage commitment." Cell100(6): 655-669.
Szabo, S. J., B. M. Sullivan, S. L. Peng and L. H. Glimcher (2003). "Molecular mechanisms
regulating Th1 immune responses." Annu Rev Immunol21: 713-758.
Takaoka, A., H. Yanai, S. Kondo, G. Duncan, H. Negishi, T. Mizutani, S. Kano, K. Honda, Y.
Ohba, T. W. Mak and T. Taniguchi (2005). "Integral role of IRF-5 in the gene induction programme
activated by Toll-like receptors." Nature434(7030): 243-249.
Taki, S., T. Sato, K. Ogasawara, T. Fukuda, M. Sato, S. Hida, G. Suzuki, M. Mitsuyama, E. H.
Shin, S. Kojima, T. Taniguchi and Y. Asano (1997). "Multistage regulation of Th1-type immune
responses by the transcription factor IRF-1." Immunity6(6): 673-679.
Tamura, T., P. Tailor, K. Yamaoka, H. J. Kong, H. Tsujimura, J. J. O'Shea, H. Singh and K. Ozato
(2005). "IFN regulatory factor-4 and -8 govern dendritic cell subset development and their
functional diversity." J Immunol174(5): 2573-2581.
Tamura, T., H. Yanai, D. Savitsky and T. Taniguchi (2008). "The IRF family transcription factors
in immunity and oncogenesis." Annu Rev Immunol26: 535-584.
Tang, F., C. Barbacioru, E. Nordman, S. Bao, C. Lee, X. Wang, B. B. Tuch, E. Heard, K. Lao and
M. A. Surani (2011). "Deterministic and stochastic allele specific gene expression in single mouse
blastomeres." PLoS One6(6): e21208.
173
Tang, F., C. Barbacioru, Y. Wang, E. Nordman, C. Lee, N. Xu, X. Wang, J. Bodeau, B. B. Tuch, A.
Siddiqui, K. Lao and M. A. Surani (2009). "mRNA-Seq whole-transcriptome analysis of a single
cell." Nat Methods6(5): 377-382.
Tang, F., K. Lao and M. A. Surani (2011). "Development and applications of single-cell
transcriptome analysis." Nat Methods8(4 Suppl): S6-11.
Tarassishin, L., A. Bauman, H. S. Suh and S. C. Lee (2013). "Anti-viral and anti-inflammatory
mechanisms of the innate immune transcription factor interferon regulatory factor 3: relevance to
human CNS diseases." J Neuroimmune Pharmacol8(1): 132-144.
Taylor-Robinson, A. W. and R. S. Phillips (1994). "Th1 and Th2 CD4+ T cell clones specific for
Plasmodium chabaudi but not for an unrelated antigen protect against blood stage P. chabaudi
infection." Eur J Immunol24(1): 158-164.
Taylor-Robinson, A. W. and R. S. Phillips (1998). "Infective dose modulates the balance between
Th1- and Th2-regulated immune responses during blood-stage malaria infection." Scand J
Immunol48(5): 527-534.
Teijaro, J. R., D. Turner, Q. Pham, E. J. Wherry, L. Lefrancois and D. L. Farber (2011). "Cutting
edge: Tissue-retentive lung memory CD4 T cells mediate optimal protection to respiratory virus
infection." J Immunol187(11): 5510-5514.
Tomayko, M. M., N. C. Steinel, S. M. Anderson and M. J. Shlomchik (2010). "Cutting edge:
Hierarchy of maturity of murine memory B cell subsets." J Immunol185(12): 7146-7150.
Trapnell, C., D. Cacchiarelli, J. Grimsby, P. Pokharel, S. Li, M. Morse, N. J. Lennon, K. J. Livak,
T. S. Mikkelsen and J. L. Rinn (2014). "The dynamics and regulators of cell fate decisions are
revealed by pseudotemporal ordering of single cells." Nat Biotechnol32(4): 381-386.
Troye-Blomberg, M., E. M. Riley, L. Kabilan, M. Holmberg, H. Perlmann, U. Andersson, C. H.
Heusser and P. Perlmann (1990). "Production by activated human T cells of interleukin 4 but not
interferon-gamma is associated with elevated levels of serum antibodies to activating malaria
antigens." Proc Natl Acad Sci U S A87(14): 5484-5488.
Tse, S. W., I. A. Cockburn, H. Zhang, A. L. Scott and F. Zavala (2013). "Unique transcriptional
profile of liver-resident memory CD8+ T cells induced by immunization with malaria sporozoites."
Genes Immun14(5): 302-309.
174
Tsuji, M., P. Romero, R. S. Nussenzweig and F. Zavala (1990). "CD4+ cytolytic T cell clone
confers protection against murine malaria." J Exp Med172(5): 1353-1357.
Tsujimura, H., T. Tamura, H. J. Kong, A. Nishiyama, K. J. Ishii, D. M. Klinman and K. Ozato
(2004). "Toll-like receptor 9 signaling activates NF-kappaB through IFN regulatory factor-8/IFN
consensus sequence binding protein in dendritic cells." J Immunol172(11): 6820-6827.
Tubo, N. J. and M. K. Jenkins (2014). "TCR signal quantity and quality in CD4+ T cell
differentiation." Trends Immunol35(12): 591-596.
Tubo, N. J., A. J. Pagan, J. J. Taylor, R. W. Nelson, J. L. Linehan, J. M. Ertelt, E. S. Huseby, S. S.
Way and M. K. Jenkins (2013). "Single naive CD4+ T cells from a diverse repertoire produce
different effector cell types during infection." Cell153(4): 785-796.
Urban, B. C., T. T. Hien, N. P. Day, N. H. Phu, R. Roberts, E. Pongponratn, M. Jones, N. T. Mai,
D. Bethell, G. D. Turner, D. Ferguson, N. J. White and D. J. Roberts (2005). "Fatal Plasmodium
falciparum malaria causes specific patterns of splenic architectural disorganization." Infect
Immun73(4): 1986-1994.
van der Heyde, H. C., D. Huszar, C. Woodhouse, D. D. Manning and W. P. Weidanz (1994). "The
resolution of acute malaria in a definitive model of B cell deficiency, the JHD mouse." J
Immunol152(9): 4557-4562.
Victora, G. D. and M. C. Nussenzweig (2012). "Germinal centers." Annu Rev Immunol30: 429-
457.
Victora, G. D., T. A. Schwickert, D. R. Fooksman, A. O. Kamphorst, M. Meyer-Hermann, M. L.
Dustin and M. C. Nussenzweig (2010). "Germinal center dynamics revealed by multiphoton
microscopy with a photoactivatable fluorescent reporter." Cell143(4): 592-605.
Villadangos, J. A. and P. Schnorrer (2007). "Intrinsic and cooperative antigen-presenting functions
of dendritic-cell subsets in vivo." Nat Rev Immunol7(7): 543-555.
Villegas-Mendez, A., R. Greig, T. N. Shaw, J. B. de Souza, E. Gwyer Findlay, J. S. Stumhofer, J.
C. Hafalla, D. G. Blount, C. A. Hunter, E. M. Riley and K. N. Couper (2012). "IFN-gamma-
producing CD4+ T cells promote experimental cerebral malaria by modulating CD8+ T cell
accumulation within the brain." J Immunol189(2): 968-979.
175
von der Weid, T., M. Kopf, G. Kohler and J. Langhorne (1994). "The immune response to
Plasmodium chabaudi malaria in interleukin-4-deficient mice." Eur J Immunol24(10): 2285-2293.
von der Weid, T. and J. Langhorne (1993). "The roles of cytokines produced in the immune
response to the erythrocytic stages of mouse malarias." Immunobiology189(3-4): 397-418.
Wakim, L. M., A. Woodward-Davis and M. J. Bevan (2010). "Memory T cells persisting within the
brain after local infection show functional adaptations to their tissue of residence." Proc Natl Acad
Sci U S A107(42): 17872-17879.
Walther, M., D. Jeffries, O. C. Finney, M. Njie, A. Ebonyi, S. Deininger, E. Lawrence, A. Ngwa-
Amambua, S. Jayasooriya, I. H. Cheeseman, N. Gomez-Escobar, J. Okebe, D. J. Conway and E. M.
Riley (2009). "Distinct roles for FOXP3 and FOXP3 CD4 T cells in regulating cellular immunity to
uncomplicated and severe Plasmodium falciparum malaria." PLoS Pathog5(4): e1000364.
Weaver, B. K., O. Ando, K. P. Kumar and N. C. Reich (2001). "Apoptosis is promoted by the
dsRNA-activated factor (DRAF1) during viral infection independent of the action of interferon or
p53." FASEB J15(2): 501-515.
Weinmann, A. S. (2014). "Roles for helper T cell lineage-specifying transcription factors in cellular
specialization." Adv Immunol124: 171-206.
Weiss, G. E., B. Traore, K. Kayentao, A. Ongoiba, S. Doumbo, D. Doumtabe, Y. Kone, S. Dia, A.
Guindo, A. Traore, C. Y. Huang, K. Miura, M. Mircetic, S. Li, A. Baughman, D. L. Narum, L. H.
Miller, O. K. Doumbo, S. K. Pierce and P. D. Crompton (2010). "The Plasmodium falciparum-
specific human memory B cell compartment expands gradually with repeated malaria infections."
PLoS Pathog6(5): e1000912.
Weiss, W. R., M. Sedegah, J. A. Berzofsky and S. L. Hoffman (1993). "The role of CD4+ T cells in
immunity to malaria sporozoites." J Immunol151(5): 2690-2698.
White, K. L., H. L. Snyder and U. Krzych (1996). "MHC class I-dependent presentation of
exoerythrocytic antigens to CD8+ T lymphocytes is required for protective immunity against
Plasmodium berghei." J Immunol156(9): 3374-3381.
Whitworth, J., D. Morgan, M. Quigley, A. Smith, B. Mayanja, H. Eotu, N. Omoding, M. Okongo,
S. Malamba and A. Ojwiya (2000). "Effect of HIV-1 and increasing immunosuppression on malaria
parasitaemia and clinical episodes in adults in rural Uganda: a cohort study." Lancet356(9235):
1051-1056.
176
WHO (2015). WHO Global Malaria Programme: World Malaria Report 2015. WHO Library
Cataloguing-in-Publication Data. W. H. Organisation.
Williams, M. A., E. V. Ravkov and M. J. Bevan (2008). "Rapid culling of the CD4+ T cell
repertoire in the transition from effector to memory." Immunity28(4): 533-545.
Wing, J. B. and S. Sakaguchi (2014). "Foxp3(+) T(reg) cells in humoral immunity." Int
Immunol26(2): 61-69.
Winter, G., S. Kawai, M. Haeggstrom, O. Kaneko, A. von Euler, S. Kawazu, D. Palm, V. Fernandez
and M. Wahlgren (2005). "SURFIN is a polymorphic antigen expressed on Plasmodium falciparum
merozoites and infected erythrocytes." J Exp Med201(11): 1853-1863.
Wipasa, J., C. Suphavilai, L. C. Okell, J. Cook, P. H. Corran, K. Thaikla, W. Liewsaree, E. M.
Riley and J. C. Hafalla (2010). "Long-lived antibody and B Cell memory responses to the human
malaria parasites, Plasmodium falciparum and Plasmodium vivax." PLoS Pathog6(2): e1000770.
Woodberry, T., G. Minigo, K. A. Piera, F. H. Amante, A. Pinzon-Charry, M. F. Good, J. A. Lopez,
C. R. Engwerda, J. S. McCarthy and N. M. Anstey (2012). "Low-level Plasmodium falciparum
blood-stage infection causes dendritic cell apoptosis and dysfunction in healthy volunteers." J Infect
Dis206(3): 333-340.
Wu, L., S. I. Candille, Y. Choi, D. Xie, L. Jiang, J. Li-Pook-Than, H. Tang and M. Snyder (2013).
"Variation and genetic control of protein abundance in humans." Nature499(7456): 79-82.
Wuthrich, M., K. Ersland, T. Sullivan, K. Galles and B. S. Klein (2012). "Fungi subvert vaccine T
cell priming at the respiratory mucosa by preventing chemokine-induced influx of inflammatory
monocytes." Immunity36(4): 680-692.
Xu, H., J. Wipasa, H. Yan, M. Zeng, M. O. Makobongo, F. D. Finkelman, A. Kelso and M. F. Good
(2002). "The mechanism and significance of deletion of parasite-specific CD4(+) T cells in malaria
infection." J Exp Med195(7): 881-892.
Xu, L., Y. Cao, Z. Xie, Q. Huang, Q. Bai, X. Yang, R. He, Y. Hao, H. Wang, T. Zhao, Z. Fan, A.
Qin, J. Ye, X. Zhou, L. Ye and Y. Wu (2015). "The transcription factor TCF-1 initiates the
differentiation of T(FH) cells during acute viral infection." Nat Immunol16(9): 991-999.
177
Yamamoto, M., S. Sato, H. Hemmi, K. Hoshino, T. Kaisho, H. Sanjo, O. Takeuchi, M. Sugiyama,
M. Okabe, K. Takeda and S. Akira (2003). "Role of adaptor TRIF in the MyD88-independent toll-
like receptor signaling pathway." Science301(5633): 640-643.
Yan, L., M. Yang, H. Guo, L. Yang, J. Wu, R. Li, P. Liu, Y. Lian, X. Zheng, J. Yan, J. Huang, M.
Li, X. Wu, L. Wen, K. Lao, R. Li, J. Qiao and F. Tang (2013). "Single-cell RNA-Seq profiling of
human preimplantation embryos and embryonic stem cells." Nat Struct Mol Biol20(9): 1131-1139.
Zhu, J. and W. E. Paul (2010). "Heterogeneity and plasticity of T helper cells." Cell Res20(1): 4-12.